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resumo 
 
 
A desregulação dos componentes da maquinaria de síntese proteica, tais 
como tRNAs, aminoacil-tRNA sintetases, e enzimas modificadoras dos tRNAs, 
é comum em tumores, levantando a hipótese de que a fidelidade da síntese 
proteica pode estar comprometida em tumores. 
Para clarificar esta hipótese, determinámos a taxa de erro da síntese proteica 
e observámos que os tumores produzem mais erros na síntese de proteínas 
que os tecidos normais. De modo a compreender o papel dos erros de 
tradução na biologia tumoral, expressámos tRNAs de Serina mutantes que 
incorporam Ser em locais de Ala (erro frequente) e Ser em locais de Leu (erro 
raro) na linha celular NIH3T3. O tRNA que incorpora Ser em locais de Ala, 
promoveu o crescimento tumoral com uma cinética semelhante à induzida pela 
mutação K-ras
V12
. A activação da via AKT e a activação diferencial da UPR, 
dependendo do tRNA expresso, também foram observadas. No entanto, a 
expressão dos tRNAs mutantes nas linha celulares derivadas das NIH3T3 não 
permitiu clarificar o papel dos tRNAs recombinantes na iniciação ou na 
progressão tumoral. Para tal, expressámos um tRNA de Serina WT e o tRNA 
mutante insere Ser em locais de Ala em células derivadas de epitélio bronquial 
normal, BEAS-2B, e em células derivadas de Carcinoma de células grandes do 
pulmão, H460. A expressão destes tRNAs na linha celular normal, aumentou a 
proliferação celular, a taxa de síntese proteica e a activação de biomarcadores 
da via da UPR, a qual é dependente do tRNA expresso. Ambos os tRNAs 
favoreceram a formação de colónias in vitro. O aumento da expressão do 
tRNA de Serina WT foi suficiente para iniciar a formação de tumores de 
crescimento lento. Quando expressámos os mesmos tRNAs nas células 
tumorais H460, observámos um aumento na cinética de crescimento tumoral e 
no potencial de invasão local das células, embora os resultados obtidos não 
permitam tirar uma conclusão definitiva acerca do envolvimento dos tRNAs na 
progressão tumoral. O aumento da expressão do tRNA de Serina WT torna 
células tumorais mais resistentes ao tratamento com cisplatina. De um modo 
geral, os nossos resultados sugerem que a desregulação de tRNAs e o 
aumento dos erros da síntese proteica são importantes para a biologia dos 
tumores. 
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abstract 
 
Deregulation of various components of the protein synthesis machinery, 
including tRNAs, aminoacyl-tRNA synthetases and tRNA modifying enzymes, 
are common in tumors, raising the hypothesis that protein synthesis accuracy is 
compromised in cancer.  
To clarify this hypothesis, we determined the relative error rate of protein 
synthesis and observed that tumors mistranslate at higher levels than normal 
tissue. To understand the role of mistranslation in tumor biology, we expressed 
mutant Ser-tRNAs that misincorporate Ser-at-Ala (frequent error) and Ser-at-
Leu (infrequent error) sites in NIH3T3 cells. The tRNA that misincorporated 
Ser-at-Ala codon sites induced tumor growth with similar kinetics of K-ras
V12
 
expressing tumors. Upregulation of the AKT pathway and differential activation 
of the UPR, depending on the tRNA being expressed, were also observed. 
However, these studies did not clarify the role of tRNA deregulation or tRNA 
misreading in tumor initiation or progression. For this, a WT-Ser tRNA and a 
tRNA that misincorporates Ser-at-Ala codon sites were expressed in cells 
derived from normal bronchial epithelium (BEAS-2B) and in cells derived from a 
Large cell lung carcinoma (H460). The BEAS-2B cell lines studies showed that 
increased cell proliferation in vitro, increased protein synthesis rate and 
activation of UPR biomarkers, which were dependent on the recombinant tRNA 
being expressed. Both tRNA constructs increased colony formation capacity in 
vitro. Interestingly, the data suggest that upregulation of the WT Ser-tRNA is 
sufficient to trigger tumor formation, albeit with very slow growth kinetics. When 
the same tRNAs were expressed in H460 cells, tumor growth kinetics and local 
invasion potential of the cells increased. Finally, upregulation of the WT-Ser 
tRNA decreases tumor cell sensitivity to cisplatin treatment. The overall study 
highlights new features of tRNA function in tumor biology and open new 
avenues to explore the role of protein synthesis in cancer. 
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MRS – Metionyl-tRNA synthetase 
mRNA – Messenger RNA 
mtDNA – Mitochondrial DNA 
mTOR – Mammalian Target Of Rapamycin 
 
N 
N – Asparagine  
NSCLC – Non-Small Cell Lung Cancer 
 
P 
P – Proline 
PERK – PKR-like Endoplasmic Reticulum Kinase 
Phe – Phenilalanine    
PI3K – Phosphoinositide 3-kinase  
PQC – Protein quality control 
 
Q 
Q – Glutamine 
 
R 
R – Arginine  
RB – Retinoblastoma protein 
RNA – Ribonucleic Acid 
ROS – Reactive Oxygen Species 
rRNA – Ribosomal RNA 
 
S 
S – Serine 
SARS – Seryl-tRNA synthetase 
Ser – Serine 
 
T 
T - Threonine 
TFIIIB - RNA polymerase III-specific transcription factor B 
TFIIIB - RNA polymerase III-specific transcription factor C 
Thr - Threonine 
tRNA – transfer RNA 
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Tyr – Tyrosine 
 
U 
U – Uridine 
UPR – Unfolded Protein Response 
UPS – Ubiquitin-Proteasome System 
 
V 
V – Valine 
Val - Valine 
VEGF - Vascular Endothelial Growth Factor  
 
W 
W – Triptophane  
WARS – Triptophanyl-tRNA synthestase 
 
X 
XBP1 - X-box binding protein 1 
 
Y  
Y – Tyrosine 
YARS – Tyrosyl-tRNA synthetase 
 
Other abbreviations will be explained when used in the text. 
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Cancer is a multifactorial disease driven by the accumulation of DNA mutations, 
chromosomal aberrations and epigenetic alterations. As a consequence, transcriptional 
and post-transcriptional deregulation occur in most tumors types. Although, and despite 
the great effort to clarify the molecular profile of all tumors, a significant percentage of 
them that cannot be explained by known driver genetic or epigenetic events. For 
instance, approximately 40% of Non-Small Cell Lung Cancer (NSCLC) tumors have 
unknown etiology. There is increasing evidence for deregulation of tRNAs, aminoacyl-
tRNA synthetases and tRNA modifying enzymes in tumors, but the consequences of 
such deregulation for tumor biology are poorly understood. A possibility is that protein 
mutations without corresponding changes in the DNA sequence explain the etiology of 
a certain fraction of human cancers. 
Supporting this hypothesis, recent works show major differences in the tRNA 
pool of tumors and normal tissue, with specific enrichment of tRNAs that stabilize 
transcripts associated with cell cycle progression and cell proliferation. Deregulation of 
tRNA expression and processing may then lead to misreading of near-cognate codons 
and protein synthesis errors (PSE), however this has not been addressed in cancer so far. 
The characteristics of the tumor microenviroment, such as amino acid starvation, may 
also potentiate the occurrence PSE, leading to the upregulation of molecular 
chaperones, activation of the ubiquitin-proteasome system and the Unfolded Protein 
Response (UPR) in tumors. Increased PSE levels have also been associated with 
antibiotic and antifungal resistance in Candida albicans and Mycobacteria, raising the 
hypothesis that they may also play a role in cancer therapy resistance.  
In this thesis we addressed the hypothesis that PSE increase in tumors, creating a 
phenotype that is advantageous for tumour cells. Its main objective is to understand 
whether PSE are increased in tumors, and if so, to characterize the impact of a mutant 
proteome in cancer cell initiation, growth kinetics and resistance to chemotherapy. To 
address this objective we developed a method to quantify PSEs and created cell line 
models of tRNA imbalance and/or misreading. With these tools in our hands, we 
designed the following specific aims: 
1. Quantify the error rate of protein synthesis in tumors and normal tissue 
and identify the most and least common PSE in tumors using Mass Spectrometry 
(Chapter 3); 
2. Elucidate whether tRNA deregulation and PSE may confer advantageous 
features to tumour cells (Chapter 3 and 5); 
1. Rational and Objectives 
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3. Understand if and how PSE and tRNA deregulation, per se, have a role 
in tumor initiation and growth kinetics (Chapter 3, 4 and 5). 
4. Understand whether activation of the Unfolded Protein Response 
influences the impact of a statistical proteome in cell lines and tumour xenografts 
(Chapter 3, 4 and 5); 
5. Assess the relevance of tRNA deregulation and PSE to chemotherapy 
(Chapter 6). 
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Disclosure of interests: The introduction of this thesis will soon be submitted to 
Trends in Molecular Medicine. 
 
2.1. Abstract  
The proteome of cancer cells is seldom different from its transcriptome, once 
imbalances in translation components are frequent and the increased demand of protein 
synthesis also comes with a cost on fidelity. The deregulation of transfer RNAs has 
been poorly studied so far in cancer biology, however, recent evidences suggest that 
these molecules have a far more important function than anticipated, once they are able 
to modulate gene expression and induce metabolism changes in cells. In this 
Introduction, we summarize not only the direct evidences implying tRNAs as major 
players in cancer biology, but also the indirect evidences that open new insights into 
their role in tumor heterogeneity and the possibility of modulating tRNAs to target 
resistance to therapy. 
2.2. Overview of tRNA structure and biology 
Transfer RNAs (tRNAs) are small conserved RNA molecules (73–90 
nucleotides)  that connect genes and proteins 1. In humans, there are 506 tRNA genes 
that are transcribed into primary transcripts by the RNA polymerase III. These pre-
tRNAs are then processed post-transcriptionally to acquire their mature 5’ and 3´ ends, 
modified nucleosides and the typical cloverleaf secondary structure. The latter has 4 
domains organized in unpaired and paired regions: acceptor-arm, D-arm, anticodon-arm 
and TΨC-arm. The 3’ CCA of the acceptor arm is added post-transcriptionally and 
accepts the amino acids. The anticodon-arm has a three nucleotide sequence in the 
unpaired region (anticodon) that interacts with mRNA codons. Mature tRNAs acquire a 
L-shape tertiary structure through base stacking and non-Watson-Crick base pairing 
between the acceptor and TΨC, D and anticodon arms (Fig.2-1).  
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tRNAs are charged with amino acids by aminoacyl-tRNA synthetases (aaRS). 
There is only one aaRS for each amino acid, but each aaRS charges multiple tRNA 
isoacceptors belonging to the same amino acid family 2. The aminoacylation of tRNAs 
involves a two step reaction where the amino acid is activated with ATP forming an 
aminoacyl-AMP which is then connected to the 3’-end of tRNAs. aaRSs are subdivided 
in two classes according to the structure of their catalytic domains: Class I aaRSs are 
usually monomeric or dimeric and aminoacylates the tRNAs in the 2-OH, whereas 
Class II aaRSs are generally di- or tetrameric and aminoacylate tRNAs in the 3’-OH. 
Some of these enzymes possess an editing domain that corrects misactivated amino 
acids and mischarged tRNAs, which is essential for translational fidelity 3. The 
abundance of tRNAs is tightly regulated and matches codon usage (Box 1) for the 
correct expression of proteins 4. Deregulation of tRNA expression, mutations that lead 
to misacylation of tRNAs by aaRS and aberrant tRNA modification by tRNA modifying 
enzymes (tRNAmods) alter gene expression and have been associated with cancer, 
neurodegenerative and metabolic diseases 5–9. We review here recent data that highlight 
tRNA contributions to tumor biology. 
Figure 2-1: tRNA structure. tRNAs have a cloverleaf shape derived from a single nucleotide chain with 
73 to 90 nucleotides in length and 4 domains organized in unpaired and paired regions: acceptor arm, D 
arm, anticodon arm and TΨC arm. The acceptor arm has a 3’ CCA tail that links the cognate amino acid, 
and the anticodon arm has a three nucleotide sequence in the unpaired region, the anticodon loop, that 
interacts with the mRNA codon. Unpaired regions also mold loops in the D and the TΨC arms and an 
unpaired region between the anticodon and the TΨC arms represents the variable arm, also known as 
extra arm. The size of the variable arm can range from 3 to 21 bases and dictates tRNA grouping in class 
I or II.  
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2.3. tRNA expression in tumors 
The first study suggesting that tRNAs may play a role in cancer was published in 
2009 by Pavon and colleagues 10. These authors observed upregulation of both 
cytoplasmatic and mitochondrial tRNAs in breast cancer, in particular of tRNA 
isoacceptors of the Serine (Ser), Threonine (Thr) and Tyrosine (Tyr) families. Since 
these tRNAs belong to amino acid families that regulate most of the cancer signaling 
cascades through phosphorylation, it was suggested that tRNA expression deregulation 
impacts on cancer signaling pathways 10. Gingold and colleagues discovered a subset of 
tRNAs that are differentially expressed in several types of cancer, but are 
downregulated in differentiating or senescent cells. These tRNAs decode codons that 
are abundant in transcripts encoding proteins related to cell growth and proliferation, 
indicating that they may modulate gene expression at the translational level in those 
tumors 11. Another study showed that overexpression of the initiator tRNAiMet in vitro 
can alter the entire tRNA expression landscape and increase cellular metabolic activity 
and proliferation rates in vitro 12. The specific role of tRNAiMet overexpression in 
tumorigenesis is not yet clear since the observed global tRNA deregulation may alter 
global protein expression, induce the acquisition of traits that could be relevant to tumor 
growth and may even constitute a novel tumor initiation mechanism. 
Recent works show that tRNAGluUUC and tRNAArgCCG are specifically 
upregulated in metastatic breast cancer cell lines, providing a link between tRNA pool 
deregulation and cancer progression 13. How tRNA upregulation contributes to cancer 
biology is poorly understood, but it is likely that the upregulated tRNAs increase the 
translation efficiency of specific disease-promoting genes that are enriched in the 
codons recognized by these anticodons, shifting the proteome landscape towards a pro-
metastatic state 13. Alteration of the tRNA landscape may also modify the cellular 
microenvironment to favor tumor progression. Indeed, upregulation of tRNAiMet in 
Box 1 – Codon Usage Bias  
Most amino acids are encoded by several synonymous codons, which are not 
used with the same frequency in the genome. Highly expressed genes tend to 
be enriched in codons that match the tRNA pool. This codon usage bias has 
been associated with increased translation accuracy, efficiency, modulation of 
translation speed, protein folding and stability of secondary structures. Poor 
correlation between codon usage and the tRNA pool may result in incorrect 
allocation of resources, namely the increase of ribosome sequestration due to a 
decrease in translation speed, reducing the global cellular fitness. 
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support fibroblasts induces secretion of collagen type II, favoring endothelial cell 
migration, angiogenesis and tumor growth 14.  In addition, the overexpression of 
tRNAiMet is sufficient to promote migration and invasion of melanoma cells, through 
mechanisms that are dependent on the α5β1 integrin, resulting in an increased 
metastatic potential without affecting proliferation and growth of the primary tumor 15. 
Moreover, recent NGS works identified 76 tRNAs that are upregulated in breast 
tumors. This tRNA set is sufficient to discriminate normal and tumor samples, showing 
that tumors have tRNA populations that are distinct from those of normal cells. 
Fourteen of these tRNAs were associated with decreased overall survival and 
augmented risk of recurrence in a case-only approach. Of these, only chr6.tRNA5-
SerAGA, chr6.tRNA50-SerAGA and chr6.tRNA51-SerTGA correlated with these 
biological features in a case-control approach 9.  
Publicly available small non-coding RNA data (sncRNA) (YM500v3 database) 
provide systematic data of sncRNAs expression profiles in different tissues, types of 
cancer and on the influence in cancer patients overall survival. The stratification of 
tumors based on the expression levels of the sncRNAs showed that increased expression 
of several tRNAs consistently associate with bad prognosis in kidney renal clear cell 
carcinoma, adrenocortical carcinoma and breast invasive carcinoma (Fig.2-2) 16. 
Moreover, increased expression of the tRNAs mentioned above is generally associated 
with bad prognosis in several types of cancer (Fig.2-2), suggesting that deregulation of 
tRNAs in tumors or tumor-support cells imposes important cellular reprogramming 
events that may sustain tumor growth and disease progression.  
 
2.4. The molecular basis of differential tRNA deregulation in tumors 
The traditional view of tRNA abundance was that it depends mainly on tRNA 
gene copy number 17, however, recent data suggest that regulation of tRNA expression 
is far more complex 10,11,13. RNA polymerase III (PolIII) has increased activity in cancer 
likely to provide sufficient tRNA to sustain the increased protein synthesis rate 
observed in tumors 18. PolIII transcription relies on the transcription factor IIIC 
(TFIIIC), a six subunit complex that binds to the A and B boxes of the tRNA genes 
internal promoters 19. The TFC4 subunit of the TFIIIC then interacts with Brf1 and 
Bdp1 to recruit the TFIIIB factor 20, which recognizes upstream regions of tRNA genes 
and directs the recruitment of PolIII to the tRNA gene promoters 19. Since the subunits 
of TFIIIB, Bdp1 and Brf1 21, have multiple isoforms that are generated by alternative 
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splicing in a tissue-specific-manner 22, they may permit differential regulation of tRNA 
expression.  
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RNA PolIII is also positively regulated by oncogenes, namely c-Myc, Ras/ERK, 
PI3K/Akt, mTOR and TERT whereas tumor suppressors (RB and p53) tend to 
downregulate its activity 23–25.  The c-Myc transcription factor which modulates cell 
growth, proliferation and apoptosis, also upregulates RNA polymerases I, II and III 26,27. 
In the case of PolIII, c-Myc recruits the histone acetyltransferase GCN5 and the cofactor 
TRRAP to target tRNAs genes. This transcription factor also recruits the Brf1 and Bdp1 
subunits of TFIIIB, dually contributing to PolIII transcription activation 27. On the other 
hand, the Cytoskeletal filamin A (FLNA) which has an ambiguous role in cancer 
depending on its isoform and location, can repress PolIII by interacting with its actin-
binding domain; its ablation upregulates some, but not all, tRNA genes in a tissue 
specific manner 28. It is not yet clear if the transcription of specific tRNAs is due to 
regulation of PolIII alone or if it involves a more complex mechanism, but those data 
indicate that tRNA expression does not dependent on tRNA gene copy number alone 
and that different isoforms of Brf1 or Bdp1 and oncogenes may stabilize the binding of 
TFIIIB in different tRNA promoters, differentially regulating tRNA expression in 
different tissues and tumors 11,13. 
 
2.5. Deregulation of tRNA-interacting partners in cancer 
Transfer RNAs are highly modified post-transcriptionally by tRNA modifying 
enzymes (tRNAmods). These nucleoside modifications are crucial for the acquisition of 
the 3D L-shaped structure and stability, interaction with other translational factors, 
namely aaRS and the ribosome and for decoding efficiency and fidelity 29–31. 
Hypomodified tRNAs become unstable and are normally degraded 32,33, in particular, 
hypomodification of the anticodon wobble position (N34), is normally deleterious and 
has been associated with several diseases 6,31,34–36. Upregulation of the enzymes that 
catalyze modifications at N34 is also associated with translational control of gene 
expression.  For example, ELP3 and CTU1/2 tRNA modifying enzymes, which catalyze 
the modification of U34 to mcm5s2-U34, are upregulated in breast cancer and this is 
apparently  necessary to support translation of specific mRNAs required for breast 
Figure 2-2: tRNA association with prognosis. tRNAs that were previously described in the literature to 
be associated with cancer were browsed on YM500v3 database for association with prognosis. Overall 
high expression of tRNAs is usually associated with bad prognosis. Legend: Red – Bad Prognosis; 
Green – Good Prognosis Black – No difference; Grey – Data not available. 
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cancer progression, namely, the proinvasive transcription factor LEF1 37. Moreover, the 
modification of G26 to dimethyil-guanine-26 (m22G26), carried out by the enzyme 
Trm1, limits the availability of a specific set of tRNAs for translation when PolIII 
transcription occurs at high rate, as in cancer, contributing to the regulation of the 
functional tRNA pool 38.  
Another class of tRNA-interacting proteins that are deregulated in tumors is the 
aaRS protein family. These enzymes can activate or suppress several cancer hallmarks 
and impact in the outcome of therapy, through non-translation related interactions with 
other cellular and extracellular molecules. This topic as been extensively reviewed 
elsewhere 39,40, and we will only highlight some of the most relevant features for cancer. 
Various aaRS respond to inflammatory stimuli, are pro-angiogenic and are frequently 
upregulated in tumors. These aaRS include the Threonyl-, Tyrosyl- and Seryl-tRNA 
synthetases (TARS, YARS and SARS, respectively).  Conversely, the Tryptophanyl or 
Glutamyl-prolyl-tRNA synthetases (WARS and EARS, respectively), are considered 
angiostatic and are typically downregulated 39,41. The Lysyl-tRNA synthetases (KARS) 
promotes cancer cell migration and induces cytokine production by immune cells, thus 
increasing inflammatory stimuli in the tumor microenvironment 39. Interestingly, the 
Leucyl-tRNA synthetase (LARS) acts as a Leucine (Leu) sensor, activating the PI-3-
kinase Vps34 and mTORC1 signalling by regulating lysosomal translocation and 
activation of the phospholipase PLD1 42. Finally, upregulation of the Methionyl-tRNA 
synthetase (MRS) is associated with advanced stage and poor prognosis in Non-Small 
Cell Lung Cancer (NSCLC) 43. 
 
2.6. Protein synthesis errors are increased in tumors 
Tumors are characterized by the capacity of sustained proliferation signaling, 
evasion of apoptosis and unrestrained growth 44. Protein synthesis rate is normally 
upregulated in cancer to sustain increased proliferation. This is achieved by 
upregulating tRNAs, aaRS, ribosome biogenesis and tRNAmods 10,45–48, but it is unclear 
whether such metabolic alterations increase translational error rate leading to aberrant 
protein synthesis in tumors 49–51. It is known that increased translation speed comes with 
a cost on translational accuracy 51 and indirect evidences such as activation of the 
unfolded protein response (UPR), frequent upregulation of molecular chaperones, 
increased proteasome activity and autophagy, show that this may also occur in tumors 
52–56. Increased proteasome activity, mitigates the accumulation of misfolded proteins in 
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tumors and is required for apoptosis evasion, which makes this organelle an useful 
therapeutic target 55,57,58. Additionally, in a tumor context, autophagy promotes cell 
survival under the conditions of metabolic stress created by the tumor 
microenvironment, through elimination of damaged mitochondria, reactive oxygen 
species (ROS) and protein aggregates derived from misfolded proteins 59,60. 
The tumor microenvironment has a profound effect on protein homeostasis 
(proteostasis) as it is usually acidic, hypoxic and poor in nutrients, due to low 
vascularization. Nutrient starvation directly influences protein glycosylation and ATP 
production, triggering synthesis of misfolded proteins, an event also supported by the 
lack of oxygen that is crucial for disulfide bond formations and proper protein folding 
61,62. Amino acid depletion may increase protein synthesis errors through tRNA 
mischarging and accumulation of uncharged tRNAs 63. The latter may trigger a cell 
surviving program through activation of GCN2, which phosphorylates the translation 
initiation factor eIF2α, and blocks cap-dependent translation initiation. This induces the 
translation of ATF4, which activates stress response genes transcription and autophagy 
to increase amino acid supply 64. ATF4 will also induce the transcription of VEGF to 
enhance angiogenesis to restore the proper amino acid supply to cells (Fig.2-3) 65.  
Figure 2-3: Amino acid starvation consequences. Amino acid starvation increases protein synthesis 
errors by inducing tRNA mischarging. Uncharged tRNAs will also be present due to lack of amino acids. 
The latter will trigger a cell surviving program through activation of GCN2, which phosphorylates the 
translation initiation factor eIF2α, blocking cap-dependent translation initiation, but inducing translation 
of ATF4 which is responsible for the transcription of stress response genes and activating autophagy to 
increase free amino acid supply in cells. 
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Inflammation triggered by innate immune cells, designed to fight infections and 
wound-healing, can support multiple tumor hallmark capabilities 44. There is a crosstalk 
between inflammation and protein misfolding since one can induce the other. Misfolded 
proteins activate the Unfolded Protein Response (UPR), which relies on the activation 
its three effectors: the inositol requiring kinase 1 (IRE1α), the double-stranded RNA-
activated protein kinase (PKR)-like endoplasmic reticulum kinase (PERK) and the 
activating transcription factor 6 (ATF6) (reviewed in 66). These UPR effectors 
contribute to tumor growth and aggressiveness, microenvironment remodeling and 
resistance to treatment 52,67–70. Regarding the microenvironment remodeling, the UPR 
can induce inflammation by increasing the release of pro-inflammatory cytokines which 
also contribute to tumor cell survival. Remarkably, tumor cells can induce the UPR in 
cells of the immune system, which further increases tumor-promoting inflammation 71. 
The tumor microenvironment is also characterized by oxidative stress caused by 
increased ROS, which can also originate misfolded proteins.  The UPR can also help to 
boost the antioxidant defenses through upregulation of the NFR2 53. 
Furthermore, the deregulation of the tRNA pool, especially that of near-cognate 
tRNAs can also result in protein synthesis errors 72. Cognate and near-cognate tRNAs 
compete for mRNA codons and upregulation of near-cognate tRNAs, may lead to 
mistranslation events and protein structural instability. (Fig.2-4A) 73.  For example, the 
upregulation of the tRNASerAGA may allow it to decode the Ala GCT codon, 
incorporating Ser at Alanine (Ala) sites, on a proteome scale (Fig.2-4A). 
Mischarging of tRNAs also results in protein mistranslation (Fig.2-4B) 5,74. The 
estimated error rate associated with the amino acylation of tRNAs is 10-4 to 10-5, which 
is similar to global protein synthesis rate 75. These errors are particularly relevant in the 
case of tRNAs that are charged with similar amino acids. Indeed, Valine (Val) tRNAs 
are often mischarged with Thr or Isoleucine (Ile) and Leu tRNAs with Ile or Val. 
Mischarging of Ala tRNAs with either Ser or Glycine (Gly) and the mischarging of 
Lysine (Lys) tRNAs with Arginine (Arg), Ala, Thr, Metionine (Met), Leu, Cysteine 
(Cys) or Ser are also frequent 75.  
Mistranslation is normally viewed as being deleterious, as 10–50% of random 
substitutions result in the production of dysfunctional or misfolded proteins. However, 
these often accumulate in toxic aggregates or become degraded by the Proteasome 
(Fig.2-5) 76,77. The remaining errors introduce protein mutations (epimutations) that can 
generate phenotypic diversity and may even contribute to adaptation to cellular stress or 
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changing physiological conditions (Adaptive mistranslation). For instance, under 
oxidative stress, the Methionyl-tRNA synthetase (MRS) is phosphorylated, loses its 
specificity and charges non-cognate tRNAs with Met, increasing the incorporation of 
Met into the proteome 78. Interestingly, this is advantageous, since Met is a scavenger of 
ROS that protects proteins from oxidation, which may be particularly important for 
tumor cells to thrive, since tumors have high levels of ROS 43,79.  Importantly, it has also 
been recognized that a more accurate translation slows down cellular growth, which is 
not compatible with most types of cancer 80.  
 
 
 
 
 
Figure 2-4: tRNAs are essential for translation accuracy. A) tRNA pool deregulation may cause 
ribosomes to choose overrepresented near-cognate tRNAs to read a codon in the mRNA, instead of 
underrepresented cognate tRNAs, thus incorporating the wrong amino acid in a polypeptide chain. B) 
tRNAs may be misacylated by aminoacyl-tRNA synthethases. If tRNAs carry the wrong amino acid, a 
missence error will be generated.  
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2.7. Implications of mistranslation for tumor heterogeneity and drug 
resistance 
There is little information about the role of tRNA deregulation and 
mistranslation in tumor heterogeneity and drug resistance. Studies in microorganisms 
have shown that mistranslation contributes to increase their adaptive potential to 
stressful environments through diversification of the proteome and population 
heterogeneity 81–83. In yeast, increased translational errors driven by tRNA misreading 
enables yeast to colonize hostile environments and to resist classical drug treatments. 
Also, mistranslation can help Mycoplasma to evade the host’s immune system and 
E.coli are more resistant to antibiotics when its MRS is able to misacylate other tRNAs 
with Met 84. Therefore, mutations in proteins that occur during mRNA decoding by the 
ribosome, produce statistical proteins, that destabilize the proteome and produce cell 
population heterogeneity. Interestingly, such protein mutations also destabilize the 
genome, increase DNA mutation rate and to reprogram the transcriptome (Fig.2-6) 83,85–
87. The role of mistranslation in tumor heterogeneity has not yet been proven, however, 
these data provide strong evidence for a pivotal role of mistranslation in genome 
instability, mutation rate, drug resistance and phenotypic diversification through 
population heterogeneity. Some works also shows that tRNAs are differentially 
expressed in tumors from different patients, which correlates positively with inter-tumor 
Figure 2-5: Protein Biosynthesis Errors’ fate. Missence errors in proteins can be originated by several 
processes. These errors create misfolded or dysfunctional proteins. Misfolded proteins may then be 
degraded by the proteasome or accumulate in toxic aggregates. However, the majority of these proteins 
are refolded and may represent a gain-of-function to the cell, contributing to the adaptation to cellular 
stress. 
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heterogeneity (YM500v3 database). This has been linked to differences in risk of 
disease recurrence and overall survival time (Fig.2-2) 9.  
 
Tumor heterogeneity is also one of the major problems regarding resistance to 
therapy. Resistance to therapy can be classified as intrinsic or acquired. Intrinsic 
resistance refers to preexisting characteristics of the cells which allow them to resist the 
drug treatments, whereas acquired resistance is induced by the treatment itself 88. Tumor 
cells normally acquire drug resistance through drug inactivation, drug target alteration, 
drug efflux, DNA damage repair, cell death inhibition, epithelial-mesenchymal 
transition (EMT) and epigenetic modifications 89. The most recent data on tRNAs imply 
that they may contribute to attenuate cell sensitivity to conventional chemotherapy 90. 
For instance, the increased load of tRNAs in tumor cells can aid on apoptosis inhibition, 
since tRNAs can bind to cytochrome c and inhibit caspase activation, independently of 
their charging state 91,92. It was also demonstrated that overexpression of specific tRNAs 
Figure 2-6: Consequences of mistranslation. Translational errors due to ribosome misreading or tRNA 
mischarging result in statistical proteomes composed by several protein isoforms. These statistical 
proteins can bestow cells with new advantageous or deleterious functions or they can be directly 
degraded by the proteasome with no further consequences to the cell. Additionally, they may impact on 
proteome homeostasis and phenotypic diversification, reprogramming the transcriptome and are able to 
flow back to DNA as compensatory mutations to mitigate proteome destabilization and loss of 
proteostasis. 
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may play a role in TGFβ-induced EMT progression or regulation 93. Furthermore, 
conventional chemotherapy increases ROS levels in tumor cells, and misacylation of 
non-methionyl-tRNAs by MRS helps to mitigate this stress in tumor cells 78,94. Also, 
imbalances in tumor cell tRNA pool can increase errors in protein synthesis 72, which 
will activate the PQC system. Activation of the PQC includes upregulation of molecular 
chaperones that will help to refold the misfolded proteins or direct them to one of the 
cellular degradation systems; upregulation of the ubiquitin-proteasome system (UPS) to 
increase protein turnover; activation of the UPR and autophagy. The concomitant 
activation of all these pathways has been observed in tumors and is often correlated 
with tumor progression, metastasis and also drug resistance 54,55,95. 
 tRNAs have the ability to modulate gene expression, increasing the translation 
efficiency of transcripts that have a codon usage bias towards them 13. Thus, we can 
hypothesize that among these transcripts, some may bestow tumor cells with phenotypic 
advantages which will confer them the ability to resist to therapy. As a matter of fact, a 
set of tRNAs has been associated with increased probability of disease recurrence, 
indicating that they may be directly involved in acquisition of drug resistance 9. The 
pool of tRNAs has also been shown to be very plastic, able to change in response to 
cellular stress 96. Chemotherapy induces changes in the tRNA landscape, depending on 
the genetic background of tumor cells, possibly allowing cells to translate more 
efficiently transcripts which confer them the ability to adapt to the new conditions 97.   
Therefore, despite lacking direct evidences of tRNA deregulation and 
mistranslation in tumor heterogeneity and drug resistance, the evidences provided by 
other model organisms and the activation of the PQC system supports the idea that their 
role is far more significant than previously anticipated. 
 
2.8. Concluding Remarks 
There are still many answered questions regarding the full role of tRNAs in 
tumor biology, mainly because until recently their deregulation was acknowledged as a 
strategy to meet the metabolism requirements. Transfer RNA transcription by PolIII is 
controlled by oncogenes but further studies are needed to demonstrate that they can bind 
to the promoter of a specific set of tRNAs and thus induce the translation of specific 
transcripts enriched in matching codons. Besides their ability to drive gene expression 
in cancer cells, tRNAs have shown to be able to protect proteins from oxidative stress 
by random insertion of methionine and misincorporations enable cells to resist to drug 
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treatments in other biological models. Their deregulation can support disease 
progression through upregulation of cell migration, invasion and metastasis and also 
promote tumor heterogeneity and therapy resistance, thus contributing to poor patient 
prognosis (Fig.2-7). 
 
Figure 2-7: Deregulation of tRNA pool in cancer contributes to poor patient prognosis.  The 
deregulation of tRNA pool in tumors has been associated to increased cell migration, invasion and 
metastasis due to preferential translation of mRNAs enriched in matching codons. On the other hand, this 
imbalance may cause an increase in tRNA misreading, which may contribute to tumor heterogeneity and 
therapy resistance. Altogether these data show that imbalances in the tRNA pool may contribute to poor 
patient prognosis. 
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3.1. Abstract  
Deregulation of tRNAs, aminoacyl-tRNA synthetases and tRNA modifying 
enzymes, are common features of cancer, raising the hypothesis that protein synthesis 
accuracy is compromised in tumors. To clarify this hypothesis, we determined the 
relative error rate of protein synthesis in normal tissue and in tumors, and confirmed 
that tumors mistranslate at higher levels than normal tissue. To understand the 
involvement of mistranslation in tumor biology, we expressed mutant Ser-tRNAs that 
misincorporate Ser-at-Ala (frequent error) and Ser-at-Leu (infrequent error) in NIH3T3 
cells. There was high tolerance to both misreading tRNA, but the Ser-to-Ala 
misincorporating tRNA induced high cell transformation capacity, stimulated 
angiogenesis and produced fast growing tumors in mice. Upregulation of the Akt 
pathway and the UPR were also observed. Most surprisingly, the relative expression of 
misreading tRNAs increased during tumor growth, suggesting that mistranslation is 
advantageous to cancer cells. These data highlight new features of protein synthesis in 
tumor biology. 
 
3.2. Introduction  
Cancer is a multifactorial disease driven by the accumulation of DNA mutations, 
chromosomal aberrations and epigenetic alterations 98. Transcriptional, post-
transcriptional and translational deregulation is also well established, however little is 
known about the contribution of translational errors to tumor initiation and growth. 
Eukaryotic cells translate mRNA with average basal error levels of 10−3 to 10−4 amino 
acid misincorporations per codon, resulting in at least one misincorporated amino acid 
in 15% of average length proteins 99–101. Cells cope relatively well with this level of 
aberrant protein synthesis and it is controversial whether such errors play any role in 
cell degeneration, aging or disease 101–104.  
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However, recent mistranslation works in model organisms show that 
translational error rates marginally above the normal background level lead to 
accumulation of misfolded proteins 87,101,105,106, saturation of protein quality control 
(PQC) systems, proteotoxic stress, re-wiring of chaperone-clients interaction networks 
and to wide deregulation of cellular functions 87. Whether mistranslation is elevated and 
produces similar phenotypes in tumors is not yet clear, but translational fidelity depends 
on tight regulation of tRNAs, aminoacyl-tRNA synthetases (aaRSs), RNA modifying 
enzymes (RNAmod), translation elongation factors (eEFs), ribosomal RNA (rRNA) 
processing, ribosome assembly and amino acid supply, which are frequently 
deregulated in tumors 10,12,107–112. Considering the direct impact of mistranslation on 
proteome mutational load and protein stability it is likely that elevation of 
mistransaltion would have significant impact in tumor biology. 
Other indirect links between tRNA deregulation, protein synthesis errors and 
cancer are provided by the activation of the unfolded protein response (UPR) 113. In 
general, mistranslated proteins sequester BiP, activate the UPR sensors PERK, IRE-1 
and ATF6, upregulate molecular chaperones and the ubiquitin-proteasome system. 
Tumor cells highjack these endoplasmic reticulum (ER) adaptive measures to thrive 114, 
explaining, at least in part, the UPR association with malignancy and aggressiveness of 
several types of cancer 69,115,116. 
In this work, we have investigated the relevance of protein mistranslation to 
tumor biology. We show that: 1) tumors mistranslate at higher level than normal tissue; 
2) codon misreading tRNAs are selected during tumor evolution, and; 3) translational 
errors alone increase cell transformation, activate the UPR and promote tumor growth. 
To achieve these results, we have determined the relative level of amino acid 
misincorporations in tumors and engineered NIH3T3 cell lines that misincorporate Ser 
at both Ala (frequent mistranslation event in tumors) and Leu (infrequent mistranslation 
event in tumors) codon sites. In vitro data showed no visible effects on cell viability, but 
cell transformation, angiogenesis, tumor growth, activation of the UPR and other 
cancer-related pathways, were evident in vivo in chicken and mouse models.  
 
3.3. Results 
3.3.1. Tumors mistranslate at higher rates than normal tissues 
To clarify whether translational fidelity is deregulated in tumors, we carried out a 
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detailed analysis of the relative amino acid misincorporation frequencies, in both normal 
and cancer human samples, as well as in mouse xenograft tumors derived from two 
human epithelial cancer cell lines (NCI-H460 and MKN74). For this, we have 
implemented a mass spectrometry data analysis pipeline to identify peptides containing 
amino acid misincorporations in complex MS/MS label free raw data sets of normal 
colon, colon adenocarcinoma (COAD) and xenograft tumor samples. We used MS/MS 
data sets produced by the National Cancer Institute Clinical Proteomic Tumor Analysis 
Consortium (CPTAC) (https://cptac-data-portal.georgetown.edu/cptacPublic/) and our 
own MS/MS data sets produced with xenograft tumors. Normal colon samples were 
randomly selected, while COAD samples were selected to represent advanced stages of 
the disease. All MS/MS datasets were analyzed using the same bioinformatics pipeline.  
We started by analyzing independently the global error rate of normal colon 
samples and tumor samples from COAD patients. The global error rate of normal 
samples was 1.97x10-3  SEM per amino acid decoded, while that of COAD samples 
was 6.49x10-3  SEM, indicating that COAD tumors are 3-fold more prone to 
translational errors than normal tissue. There was high dispersion of error values among 
the COAD samples, probably due to the high heterogeneity in cell type composition of 
tumor tissues, which normally include tumor, stromal, support and immune cells in 
different proportions. To clarify whether tumor cells were the main contributors to the 
global error rate detected, and whether the error values obtained for COAD tumors 
could be extrapolated to other tumors, we determined the error rate of tumors derived 
from two different human cancer cell lines grown in mice, namely MKN-74 (Gastric 
tubular adenocarcinoma) and H460 (Non-Small Cell Lung Cancer), in which more than 
90% of the tumor mass is composed of tumor cells. The mistranslation rate of the 
MKN74-derived tumor was 6.85 x10-3 and that of H460-derived tumors was 7.81 x10-3; 
i.e., 3.4-fold (p<0.05) and 4.2-fold (p<0.01) higher that the average error observed in 
normal tissue samples (Fig.3-1A). We also determined the frequency of 
misincorporation of different amino acids at the protein sites corresponding to each 
codon family and there was a clear error elevation at all but Asn (N) codon family sites 
in COAD samples relative to normal tissue (Fig.3-1B). Interestingly, Asn sites were the 
most error prone sites in both tumors and normal tissue (Fig.3-1B).  
We next analyzed the frequency of specific misincorporations in MKN74- and 
H460-derived tumors where more than 90% of the tumor mass is composed of tumor 
cells. As the complexity of the mistranslation MS/MS data space was very high, we 
3. Codon misreading tRNAs promote tumor growth in mice 
35 
 
focused our efforts on the identification of a sub-group of errors associated with tRNA 
misacylation by Class II aaRS (probable errors) and in errors that cannot be explained 
by tRNA misacylation, near-cognate codon decoding nor other genetic code rules 
(improbable errors). Our expectation was that the theoretically probable errors predicted 
by genetic code rules would occur in proteins at much higher frequency than the 
theoretically improbable errors. We verified that, among errors associated with tRNA 
misacylation by Class II aaRS, Ser misincorporations at Ala codon sites were the most 
frequent errors found in proteins from xenograft tumors (Fig.3-1C). On the other hand, 
misincorporations of Phe at Ser and Ser at Leu codon sites, that do not conform with 
genetic code rules, were present at much lower level in the proteins of our dataset (rare 
misincorporations). These data are in line with previous data showing that 
mistranslation rates are amino acid and codon specific 2,117.  
We then evaluated the relevance of both frequent (probable) and infrequent 
(improbable) errors in cancer. Since evolutionary optimization of the genetic code 
minimizes the impact of mistranslation on protein structure 101, we reasoned that 
theoretically probable misincorporations should be less deleterious (involving 
chemically similar amino acids), than those involving theoretically unlikely errors 
(involving chemically distinct amino acids). To address this hypothesis, we altered the 
anticodon of a Ser-tRNA to produce mutant Ser tRNAs that incorporate Ser at Ala 
(frequent) and Ser at Leu (infrequent) codon sites on a proteome wide scale. The Ser-
tRNA was chosen as proof of concept since its anticodon can be mutated to read 
multiple codons, without affecting its acylation specificity by the SerRS 118.  
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3.3.2. Mammalian cell lines are highly tolerant to codon misreading tRNAs 
We constructed mutant tRNAs that decode Ala-GCU/GCC (tRNASerAla), and 
Leu-CUU/CUC (tRNASerLeu) codons (Fig.3-2A, left panel) as Ser. These Ser 
misincorporating tRNA genes were then cloned into the pIRE1-10-DsRed and were 
transfected into NIH3T3 cells. Cell lines stably expressing the engineered tRNAs and 
the wild-type tRNASerAGA (tRNA
Ser WT) were then selected for phenotypic 
characterization (Fig.3-2A, right panel). Cells transfected with the empty vector 
(Mock) were used as controls. The transfection efficiency was determined by Real-Time 
PCR, using the pIRE1-10 DsRed gene as a readout probe and the data showed 100% 
transfection efficiency for the Mock, tRNASer(WT) and tRNASer(Ala) cell lines, and 
72% for the tRNASer(Leu) cell line. The integration of the misreading tRNA genes in 
the genome of the transfected cells was further confirmed by PCR and Sanger 
sequencing (Fig.3-9A). tRNA expression was determined using a primer extension 
assay (SNaPshot analysis) that permitted the detection of each mutant misreading tRNA 
and also the WT tRNASer gene. The cellular level of the endogenous WT tRNASer was 
19.4-fold higher than the mutant tRNASer(Ala) and 49.5-fold higher than the mutant 
tRNASer(Leu) (Fig.3-2B).  
We used cell viability, proliferation and apoptosis assays to evaluate the 
phenotypic consequences of expression of the mutant misreading tRNAs in the NIH3T3 
Figure 3-1: Tumors mistranslate at higher rates than normal tissue. A) Normal colon samples and 
colon adenocarcinoma (COAD) samples from patients and xenograft tumors derived from two epithelial 
cancer cell lines H460 and MKN74 cell lines were analysed. For each sample we counted the total 
number of mutations in the proteome, obtained using a blind search approach with the SPIDER tool in 
PEAKS8 software against Homo sapiens reference proteome. The misincorporation count was 
normalized for the total number of amino acids in the sample. The data show that these tumors have 
higher error rates, than the normal samples analysed. Data was analysed by two-tailed unpaired Student’s 
t-test. Significant p-values are shown (*p˂0.05; ** p˂0.01). Graphics depicts average +/- SEM (n=3). 
Normal Colon Samples and COAD samples raw MS/MS data was generated by the CPTAC consortium. 
B) Analysis of amino acids misincorporated at protein primary structure sites (codon/amino acid family 
sites) showing that COAD tumors misincorporate higher number of amino acids than the normal samples, 
except for Asparagine site (N) where both normal and tumor tissue misincorporate similar levels of the 
different amino acids. The total number of amino acids misincorporated at each protein site was 
normalized to the total number of peptides present in each sample dataset (proteome space). Letters in the 
X axis represent the 20 amino acids and errors correspond to the total number of non-cognate amino acids 
misincorporated. For example N= total number of Asn sites present in the proteome space that contain at 
least one misincorporation. C) Misincorporations of Serine at Alanine sites were the most frequent found 
in tumor xenograft samples and misincorporations of Serine at Leucine sites were among the least 
common. We determined the number of specific misincorporations and normalized them to the total 
number of peptides present in each sample data set. Graphics B and C depict average +/- SEM (n=3).  
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cells. Trypan Blue staining showed no impact on viability (Fig.3-9B) and the Annexin 
V Apoptosis assay showed a basal necrosis level (≤1% of cells) and low percentage of 
cells in late (ca. 5% of cells) and early apoptosis (7-8% of cells) (Fig.1-2C). Cell 
proliferation was also not significantly affected (Fig.3-9C), and cell cycle progression 
demonstrated a similar pattern in all cell lines (Fig.3-9D), indicating that NIH3T3 cells 
tolerated well the mutant misreading tRNAs. However, these mutant tRNAs increased 
the production of foci in vitro (Fig.3-2D), raising the hypothesis that they have the 
potential to transform NIH3T3 cells. 
 
 
Figure 3-2: In vitro phenotypic effects induced by misreading tRNAs. A) Schematic tRNA model. 
Left panel) The human tRNASerAGA gene (Chr6 tRNA#5), was cloned into pIRES2-DsRed plasmid and 
misreading constructs were generated by site-directed mutagenesis (green: Ala(AGC) and red: 
Leu(AAG)). Domains highlighted in grey are important for tRNASer recognition by SerRS. Right panel) 
Serylated misreading tRNAs misincorporate Ser at the non-cognate codons indicated.  B) Expression of 
misreading tRNAs on stably expressing cells was confirmed using SNaPshot. Samples were sequenced 
and analysed using Peak Scanner software. The endogenous copies of tRNASer were 32 and 49.5-fold 
more expressed than tRNASer(Ala) and tRNASer(Leu) respectively. Grey: Non-mutated Serine tRNA; 
Black: Misreading Serine tRNA. C) Percentage of cells in necrosis, early and late apoptosis were 
determined by flow cytometry using AnnexinV-FITC (1:100) and Propidium iodide (2.5µg/ml) staining. 
D) The number of foci arising from NIH3T3 cells was counted after 13-21 days after transfection. Data 
represents average ± SEM (n=2-3) and was analysed with One-way ANOVA with Dunnett’s post-test 
using Mock cell line as control. There are no significant differences among cell lines (p˃0.05). 
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3.3.3. Phenotypic traits induced by misreading tRNAs are exposed by cancer 
microenvironment stimuli. 
Previous works carried out in our laboratory, using yeast as a mistranslation 
model,  showed that mistranslation is mostly deleterious under normal growth 
conditions, but can be advantageous if cells are exposed to environmental stress 119. 
Since both the mutant misreading and the WT tRNASer were well tolerated and did not 
produce advantageous or deleterious phenotypes in vitro, we reasoned that external 
stimuli could be necessary to reveal putative phenotypic variation. To clarify this issue, 
we exposed the NIH3T3 cell lines expressing Mock, tRNASer(WT) and the mutant 
misreading tRNAs to the pro-inflammatory tumor necrosis factor alpha (TNF-α) for 
different time periods, and used Akt and p38 phosphorylation as phenotypic readouts 
(Akt-P/Akt and p38-P/p38) (Figs.3-3 and 3-10). The p38 pathway was activated in 
tRNASer(Leu) cells after 30 minutes and persisted up to 4 hours of exposure (3.43 and 
2.1-fold change, respectively). A slight activation was also observed in tRNASer(Ala) 
expressing cells at 30 minutes, but was lost after 4h (Fig.3-3). The Akt pathway was 
only significantly activated in tRNASer(Ala) expressing cells after 30 minutes (2.6-fold 
change) (Fig.3-3A). This responsiveness to external stimuli and the tendency to increase 
transformation ability in vitro, lead us to hypothesize that cells expressing misreading 
tRNAs could have a growth advantage if inoculated in vivo. 
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3.3.4. Expression of misreading tRNAs promotes tumor growth in vivo 
 We tested the behavior of the cells expressing the mutant misreading tRNAs in 
the in vivo chick chorioallantoic membrane assay (CAM) and took particular attention 
Figure 3-3: Pathways activated by TNFα induction. A) Treatment of cells misexpressing the 
tRNASer(WT) and misreading tRNAs with TNFα (30ng/ml) for 30 minutes. Upper panel) Relative 
activation ratios of p38 in cell lines exposed to TNFα. Middle panel) Relative activation ratios of Akt in 
cell lines exposed to TNFα. Lower panel) Representative immunoblots of p38-P, total p38, Akt-P and 
total Akt in cell lines. β-tubulin was used as a loading control. B) Treatment of misexpressing 
tRNASer(WT) and misreading tRNAs expressing cell lines with TNFα (30ng/ml) for 4 hours. Upper 
panel) Relative activation ratios of p38 in cell lines exposed to TNFα. Middle panel) Relative activation 
ratios of Akt in cell lines exposed to TNFα. Lower panel) Representative Immunoblots of p38-P, total 
p38, Akt-P and total Akt in cells lines. β-tubulin was used as a loading control. Data represents average ± 
SEM (n=3) and was analysed using One-way ANOVA with Dunnett’s post-test and relevant p-values are 
displayed (*p˂0.05; **p<0.01). 
3. Codon misreading tRNAs promote tumor growth in mice 
41 
 
to their effect in angiogenesis and growth (tumorigenic potential) relative to Mock cells. 
Only cells expressing tRNASerAla produced larger tumors and had stronger angiogenic 
response in the CAM assay (Fig.3-4A). These results were further confirmed by 
inoculating cells expressing tRNASer(WT), tRNASer(Ala), tRNASer(Leu) or K-rasV12 on 
the left dorsal flank of at least five mice (for each cell line) and control cells (Mock) on 
the corresponding right dorsal flank of every mice. Within 14 to 21 days post-
inoculation (p.i.), tumors were produced by cells expressing K-rasV12 (5/5 mice), 
tRNASer(Ala) (6/6 mice) and tRNASer(Leu) (5/5 mice) (Fig.3-4B, upper panel). At day 
27 p.i., 12/21 (57.1%) mice inoculated with Mock cells and 5/5 mice inoculated with 
tRNASer(WT) cells developed equivalent smaller sized tumors. At this stage (day 27 
p.i.), tumors produced by cells expressing tRNASer(Ala) were the largest. At day 31 p.i., 
the experiment was terminated; tRNASer(Ala) and K-rasV12 tumors were similar in size 
distribution and were statistically different from Mock tumors (p<0.01) (Fig.3-4B, 
upper and middle panel). Therefore, the mutant tRNASer(Ala) accelerated significantly 
tumor growth, while Ser misincorpoartion at Leu codons and misexpression of WT 
tRNASer  resulted in tumors that were marginally larger than those produced by control 
Mock cells. 
Histological characterization of resected tumors unveiled high grade sarcomas 
with high proliferative index, as determined by Ki67 labeling (Fig.3-4B, lower panel, 
Fig.3-11C). Histopathological analysis of murine organs (ganglion, lung, kidney, liver, 
bladder, pleura and stomach), collected at day 31 p.i., revealed the presence of lung 
metastases in K-rasV12 expressing tumors, and no metastases in all other mice.  
DNA extracted from tumors, from both CAM and mice experiments, was 
sequenced and genomic incorporation of all plasmids was validated (Fig.3-11A,B). 
tRNA expression in mice tumors was determined using the primer extension assay 
described above. Surprisingly, expression levels of misreading tRNAs was much higher 
in tumors than in the corresponding cell lines, i.e., 8- and 8.4-fold higher for the 
tRNASer(Ala) and tRNASer(Leu), respectively when compared to the endogenous WT 
tRNA genes (Fig.3-4C). In other words, expression of misreading tRNAs increased 
during tumor evolution, suggesting that codon misreading is advantageous for tumor 
cells growing in vivo (Fig.3-2B,4C). 
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To confirm that the mutant misreading tRNAs mediated the elevation of Ser 
misincorporation into proteins, we analyzed the soluble protein fraction (SF) of tumors 
derived from our cell lines, resourcing to the MS/MS data analysis approaches used 
before. To further validate our methodology, we investigated whether Ser was 
Figure 3-4: Impact of mistranslation on angiogenesis and tumor formation in vivo. A) CAM assay. 
Upper panel) Representative images of tumors and vessels produced by cell lines expressing Mock, 
tRNASer(Ala), tRNASer(Leu) and misexpressing tRNASer(WT). Lower panel, left) Quantitative evaluation 
of new vessels’ formation. Lower panel, right) Relative tumor area. Data is presented as the percentage 
relative to Mock. Graphics depict average ± SEM (n=12-14). Data was analysed by two-tailed paired 
Student’s t test (*p˂0.05; **p<0.01). B) Tumorigenic capacity of misreading tRNAs in mice. Upper 
panel) Kinetics of tumor growth determined after inoculation of cells expressing Mock plasmid, the 
tRNASer(WT), tRNASer(Ala), tRNASer(Leu) and K-rasV12 (positive control) constructs. Middle panel) 
Quantitative evaluation of tumor area at 31 days p.i.. Graphics depict the average ± SEM (n=5-10). Data 
was analysed by One-way ANOVA with Dunnett’s post-test (**p˂0.01; ***p<0.001). Lower panel) 
Photographs of representative tumors, H&E and Ki67 staining (40x amplification) from each condition. 
C) Expression of misreading tRNAs in mice tumors measured by SNaPshot. Samples were sequenced 
and analysed using Peak Scanner software. Expression of the misreading tRNASer(Ala) and tRNASer(Leu) 
were 4 and 5.9-fold lower than the endogenous tRNASer, respectively. Grey: Non-mutated Serine tRNA; 
Black: Misreading Serine tRNA. 
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misincorporated at the codon sites decoded by our mutant tRNAs. As theoretically 
expected, the data confirmed the increase in the incorporation of Ser at Ala sites (GCU 
codon) in the cell line containing the misreading tRNASer(Ala) (Fig.3-5, Upper panel). 
But, we could only detect a small increase of Ser-to-Leu misincorporation at the near-
cognate codon CUC. Since Ser (polar amino acid) misincorporation at Leu sites 
(hydrophobic amino acid) is much more disruptive to protein structure than Ser-to-Ala 
mutations, we postulate that Ser-Leu mistranslated proteins are mainly degraded by the 
proteasome, making it harder to detect Ser-to-Leu misincorporations by MS/MS (Fig.3-
5, Lower panel).  The inability to detect Ser-to-Leu mutations at the CUU cognate 
codon may be related to differences in Leu tRNA isoacceptor abundances and codon 
usage in the human transcriptome. Indeed, the CUC codon has no specific isoacceptor 
tRNA to decode it and is read by the near cognate tRNA isoacceptor that decodes the 
CUU codon. It is also used more frequently than the CUU codon 
(http://www.kazusa.or.jp/codon/). In other words, the mutant misreading Ser-tRNA may 
read the CUC codon more frequently than the CUU codon. Interestingly, the G-ending 
Leu CUG and UUG codon are much more prone to translational error than the CUU or 
CUC codons (Fig.3-5, lower panel), but the reasons for such differences in translational 
accuracy need to be clarified in future studies. 
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3.3.5. Expression of misreading tRNAs activates the UPR 
Since the UPR is frequently activated in cancer and is also an endpoint of 
protein mistranslation 87,120, we have tested whether it was also activated in our models. 
For this, we monitored the three UPR branches: IRE-1, PERK and ATF6. Activation of 
the IRE-1 pathway was evaluated by determining splicing levels of the XBP-1 
transcription factor, using RT-PCR. The data showed activation of the IRE-1 pathway 
by 7% and 14% in tumors expressing tRNASer(Ala) and tRNASer(Leu), respectively 
(Fig.3-12). ATF6 activation was higher in tumors expressing tRNASer(Ala) and the 
Figure 3-5: Misreading tRNAs misincorporate Ser at Ala and Leu codon sites. Upper Panel) 
Graphic depicts the absolute number of misincorporations of Ser detected at Ala sites in the soluble 
fraction of proteins extracted from tumors derived from our cell lines. There was a relative increase in the 
incorporation of Ser at Ala sites in the cell line expressing the misreading tRNASer(Ala) at the cognate 
codon GCT only. tRNASer(Leu) expressing cell line was used as a negative control to show that the 
increase in misincorporations is induced by tRNASer(Ala). Lower Panel) Graphic depicts the absolute 
number of misincorporations of Ser detected at Leu sites in the soluble fraction of proteins extracted from 
tumors derived from our cell lines. We detected an increase of Ser to Leu misincorporations at the near-
cognate codon CTC. tRNASer(Ala) expressing cell line was used as a negative control to show that the 
increase in misincorporations is induced by tRNASer(Leu). 
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tRNASer(WT) than in Mock tumors (3.1- and 2.15-fold, respectively) (Fig.3-6A,C). We 
next assessed the phosphorylation status of eIF2α, the downstream target of PERK, to 
confirm UPR activation and also to clarify whether these tRNAs affected translation 
initiation rate. The levels of eIF2α-P (the inactive form of eIF2α) were 77% lower in 
tRNASer(Ala) tumors relative to Mock controls, and did not change in other tumors 
(Fig.3-6B,C), raising the hypothesis that PERK could be downregulated or that the 
catalytic subunit of the PP1α phosphatase could be upregulated. Western blot analysis 
showed 6-fold upregulation of the PP1α catalytic subunit (Fig.3-6B,C), indicating that 
the fast growth rate of tRNASer(Ala) tumors was likely due to upregulation of protein 
synthesis rate, through dephosphorylation of eIF2α by the PP1α-GADD34 phosphatase 
complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-6: Activation of the UPR by misreading tRNAs in vivo. A) Activation of ATF6 in tumors 
harbouring the wild-type and misreading tRNAs. Total ATF6 and ATF6 fragment were detected by 
immunoblotting. B) eIF2α-P and PP1Α catalytic subunit levels in each tumor lysate were analysed by 
immunoblotting and relative expression values are shown. β-tubulin levels served as protein loading 
control. C) Representative immunoblots for total ATF6, ATF6 fragment, total eiF2α, eIF2α-P, PP1α 
catalytic subunit and β-tubulin for each membrane. Graphics depict average ± SEM (n=3). Data was 
analysed by One-way ANOVA with Dunnett’s post-test and significant p-values are shown (*p˂0.05; 
***p<0.001).  
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3.3.6. Expression of misreading tRNAs influences cancer-associated signaling 
pathways 
Serine, Threonine and Tyrosine tRNAs are among the most overexpressed 
tRNAs in breast cancer 10. The respective amino acids can be phosphorylated and their 
misincorporation at non-cognate sites may cause aberrant phosphorylation and 
alteration of signaling transduction pathways 10. This lead us to hypothesize that the 
Ras/Raf/MEK/ERK and the Ras/PI3K/PTEN/Akt signaling pathways could be affected 
in our model of Ser misincorporation, promoting unrestrained cellular growth, 
proliferation and tumor formation 121. Indeed, global Ser phosphorylation was increased 
in tRNASer(Ala) and tRNASer(Leu) expressing tumors (1.53 and 1.71-fold, respectively) 
(Fig.3-7A), confirming that cell signaling could be deregulated. We then analyzed the 
activation of Akt, ERK1/2 and p38 in the same tumors and observed activation of the 
Akt pathway in all tRNA misreading tumors (Fig.3-7B) and downregulation of the 
ERK1 (64%) and ERK2 (54%) pathways in tumors expressing tRNASer(Leu) (Fig.3-
13A,C). p38 was downregulated 82% in tRNASer(WT) relative to Mock, but was 
unchanged in the other tumors (Fig.3-13B,C). Therefore, tumorigenesis induced by 
misreading tRNAs is likely associated with activation of the Akt pathway, while growth 
rate differences between tumors could be linked to differential activation of the ERK1/2 
pathways.  
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3.4. Discussion 
Imbalance of tRNA pools promotes the formation of non-cognate tRNA-aaRS 
pairs and tRNA mischarging 122. Pavon et al. reported increased expression of certain 
tRNAs associated with malignant phenotypes and Gingold et al. reported enrichment of 
tRNAs required for fast translation of proliferation genes in cancer 10–12, suggesting that 
protein synthesis accuracy could be deregulated in tumors. Since mistranslation impacts 
proteostasis and produces important phenotypic diversification, drug tolerance and 
resistance in other biological models 85,123,124, we have hypothesized that it may also 
interfere with tumor growth, heterogeneity and response to therapy. In this first attempt 
to tackle these issues, we have expressed mutant misreading tRNAs that recapitulate 
both frequent and rare amino acid misincorporations detected in tumors of human 
patients and in near-normal NIH3T3 cell lines.  
Figure 3-7: Classical cancer-associated pathways activated in mice tumors. A) Evaluation of total 
phosphoserine levels in tissue lysates from mice tumors. B) Relative activation ratio of Akt in tumor 
lysates compared to the Mock and representative immunoblots of Akt-P, total Akt and β-tubulin (loading 
control) from tumor lysates. Graphics depict average ± SEM (n=3). Data was analysed by One-way 
ANOVA with Dunnett’s post-test and significant p-values are shown (*p˂0.05; **p<0.01). 
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Our mutant misreading tRNAs were well tolerated in vitro and did not produce 
visible effects on cell viability, apoptosis, proliferation and cell cycle progression, but 
induced foci formation, promoted angiogenesis and tumor growth in vivo. In particular, 
the mutant misreading tRNA that misincorporated Ser at Ala codon sites (tRNASerAla), 
produced tumors that grew as fast as K-rasV12 tumors in nude mice. Previous studies 
have shown that Ser misincorporation at Ala codon sites, due to an inactivating 
mutation of the editing site of the AlaRS, induces rapid loss of purkinge cells, ataxia 
and premature death in mice 5, contradicting our tumor results. Therefore, it is likely 
that tRNA misreading effects are cell type dependent, i.e., they may lead to apoptosis in 
purkinge cells and to transformation and neoplasia in other cell types.  
The selection and increased expression of the mutant misreading tRNAs in mice 
tumors (Fig.3-4C) indicates that tRNA misreading is adaptive in tumor contexts and 
depends on the tumor microenvironment. These data are in agreement with previous 
works showing that mistranslation increases yeast tolerance to stress and allows for 
growth in the presence of lethal doses of drugs and chemicals 81,82. Yeast mistranslating 
cells adapt to the deleterious effects of mistranslation by altering genomic architecture, 
increasing protein synthesis, protein degradation and glucose uptake rates 106. In other 
words, the deleterious effects of tRNA misreading are rapidly mitigated through 
genomic, metabolic and proteomic changes, raising the hypothesis that mistranslation 
may have consequences for tumor biology that go beyond the expected proteome 
instability.  
The impressive growth rate of the tumors expressing the tRNASer(Ala) is likely 
due to decreased levels of eIF2α-P (Fig.3-6B) since the relative increase of eIF2α levels 
alone is sufficient to transform NIH3T3 cells 125. This requires up-regulation of the 
PP1α catalytic activity by cancer signaling pathways, namely the MAPK pathway or 
recruitment of active PP1α to its eIF2α-P substrate by the regulatory subunit GADD34 
66,126. Since there was no difference in the activation status of the ERK1/2 downstream 
effectors of the MAPK it is likely that eIF2α-P dephosphorylation is mediated by the 
UPR through activation of the ATF4 transcription factor which upregulates GADD34.  
The observed activation of the other UPR mediators ATF6 and IRE-1 may also 
contribute to that fast growth of those tumors as they are associated with cellular 
protection and growth stimulation  115,127,128. Moreover, UPR coupled with induced 
tumor dormancy protects neoplasic cells from apoptosis and permits recurrence once 
favorable growth conditions are restored 129.  
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It is well established that tumor development needs genetic and epigenetic 
changes as well as cooperation of microenvironment components to promote adaptation 
and growth 130. Common adaptive responses include enhanced plasticity, cell motility, 
resistance to apoptosis and survival in hostile environments where hypoxia, acidity, 
amino acid deprivation, inflammatory cytokines and induction of the UPR are common 
131,132. Importantly, PERK activity and eIF2α-P levels are reduced in mouse breast 
tumors, where Akt is activated 133. In line with these results, tumors expressing both 
types of misreading tRNAs showed concomitant activation of the Akt pathway and 
UPR induction. We postulate that this conjugation of factors may drive apoptosis 
evasion, cell survival and potentiation of tumor growth (Fig.3-8). 
 
Although remarkable progress has been made on the elucidation of the 
molecular basis of cancer, the etiology of most cancers is still unknown. In the past few 
years, new molecular links between cancer and translation deregulation have been 
unraveled, highlighting this setting as etiopathogenic 134. Our model supports and 
Figure 3-8: Representation of the stress response induced by misreading tRNAs. The mutant misreading 
tRNAs expressed in NIH3T3 cells exposed to microenvironment stimuli in vivo induce ER stress and 
activation of the Akt pathway. These events lead to UPR activation, increasing the cells capacity to survive, 
evade apoptosis and upregulate protein synthesis, especially in tRNASer(Ala) expressing cells where eIF2α-P 
is downregulated by upregulation of PP1α catalytic subunit. Overall these molecular mechanisms accelerate 
in tumor growth. Adapted from Servier Medical Art collection (http://www.servier.com). 
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extends this link by disclosing unexpected selection and up-regulation of mutant 
misreading tRNAs in tumors and that mistranslation alone is sufficient to accelerate 
tumor growth. It will be fascinating to clarify in future studies if the proteome instability 
and heterogeneity produced by mistranslation generates tumor heterogeneity and 
increases resistance to anti-cancer drugs, as is the case in yeast. 
 
3.5. Materials and Methods 
3.5.1. Construction of misreading tRNA plasmids 
A DNA fragment of 248kb corresponding to part of the gene encoding human 
wild type tRNASerAGA (Chr6 tRNA#5) and it’s flanking region were amplified by 
PCR from genomic DNA using the primers: forward 5’- 
GCCGAATTCAGCTATTATTAAATCCCTAATAAAAGG-3’ and reverse 5’-
CGCCTCGAGTTGTAAAAGATCGAAAGCCTTTTTA-3’. The amplified region has 
the sequence: 5’-
AGCTATTATTAAATCCCTAATAAAAGGAGTACAATATGTGATGTATGGAAA
CATGTAAGACATTTAATAAGGTTTTTGGTATCTGTAGTCGTGGCCGAGTGGT
TAAGGCGATGGACTAGAAATCCATTGGGGTCTCCCCGCGCAGGTTCGAATC
CTGCCGACTACGGCAGTGGGTTTTTGCATCTTCAAGCAGGTTTCATCCGACC
GATCGATATTTCACGTGTAAAAAGGCTTTCGATCTTTTACAA-3’. The 
amplified region was cloned into modified vector pIRE1-10-DsRed with new MCS, 
using the enzymes EcoRI (Thermo Scientific,#ER0275), XhoI (Thermo 
Scientific,#ER0695) and T4 DNA ligase (Thermo Scientific,#EL0011). Site-directed 
mutagenesis was carried out to change the anticodon of the tRNASerAGA by other 
anticodons. The primers used for site-directed mutagenesis of human tRNASerAGA 
were the following: forward to tRNASerAAG(Leu) 5’-
GGTTAAGGCGATGGACTAAGAATCCATTGGGGTCTCCC-3’; reverse to 
tRNASerAAG(Leu) 5’-
GGGAGACCCCAATGGATTCTTAGTCCATCGCCTTAACC-3’; forward to 
tRNASerAGC(Ala) 5’-GTTAAGGCGATGGACTAGCAATCCATTGGGGTCTCCC-
3’; and reverse to  tRNASerAGC(Ala) 5’-
GGGAGACCCCAATGGATTGCTAGTCCATCGCCTTAAC-3’. 
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3.5.2. Cell culture 
Mouse Embryo Fibroblast cell line (NIH3T3) was obtained from the American 
Type Culture Collection (ATCC® CRL-1658™). The cell line was grown in DMEM 
(Gibco,#11965092) supplemented with 10% fetal bovine serum (FBS; 
Hyclone,#SH30088.03HI) and 1% penicillin–streptomycin (Invitrogen,#15140122) in a 
humidified atmosphere at 37ºC in the presence of 5% CO2. 
 
3.5.3. Generation of mistranslating cell lines 
Cells with 60–80% confluency were transfected with 1µg DNA of plasmid using 
Lipofectamine 2000 (Invitrogen,#11668019), following the manufacturer’s instructions. 
Stably transfected cell lines were established with 1000 µg/ml G418, after 72 h 
transfection, for 1 month before being used to perform assays. Cells were transfected 
with the empty vector (Mock) or the plasmid containing the wild type tRNASerAGA 
(WT) or the misreading tRNAs: tRNASerAGC(Ala) and tRNASerAAG(Leu). 
 
3.5.4. Polymerase chain reaction analysis 
To prove the incorporation of the plasmid in the generated cell lines, genomic 
DNA was used as template for PCR amplification across the fragment of pIRE1-10-
DsRed plasmid containing the tRNA insert. Primers used were: 5’-
CAATACGCCCGCGTTTCTT-3’ and 5’-TTATCCAAAAAGGATCTTCACCTAGA-
3’.   PCR conditions were: 95°C for 15 min; 95°C for 30 sec; 54°C for 1min 30 sec; 
72°C for 1 min 30 sec with 35 cycles of amplification and a final step of extension at 
72°C for 10 min. A 297 bp amplicon was generated, which corresponds to part of the 
pIRE1-10-DsRed vector without the tRNA insert (Mock) and a 547 bp amplicon, which 
corresponds to part of the pIRE1-10-DsRed plasmid with the tRNA inserted 
[tRNASer(WT), tRNASer(Ala) and tRNASer(Leu)]. We analyzed the PCR product in a 
1% agarose gel and PCR product was analyzed via Sanger sequencing (Supplementary 
figure 1). This technique was also performed using genomic DNA extracted from the 
tumors to prove that our cells were indeed the origin of the tumor. 
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3.5.5. Confirmation of misreading tRNA expression in cell lines and tumors 
The RNA extraction was followed by purification with the standard protocol of 
DNaseI Amplification Grade kit (Invitrogen,#18068015). RNA was then precipitated 
with a standard Phenol/Chlorophorm extraction and conserved at -80ºC. cDNA was 
obtained with Ncode™ VI20™ miRNA cDNA synthesis kit (Invitrogen,#A11193050), 
using 200ng of RNA. Amplification of the cDNA or DNA of interest was done by PCR 
with the following primers: 5’-CGTAGTCGGCAGGATTCGAA-3’ and 5’-
GTCGTGGCCGAGTGGTTAAG-3’. PCR conditions were: 95ºC for 15min, (95ºC for 
30 sec, 62ºC for 1 min and 30 sec, 72ºC for 1 min and 30 sec, 3 cycles) (95ºC for 30 
sec, 60ºC for 1 min and 30 sec, 72ºC for 1 min and 30 sec, 3 cycles); (95ºC for 30 sec, 
58ºC for 1 min and 30 sec, 72ºC for 1 min and 30 sec, 30 cycles) and a final step of 
extension at 72°C for 10 min.  Due to the similarity among serine tRNA bodies, our 
primers will not only amplify the recombinant tRNAs, but also other endogenous copies 
of serine tRNAs (tRNA-Ser-AGA-2-6; tRNA-Ser-AGA-2-5; tRNA-Ser-AGA-2-4; 
tRNA-Ser-AGA-2-3; tRNA-Ser-AGA-2-2; tRNA-Ser-AGA-2-1; tRNA-Ser-TGA-2-2 
and tRNA-Ser-TGA-2-1 isoforms). PCR product was run on a 2% agarose gel and the 
band (~90bp) was excised and purified using Ilustra™ GFX™ PCR DNA and Gel Band 
Purification Kit (GE,#28-9034-71). Reamplification of the fragment was performed 
using the same primers used before and PCR conditions were: 95ºC for 15min, (95ºC 
for 30 sec, 62ºC for 1 min and 30 sec, 72ºC for 1 min and 30 sec, 3 cycles) (95ºC for 30 
sec, 60ºC for 1 min and 30 sec, 72ºC for 1 min and 30 sec, 3 cycles); (95ºC for 30 sec, 
58ºC for 1 min and 30 sec, 72ºC for 1 min and 30 sec, 25 cycles) and a final step of 
extension at 72°C for 10 min.  3 µl of PCR product were run on a 2% agarose gel to 
confirm the presence of just one band and 10 µl of the product were purified with 1µl of 
ExoI (Thermo Scientific,#EN0581) and 1µl of FastAp (Thermo Scientific,#EF0651) for 
1 hour at 37ºC and 15 min at 85ºC. SNaPshot reaction was performed with the 
following primer: 5’-GGGAGACCCCAATGGATT-3’ and using SNaPshot Multiplex 
Ready Reaction Mix (Applied Biosystems,#4323151). The reaction was preformed with 
the following temperature cycles: 96ºC for 10 sec, 54ºC for 5 seconds and 60ºC for 30 
sec, 15 cycles. The snapshot product was purified adding 1µL of FastAp (Thermo 
Scientific,#EF0651) and the samples were incubated for 1h at 37ºC and 85ºC for 15 min 
(inactivation step). Samples were then sequenced and analysed on Peak Scanner 
software (Applied Biosystems,#4381867). 
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3.5.6. Viability and proliferation cell assays 
To measure cell viability, 1x106 stable cells were plated in T25 cm2 flasks in the 
presence 1000 µg/ml G418 for 48 h. Number of viable cells was counted after trypan 
blue staining (0.4%) (Gibco,#15250061). 
To access cell proliferation, 2x105 stable cells were plated in the presence 1000 
µg/ml G418 in 6-well plates containing 10 mm cover slips for 48 h and incubated with 
Bromodeoxyuridine (BrdU) for 1 h. Afterwards, medium was aspirated and cells were 
washed twice with PBS and fixed with paraformaldehyde 4% for 30 min and then 
stored in 4ºC until used. On the day of analysis, cover slips were washed three times 
with PBS, treated with HCl 2M for 20 min at room temperature and washed again twice 
with PBS and twice with PBS-0.5%-Tween 20-0.05% BSA. Subsequently, cover slips 
were incubated with 1:10 mouse anti-BrdU (Roche,#11170376001) and 1:500 goat anti-
mouse Ig Alexa Fluor 488 (Invitrogen,#A-11001). Fluorescence images were digitally 
recorded in 5 randomly chosen fields (200x magnification) and positive cells were 
scored. Total number of cells was counted by staining with DAPI. 
For cell-cycle analysis, stable cells were plated at a density of 105 cells in 6-well 
plates and cultured for 48h before in the presence 1000 µg/ml G418, washed twice in 
PBS and harvested with trypsin (Gibco,#25200056). Cells were centrifuged at 1200 rpm 
for 5 min, washed three times in PBS, and then fixed by adding 2 ml of ice-cold 
absolute ethanol in a drop-wise fashion, with gentle agitation. Cells were stored at 4ºC 
in the dark until used. On the day of analysis, fixed cells were washed once with PBS, 
re-suspended in RNase A (Sigma, 100 mg/ml) and propidium iodide (PI; Sigma,1 
mg/ml,#P4864), and incubated in the dark at room temperature for 15 min before flow 
cytometry analysis (BD Immunocytometry Systems FACS Calibur). 
For cell death assay, cells were seeded in the presence 1000 µg/ml G418 in 6-
wells plates, at a final concentration of 1x105cells/ml, for 24h. The procedure up to the 
centrifugation step of the cell suspension was the same as in the cell cycle analysis. 
After the centrifugation, the supernatant was discharged, and cells were resuspended in 
500μl of 1x binding buffer. After, 1:100 of Annexin V-FITC and 2.5 µg/ml of 
propidium iodide (Invitrogen) were added, and the cells were incubated for 5 minutes at 
room temperature in the dark. Then, the cells were analyzed by flow cytometry (BD 
Immunocytometry Systems FACS Calibur). All flow cytometry results were analyzed 
using the FlowJo software. 
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3.5.7. Focus formation assay 
Low-passage NIH3T3 cells seeded on 6-well plates at 60%–80% confluence 
were transfected using Lipofectamine 2000 (Invitrogen) with a total of 1 µg of plasmid 
DNA, according to the manufacturer’s instructions. Seventy-two hours later, cells were 
trypsinized, and 1x105 cells were plated in three 100mm dishes and maintained in 
DMEM plus 5% (v/v) FBS (Hyclone) and 1% penicillin–streptomycin (Invitrogen). The 
medium was renewed every 3 days thereafter. After 13 (for the cells expressing the K-
RasV12 vector) and 21 days (for the cells expressing our vectors), cells were fixed with 
ice-cold methanol and stained with 0.5% crystal violet in methanol to count the foci and 
photograph the dishes. The pEGFP vector containing K-RasV12 was used as positive 
control 1. The results were confirmed by two independent experiments. 
 
3.5.8. TNFα induction assay 
3.45 x 105 cells were plated in 6-well plates the day before the induction. Cells 
were then incubated with 30ng/ml for 30 minutes and 4 hours. The concentration of 
TNFα (PeproTech,#300-01A) as well as time points were chosen according to 
information in literature and previous protocol optimization [4,5]. After incubation cells 
were recovered for protein extraction.  
 
3.5.9. Chick embryo CAM assay 
The chicken embryo chorioallantoic membrane (CAM) model was used to 
evaluate the angiogenic response and growth capability of cells containing the empty 
vector (Mock) in comparison with tRNASer(WT) and misreading tRNASer(Ala) and 
tRNASer(Leu) expressing cells. Briefly, fertilized chick (Gallus gallus) eggs obtained 
from commercial sources were incubated horizontally at 37.8°C in a humidified 
atmosphere and referred to embryonic day (E). On E3 a square window was opened in 
the shell after removal of 1.5-2ml of albumin to allow detachment of the developing 
CAM. The window was sealed with a transparent adhesive tape and the eggs returned to 
the incubator. Cells, re-suspended in 10µl of complete medium, were placed on top of 
E10 growing CAM (1x106 cells per ring) into 3mm nylon rings under sterile conditions. 
Two rings were placed in each CAM, one was filed with Mock cell suspension and the 
second with one of the tRNA’s transfected cells (WT, Ala or Leu; N=14 for each paired 
group). The eggs were re-sealed and returned to the incubator for additional 3 days 
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incubation. After removing the rings, the CAM was excised from the embryos and 
photographed ex ovo under a stereoscope (Olympus, SZX16 coupled with a DP71 
camera) at 20x magnification. The number of new vessels (with less than 15 µm 
diameter) growing radially towards the ring area was counted in a blind fashion manner. 
The area of CAM tumors was determined using the Cell A (Olympus) program. Some 
of the tumors were frozen in liquid nitrogen and stored at –80ºC until used. 
A two-tailored paired Student's t test (for samples with unequal variance) was 
used to calculate significance in an interval of 95% confidence level (values of p<0.05 
were considered to be statistically significant) between each group (tRNASer(WT), 
tRNASer(Ala), tRNASer(Leu)) and their respective control (Mock). 
 
3.5.10. Tumor induction assay 
Six-week-old male N:NIH(s)II:nu/nu nude mice were obtained previously from 
the Medical School, University of Cape Town in 1991 and then reproduced, maintained 
and housed at IPATIMUP Animal House at the Medical Faculty of the University of 
Porto, in a pathogen-free environment under controlled conditions of light and 
humidity. Male nude mice, aged 6-8 weeks, were used for in vivo experiments. Animal 
experiments were carried out in accordance with the Guidelines for the Care and Use of 
Laboratory Animals, directive 2010/63/EU.  To measure tumorigenic potential in vivo, 
NIH3T3 cell lines harboring the empty vector (Mock), the tRNASer(WT) and the 
misreading tRNASer(Ala) and tRNASer(Leu) were subcutaneously injected in the 
dorsal flanks using a 25-gauge needle with 1x106 of each cell line. A total of 5 mice per 
group were used.  Each mouse was injected in the right flank with the Mock variant and 
in the left flank with the cells misexpressing the Wt variant or misreading variants of 
each previously described clone. Mice were weighed, and tumor width and length were 
measured with calipers three times per week. Tumor volumes were calculated assuming 
ellipsoid growth patterns. Mice were humanely euthanized when tumors reached a 
median volume of 2000-4000mm3 or whenever any signs of disease were detected. Due 
to exponential pattern of growth some mice had larger tumors as seen on Fig.3B. 
Tumors, lungs, liver, kidney, bladder, stomach, pleura and lymph nodes were collected, 
fixed in 10% buffered formalin, paraffin embedded and then sectioned for 
histopathological examination. A part of each tumor was frozen in liquid nitrogen for 
microarray analysis and stored at –80ºC until used. 
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3.5.11. RNA and DNA isolation 
Total RNA was isolated from mouse frozen tumors and genomic DNA was 
extracted from mouse and CAM frozen tumors and stable cell lines using the AllPrep 
DNA/RNA/Protein Mini Kit (Qiagen,#8004) according to the manufacturer’s protocol. 
RNA quantity and integrity were assessed using the Nanodrop 1000 Spectrophotometer 
(Thermo Scientific) and Agilent 2100 bioanalyser system, respectively. Total RNA 
fraction was used to determine its RIN, which were in the range of 7.5 to 10. DNA 
quantity and integrity were assessed using Nanodrop 1000 Spectrophotometer and 
agarose gel, respectively. 
 
3.5.12. Isolation of protein fractions for mass spectrometry analysis 
25 mg of tumor tissue (H460-, MKN74-, and NIH3T3-derived tumors) were 
homogenized in Protein Lysis Buffer (0.5% Triton X-100, 50mM HEPES, 250mM 
NaCl, 1mM DTT, 1mM NaF, 2mM EDTA, 1mM EGTA, 1mM PMSF, 1mM Na3VO4 
supplemented with a cocktail of protease inhibitors (Complete, EDTA-free, Roche). 
Cells were sonicated with a probe sonicator in 5 pulses of 5 seconds, incubated on ice 
for 30min and centrifuged at 5000rpm for 15min at 4ºC. 10µL of the supernatant (total 
protein fraction) were stored to measure protein concentration with BCA assay (Thermo 
Fisher Scientific). 300µg of total protein were centrifuged again at 12000rpm for 20min 
at 4ºC to isolate the Soluble Fraction of the protein extract present in the supernatant. 
The supernatant was concentrated under vacuum (SpeedVac®, Thermo Savant, USA) 
until a volume of 20µL was reached. The total volume was then resolved in a 10% SDS-
PAGE gel. 
 
3.5.13. Protein identification and characterization by mass spectrometry  
Complete lanes of were manually cut out of the SDS-PAGE gel and sliced into 8 
sections, destained with 25 mM ammonium bicarbonate/50% acetonitrile and dried 
under vacuum (SpeedVac®, Thermo Savant, USA). The dried gel pieces were 
rehydrated with 25 μL of 10 µg/mL trypsin (Promega V5111) in 50 mM ammonium 
bicarbonate and digested overnight at 37 °C. Tryptic peptides were extracted from the 
gel with 10% formic acid/ 50% acetonitrile and were then dried in a vacuum 
concentrator and re-suspended in 10 µL of a 50% acetonitrile/0.1% formic acid 
solution. Separation of tryptic peptides by nano-HPLC was performed on the module 
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separation Proexeon EASY-nLC 1000 from Thermo equipped with a 50-cm EASY C18 
column with particle size 2-µm.  Each sample was separated over a gradient of 5-32 % 
ACN in 90 at 250 nl/min. Peptide cations were converted to gas-phase ions by 
electrospray ionization and analyzed on a Thermo Orbitrap Fusion Lumos mass 
spectrometer. Precursor scans were performed from 300 to 1,500 m/z at 120K 
resolution (at 445 m/z) using a 1 x 105  AGC target. Precursors selected for tandem MS 
were isolated at 1 Th with the quadrupole, fragmented by HCD with a normalized 
collision energy of 30, and analyzed using rapid scan in the ion trap. The maximum 
injection time for M1-10 analysis was 50 ms, with an AGC target of 1 x 104. Precursors 
with a charge state of 2-5 were sampled for M1-10. Dynamic exclusion time was set at 
60 seconds, with a 5 ppm tolerance around the selected precursor.  
We used MS/MS data sets produced by the National Cancer Institute Clinical 
Proteomic Tumor Analysis Consortium (CPTAC) (https://cptac-data-
portal.georgetown.edu/cptacPublic/) and our own MS/MS data sets produced using 
xenograft tumors, prepared as described above. Normal colon samples were randomly 
selected (Sample codes: JX0008, JX0025A, JX0030A) while COAD samples were 
selected to represent advanced stages of the disease by analyzing the metadata available 
(Sample codes: TCGA-AA-3695-01A-22-2150-27, TCGA-AA-A02E-01A-23-A20O-
27, TCGA-AA-A02H-01A-32-A20O-27). Normal samples MS/MS raw data was 
downloaded from https://cptac-data-portal.georgetown.edu/cptac/s/S019 and COAD 
samples MS/MS raw data downloaded from https://cptac-data-
portal.georgetown.edu/cptac/s/S016. All MS/MS datasets were analyzed using the same 
bioinformatics pipeline. 
The raw files were searched directly against the Mus musculus or Homo sapiens 
reference proteomes obtained from UniprotKB, using PEAKS8 software and mutations 
in the proteome were found using the SPIDER tool 135. Searches were carried using a 
precursor search tolerance of 5 ppm. Search criteria included a static modification of 
+57.0214 Da on cysteine residues, variable modification of +15.9949 Da on oxidized 
methionine to reduce false positives; some misincorporations and amino acid 
modifications may produce similar spectra. Searches were performed with semi-tryptic 
digestion and allowed a maximum of three missed cleavages on peptides analyzed by 
the sequence database. False discovery rates (FDR) were estimated with decoy-fusion 
and then set to 1% for each analysis, as previously reported 136. The sequences of the 
mutated peptides observed in this analysis were used to generate a modified database, 
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containing new entries with the proteins harboring those mutations; to rule out false 
positives. These samples were re-analyzed using the PEAKS software, but this time 
against the modified databases, validating only the mutated peptides which aligned with 
the mutated sequence. Data was filtered so that each protein was represented by a single 
entry to avoid overestimation of protein mistranslation events. The number of spectra 
for each peptide was taken into account to calculate the total number of 
misincorporations in the samples. 
 
3.5.14. Reverse transcriptase PCR and quantitative real-time PCR  
Poly A mRNA from tumors was reverse-transcribed using the SuperScript II RT 
system (Invitrogen,#18064014). cDNA was used as template for PCR amplification 
across the fragment of the Xbp-1 cDNA bearing the intron target of IRE1α ribonuclease 
activity. Primers used were: murine Xbp-1, 5’-TTACGGGAGAAAACTCACGGC-3’ 
and 5’-GGGTCCAACTTGTCCAGAATGC-3’. PCR conditions were: 95°C for 15 min; 
94°C for 30 sec; 57°C for 30 sec; 72°C for 2 min with 35 cycles of amplification and a 
final extension step at 72°C for 10 min. A 289 bp amplicon was generated from 
unspliced Xbp-1 (Xbp-1un); a 263 bp amplicon was generated from spliced Xbp-1 
(Xbp-1s) and a 315 bp amplicon was generated from hybrid Xbp-1 (Xbp-1H). PCR 
products were resolved on on QIAxcel DNA Fast Screening Kit (20-50 bp resolution) 
and agarose gel 4%. As previously reported, a minor hybrid amplicon species consisting 
of unspliced Xbp-1 annealed to spliced Xbp-1 was also produced through the PCR 
reaction and appeared above the unspliced amplicon 2. Quantification of Xbp-1 
activation (in percentage) was performed using the following formula: 100 x [Xbp-1s + 
0.5 Xbp-1H] / [Xbp-1s + Xbp-1H + Xbp-1un], as previously described 3.  
TaqMan assays were performed to determine the expression of the mRNA by 
quantitative real-time PCR (qRT-PCR). The primers used to evaluate the expression of 
mouse DsRED and Gapdh mRNAs were obtained commercially from Integrated DNA 
Technologies. All assays including no template controls were carried out in triplicate. 
The threshold cycle data (CT) and baselines were determined using auto settings. Gapdh 
mRNA levels served as an internal normalization standard for to determine expression 
levels of DsRED in each sample. The 2-ΔΔCT analysis method was applied in all 
experiments. 
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3.5.15. Immunoblot analysis 
Tissue lysates were homogenized using the tissue homogenizer Precellys  24 
(Precellys) in RIPA lysis buffer, containing phosphatase (Sigma-Aldrich) and protease 
(Roche) inhibitor cocktails. Whole tissue protein lysates were loaded onto 10-12% 
SDS-PAGE and blotted onto nitrocellulose membranes according to standard 
procedures. For our analysis we used antibodies against phoshoserine (1:500; 
Invitrogen); eIF2α (1:1000; Cell signalling); phospho-eIF2α (1:1000; Abcam); ATF6 
(1:400; Stressgen); PP1α catalytic subunit (1:400; ThermoFisher Scientific); Akt 
(1:1000; Cell signaling); phospho-Akt (1:1000; Cell signaling); ERK1/2 (1:1000; Cell 
signaling); phospho-ERK1/2 (1:1000; Cell signaling); phosphor-p38 (1:1000; Cell 
signaling); p38 (1:1000; Cell signaling) and β-tubulin (1:1000; Invitrogen). Bound 
antibody was visualized by incubating membranes with an IRDye680 goat anti-rabbit or 
IRDye800 goat anti-mouse secondary antibodies (Li-cor Biosciences, Lincoln, NE, 
USA) at 1:10000 dilution. Detection was carried out using an Odyssey Infrared Imaging 
system (Li-cor Biosciences). The amount of β-tubulin was used to normalize the amount 
of the loaded proteins. Lysates from TNFα induction assay were analyzed for p38 and 
Akt antibodies (phosphorylated and total forms).  
 
3.5.16. Ki67 immunohistochemistry 
Tumor sections obtained from mice tumors were de-paraffinized, re-hydrated 
with graded ethanol and washed in distilled water followed by PBS.  Heat induced 
antigen retrieval was performed using 0.01M citrate buffer, pH 6.0, for 40 min. To 
block endogenous peroxidase activity, slides were treated with 0.5% H2O2 in methanol, 
for 20 min at room temperature (RT). To block non-specific binding, slides were 
exposed to large volume of ultra V block solution (LabVision), for 30 min at RT. Slides 
were subsequently incubated with rabbit monoclonal antibody against Ki67 (clone SP6; 
Thermo Scientific) at 1:400 in large volume ultra Ab dilution (Lab Vision), for 2h at 
RT. After washing, sections were incubated with Envision detection system 
peroxidase/DAB (Dako) followed by hematoxilin staining using the standard protocol. 
 
3.5.17. Statistical analysis  
For all the assays, except for the in vivo experiments, our data represents 3 
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replicates and 2-3 independent experiments. Data are reported as the average values + 
SEM (standard error of the mean). Statistical significance was determined using One-
way ANOVA with Dunnett’s post-test. The CAM experiments were analyzed using 
paired two-tailored Student’s t-test.  
 
3.6. Supplementary Figures 
 
Figure 3-9: Integration of pIRES2-DsRed and recombinant tRNAs in the cell lines and its 
phenotypic effects. A) Agarose gel (1%) of the PCR product obtained by amplification of genomic DNA 
from cell lines across the fragment of pIRES2-DsRed plasmid containing the tRNA insert. NTC 
represents the negative control. B) To access the cell viability, cells were grown for 48h and then stained 
with trypan blue (0.4%). Number of viable cells was then registered and then normalized to the Mock cell 
line. C) To check if there were differences in proliferation, stable cell lines were grown in 10 mm cover 
slips for 48h and then incubated with BrdU for 1h. Cover slips were incubated with1:10 mouse anti-BrdU  
and 1:500 goat anti-mouse Ig Alexa Fluor® 488. Total number of cells was counted by staining with 
DAPI. Number of proliferating cells was determined and normalized to the Mock cell line. D) For cell-
cycle analysis we performed flow cytometry (Propidium Iodide (1mg/ml) staining). The percentage of 
cells detected in each phase of the cell cycle (G0/G1; S; G2/M) is shown. Data represents average ± SEM 
(n=3). Statistical significance was determined using unpaired two-tailored Student’s t-test. Results are not 
statistically significant (p ˃ 0.05). 
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 Figure 3-10: Negative Controls of TNFα induction assay. A) Negative controls of cells treated 
with TNFα for 30 minutes. Upper panel) Relative activation ratios of p38 in the cell lines not 
exposed to TNFα. Middle panel) Relative activation ratios of Akt in the cell lines not exposed to 
TNFα. Lower panel) Representative immunoblots of phosphorylated p38, p38, phosphorylated 
Akt and total Akt in cells lines that were not treated with TNFα. β-tubulin was used as a loading 
control. B) Negative controls of cells treated with As with TNFα for 4 hours. Upper panel) 
Relative activation ratios of p38 in the cell lines not exposed to TNFα. Middle panel) Relative 
activation ratios of Akt in the cell lines not exposed to TNFα. Lower panel)  Representative 
immunoblots of phosphorylated p38, p38, phosphorylated Akt and total Akt in cells lines that 
were not treated with TNFα. β-tubulin was used as a loading control. Data represents average ± 
SEM (n=3). Statistical significance was determined using unpaired two-tailored Student’s t-test. 
Results are not statistically significant (p ˃ 0.05), showing that there are no differences among 
cell lines when they are not exposed to any stimuli in vitro. 
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Figure 3-11: Presence of the plasmid pIRES2-DsRed and recombinant tRNAs in the tumors CAM and 
mice) and histological analysis of representative tumors. A) Agarose gel of the PCR product obtained by 
amplification of genomic DNA from tumors, extracted from chicken embryo chorioallantoic membrane 
(CAM) model, across the fragment of pIRES2-DsRed plasmid containing the tRNA insert. NTC represents 
the negative control. B) Agarose gel of the PCR product obtained by amplification of genomic DNA from 
tumors, extracted from mice model, across the fragment of pIRES2-DsRed plasmid containing the tRNA 
insert. NTC represents the negative control. C) Histological analysis. Upper panel) Hematoxylin and eosin 
staining (H&E) on paraffin-embedded tumor tissues showing high grade sarcomas (40x amplification). 
Lower panel) Immunohistochemical analysis with anti-Ki67 antibody (1:400) on paraffin-embedded tumor 
tissues presenting high level of proliferation in all tumors (40x amplification). 
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Figure 3-12: Activation of XBP-1 in tumors expressing misreading tRNAs.  Left panel) The 
presence of unspliced (un), hybrid (H) and spliced (s) XBP-1 forms was checked by RT-PCR. Actin 
β served as a loading control. Right panel) Activation of XBP-1 was determined using the formula: 
100x[XBP-1s+0.5 XBP-1H]/[XBP-1s+XBP-1H+XBP-1un]. Graphics depict average ± SEM (n=3). 
Data was analysed by One-way ANOVA with Dunnett’s post-test and significant p-values are 
shown (*p˂0.05). 
Figure 3-13: Classical cancer-associated pathways modulated in mice tumors. A) ERK1/2 
relative activation ratio among tumor lysates. B) Relative activation ratios of p38 in tumor lysates. 
C) Representative immunoblots of ERK1/2-P, ERK1/2, p38-P, total p38 and the respective β-
tubulin (loading control) from tumor lysates. Graphics depict average ± SEM (n=3). Data was 
analyzed by One-way ANOVA with Dunnett’s post-test and significant p-values are shown 
(*p˂0.05; **p<0.01). 
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4.1. Abstract 
Although tRNAs are often overexpressed in tumors, their role in tumor biology 
and specially in tumor initiation is unknown. In normal breast cells, upregulation of 
specific tRNAs can increase metabolic activity and cell proliferation, but the 
contribution of tRNA overexpression to tumor initiation has not yet been addressed. 
tRNA deregulation may cause protein misincorporation at near-cognate codon sites and, 
depending on the level of protein misfolding, may also activate the protein quality 
control (PQC) system. There are evidences that the PQC and specifically the unfolded 
protein response (UPR) are activated in tumors, but the role of amino acid 
misincorporations in tumorigenesis is also unexplored. In order to tackle these 
questions, we have overexpressed both a Wild Type (WT) Ser tRNA, which was found 
to be upregulated in tumors, and a misreading tRNA that misincorporates Ser at Ala 
codons in near-normal cells BEAS-2B. We found that stable expression of these tRNAs 
increases cellular proliferation, accompanied by increased protein synthesis and 
activation of the PERK branch of the UPR. Both tRNA constructs were able to increase 
in vitro colony formation, indicating increased tumorigenic capacity. Our preliminary 
data further suggests that overexpression of the WT Ser tRNA may be enough to initiate 
tumor formation with slow growth kinetics. 
 
4.2. Introduction 
The expression levels of tRNAs belonging to families of amino acids that can be 
phosphorylated are often elevated in tumors 10,11.  Additionally, tRNA profiles alone are 
sufficient to discriminate tumor samples from normal tissue 9. The role of tRNA 
deregulation in cancer remains elusive, however, it has been associated with increased 
translation of specific transcripts that are enriched in codons that are decoded by the 
deregulated tRNAs 13. Overexpression of tRNAiMet was also associated with increased 
metabolic activity and cell proliferation of a normal breast cell line; features that are 
associated with cell transformation 12. Moreover, the overexpression of Ser tRNAs has 
been associated with poor prognosis in several types of cancer and also with increased 
risk of recurrence in breast cancer 9. Whether these tRNAs play a role in tumor initiation 
and how they may do so, remains elusive. It is possible that the over-representation of 
Ser tRNAs can lead to misreading of near-cognate codons, such as the Ala (AGC) 
codon 51. In line with this, we observed that misincorporation of Ser at Ala sites is one 
of the most abundant mistranslation events in tumor cells (previous chapter). 
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Mistranslation can induce the formation of aberrant misfolded proteins, which in turn 
activate the proteome quality control (PQC) system, consisting of several molecular 
chaperones and degradation systems that work together to ensure a healthy and 
functional proteome 137. We observed that tumors with high mistranslation rates activate 
the different branches of the Unfolded Protein Response (UPR) (Chapter 3). 
When misfolded proteins accumulate in the Endoplamic Reticulum (ER) they 
sequester the molecular chaperone BiP (or GRP78) 138. This chaperone releases the 
UPR effectors PERK, ATF6 and IRE1α. PERK and IRE1α autophosphorylate 
themselves and ATF6 migrates to the Golgi where it is cleaved and activated 113. 
Together, these branches activate a pro-survival cellular response, but when the stress is 
prolonged they switch into a pro-apoptotic signaling mode 139. Cancer cells can hijack 
the UPR and profit from its pro-survival measures, to increase tumor aggressiveness, 
tumor-promoting inflammation, survival during hypoxia and tumor resistance to 
treatment  140–143. The PERK branch of the UPR is responsible for controlling the 
protein synthesis rate to prevent ER overloading with misfolded proteins 144,145. PERK 
directly phosphorylates the initiation factor eIF2α, thus inhibiting the assembly of the 
translation initiation complex. Nevertheless, selective translation of stress response 
transcripts, such as the transcription factor ATF4, CHOP and BiP, occurs to counteract 
the stressful cellular conditions 146. ATF4 induces the transcription of stress response 
genes, such as GADD34, which directs PP1α to dephosphorylate eIF2α  and restore 
global protein synthesis rate 147. Decreased levels of eIF2α phosphorylation are 
sufficient to trigger transformation on a near-normal Mus musculus cell line 125. PERK 
can also activate known oncogenes such as Akt, mTOR and MAPK through 
phosphorylation of diacylglycerol (DAG) and generation of phosphatidic acid 148,149. 
Furthermore, PERK is able to phosphorylate the transcription factor Nrf2, which is 
responsible for transcription of antioxidant cellular defences 150. This branch of the UPR 
is essential for tumor establishment and growth 151. Moreover, ER stress and UPR 
activation were detected in pre-malignant lesions that precede hepatocellular carcinoma 
(HCC), and when combined with hypernutrition their activation leads to HCC 
development 152. 
In this chapter, we clarify the role of Ser-tRNA deregulation and tRNA 
misreading in tumor initiation and unveil the contribution of the PERK branch of the 
UPR to this phenotype. To do so, we overexpressed both a Ser WT tRNA and a 
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misreading Ser tRNA (which reads Ala codons) in a normal cell line derived from 
normal bronchial epithelium, BEAS-2B. We found that overexpression of the WT Ser-
tRNA and expression of the misreading Ser tRNA can increase protein synthesis rate 
and proliferation in a normal cell line. Increased expression of this WT Ser-tRNA is 
likely sufficient to initiate the formation of slow growing tumors. Modulation of the 
UPR was similar in both cell lines, however the factors that contribute to the decreased 
phosphorylation of eIF2α in the cell line expressing the misreading tRNA have to be 
identified in the future. 
 
4.3. Results 
4.3.1. Misreading and WT tRNAs have a positive impact on cellular fitness 
Our previous results showed that tRNAs are involved in tumor growth, but it is 
unclear whether tRNA misreading or deregulation of WT tRNA expression or both are 
involved in tumor initiation and/or in tumor progression. To elucidate if tRNAs are 
involved in tumor initiation, we expressed a tRNASer(Ala) misreading tRNA and 
overexpressed the Ser WT tRNA, selected from our previous work (Chapter 3), in a 
normal cell line (BEAS-2B). To exclude the hypothesis that the phenotypes observed 
were transfection specific, we established three independent stable cell lines for each 
condition (Fig.4-1A,B). Regarding the expression of the recombinant tRNAs, in the 
BEAS tRNASer(WT) the expression of the WT Ser tRNA was upregulated by 1.6-fold 
(p<0.05), when comparing to the Mock cell line (Fig.4-1C), and in the BEAS 
tRNASer(Ala) cell line the misreading tRNASer(Ala) was 16-fold less expressed than the 
endogenous WT Ser tRNA (Fig.4-1C).  
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 Similarly to other published results, upregulation of the WT Ser tRNA and the 
expression of the misreading tRNASer(Ala), did not affect the viability of BEAS-2B, 
once stable cell lines were achieved (Fig.4-2).  
 
 
 
 
 
 
 
Figure 4-2: Stable expression of recombinant tRNAs do not impact cell viability. Cells grown for 
48h were stained with trypan blue (0.4%) to determine the cell viability of BEAS-2B derived cell lines 
(n=3, with 3 technical replicates). Graphic depicts the percentage of viable cells ±SEM. Data was 
analyzed with One-way ANOVA and Holm Sidak’s post-test (p>0.05). 
 
Figure 4-1: Integration of pIRES2-DsRed and recombinant tRNAs in the cell lines. A) Agarose gel 
(1%) of the PCR product obtained using gDNA. DNA bands correspond to the fragment of pIRES2-
DsRed plasmid containing the tRNA gene insert. Legend: M – Molecular Marker; 1, 2, 3 – BEAS Mock 
1, 2 and 3, respectively; 4, 5, 6 – BEAS tRNASer(WT) 1, 2 and 3, respectively; 7, 8 and 9 BEAS 
tRNASer(Ala)  1, 2 and 3, respectively; N  -Negative  control. B) Sanger sequencing of the PCR products 
showing the mutation in the anticodon of the tRNA from AGA in tRNASer(WT) cell lines to AGC in the 
tRNASer(Ala) cell lines, indicated by the red arrow. (C) Quantification of tRNA expression by Snapshot 
sequencing. tRNAs were quantified based on a primer extension assay and values were normalized for 
the expression of GAPDH. tRNASer(WT) expression was upregulated 1.6-fold increase relative to the 
Mock cell line. The graph confirms that tRNASer(Ala) was also expressed in BEAS tRNASer(Ala) cell 
line. Graphic depict average ± SEM (n=3). Data was anlalysed with unpaired, two-tailed Student´s t-test 
with Welch correction and significant p-values are shown (*p<0.05) 
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In BEAS-2B derived cell lines expression of tRNASer(WT) and tRNASer(Ala) 
increased proliferation by 1.35-fold (p<0.01) and e 1.14-fold (p<0.05), respectively 
(Fig.4-3A). Since cell proliferation was increased by the expression of both tRNAs, we 
investigated if protein synthesis rate was also changed. We did so by measuring the 
incorporation of puromycin into proteins, using the SunSET technique. There was an 
increase of 1.34- and 1.37-fold in protein synthesis rate in the cell lines expressing the 
tRNASer(WT) and tRNASer(Ala), respectively (p<0.05 in both cases) (Fig.4-3B,C). 
Therefore, the increased cell proliferation is accompanied by an increase in protein 
synthesis rate in these cells. 
 
Figure 4-3: Expression of recombinant tRNAs increase cell proliferation and protein synthesis rate. 
(A) To evaluate cellular proliferation, 5x103cells/well were plated in 96-well plates and incubated for 48h 
prior to measuring BrdU incorporation during DNA synthesis, using a colorimetric immunoassay. 
Relative proliferation of BEAS-2B derived cell lines – The expression of tRNASer(WT) and tRNASer(Ala) 
increased cellular proliferation capacity in vitro. (B) The tRNASer(WT) and tRNASer(Ala) increased 
protein synthesis rate in BEAS-2B-derived cell lines. (C) Protein synthesis rate was estimated by 
immunoblot against puromycin. GAPDH served as a protein loading control. Graphics depict average 
±SEM of n=3, with 3 technical replicates. Data was analyzed with One-way ANOVA and Holm Sidak’s 
post-test and significant p values are shown (*p<0.05; **p<0.01). 
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4.3.2. Expression of misreading and WT tRNAs induce the Unfolded Protein 
Response in BEAS-2B cells 
We have investigated the activation of the PERK branch of the UPR and BiP 
deregulation in BEAS-2B cells. We observed that BiP was upregulated in the cell line 
overexpressing the tRNASer(WT) by 1.54-fold (p<0.05), but its levels were unchanged 
in the cell line expressing the misreading tRNASer(Ala) (Fig.4-4A,E). Phosphorylation 
levels of eIF2α were decreased by 0.21- and 0.31-fold in tRNASer(WT) and 
tRNASer(Ala) expressing cell lines, respectively, relative to the Mock cell line (p<0.05) 
(Fig.4-4B,E), which is in agreement with our previous results (Chapter 3). These results 
are positively correlated with the increased protein synthesis rate observed in Fig.4-3. 
eIF2α dephosphorylation is often preceded by increased ATF4 activity, which starts a 
negative feedback loop to restore global levels of protein synthesis rate. We observed 
that tRNASer(WT) and tRNASer(Ala) expressing cell lines have increased activity of 
ATF4 (1.49-fold (p<0.01) and 1.23-fold (p<0.05), respectively (Fig.4-4C,E). 
Additionally, the cell line overexpressing the tRNASer(WT) upregulates the GADD34 
regulatory subunit that directs PP1α to eIF2α, by 6.86-fold (p<0.05). However, its levels 
in tRNASer(Ala) expressing cells were unchanged (Fig.4-4D,E), suggesting that 
GADD34 is not involved in modulating  eIF2α–P levels in this cell line. 
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4.3.3. Recombinant tRNAs increase in vitro transformation ability of BEAS-2B-
derived cell lines 
Regarding modulation of transformation ability, both constructs were able to 
increase the number of colonies of BEAS-2B, in an anchorage-dependent colony 
formation assay. Upregulation of the tRNASer(WT) increased colony formation by 1.43-
fold (p<0.01) and expression of the misreading tRNASer(Ala) increased it by 1.52-fold 
(p<0.01) (Fig.4-5).  Interestingly, the number of colonies obtained with this assay for 
BEAS tRNASer(WT) and BEAS tRNASer(Ala) different transfections was very similar, 
indicating that this phenotype is not transfection-specific (Fig.4-5). These results 
suggest that deregulation of tRNA expression or mistranslation alone are sufficient to 
transform normal immortalized cell, and are likely to induce tumorigenesis in the same 
normal cell lines. 
 
 
Figure 4-4: UPR deregulation induced by recombinant tRNAs. (A) Expression of tRNASer(WT) but 
not tRNASer(Ala) increases BiP expression on BEAS-2B cells. (B) Both tRNA constructs reduced the 
levels of eIF2α-P. (C) tRNASer(WT) and tRNASer(Ala) expression in BEAS2B cell line increased the 
activation of ATF4 transcription factor. (D) Expression of GADD34 was only increased in BEAS-2B 
tRNASer(WT) cell line. (E) Immunoblots against BiP, eIF2α-P, eIF2α, ATF4-P, ATF4 and GADD34. Β-
tub served as protein loading control. Graphics depict average ± SEM (n=3), with 3 technical replicates. 
Data was analyzed with One-way ANOVA and Holm Sidak’s post-test and significant p values are 
shown(*p<0.05; ***p<0.001). 
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4.3.4. The impact of tRNA deregulation in tumor initiation  
To assess the impact of tRNA deregulation in tumor initiation, we inoculated 
4.5x106 cells of BEAS 2B-derived cell lines harboring our tRNA constructs in the right 
dorsal flank of four mice (for each tRNA construct) and control cells (Mock) on the 
corresponding left dorsal flank of every mice. After 3 months, the experiment was 
terminated because tumors were growing very slowly and were still hard to measure 
accurately. In the BEAS tRNASer(WT) experimental arm, all mice developed tumors for 
the cell line expressing the tRNASer(WT) construct, whereas only two animals 
developed tumors expressing the Mock construct. These tumors were much smaller than 
the tRNASer(WT) expressing tumors (Fig.4-6, 4-7A). Regarding the BEAS 
tRNASer(Ala) experimental arm, the results were variable: one mouse died of causes 
non-related to the experiment; one mouse developed a tumor expressing the Mock 
construct; one mouse developed a tumor expressing the tRNASer(Ala) construct and a 
tumor expressing the Mock construct; and one mouse only developed a tumor 
expressing the tRNASer(Ala) construct (Fig.4-6, 4-7B). Despite the inconclusiveness of 
results from the last arm, in the first arm, overexpression of the WT Ser tRNA could 
trigger tumor formation with slow kinetics, since all mice developed tumors expressing 
this construct, as opposed to controls. In any case, this experiment need to be repeated 
with greater numbers (more animals) and with a greater number of injected cells per 
mice. 
Figure 4-5: Deregulation of WT tRNA expression and mistranslation increase tumorigenic capacity 
of normal cells in vitro. Overexpression of tRNASer(WT) and expression of the misreading tRNASer(Ala) 
increases anchorage-dependent colony formation in BEAS-2B-derived cell lines, indicating that they may 
bestow these cells with increased tumorigenic capacity. 
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Figure 4-6: Effect of tRNA deregulation in tumor initiation. All animals inoculated with BEAS 
tRNASer(WT) developed a tumor, whereas BEAS Mock tumors only developed in 2/4 mice and had a 
small size. In the tRNASer(Ala) arm, one mouse only developed a BEAS Mock derived tumor, one mouse 
developed tumors derived from both cell lines and one mouse only developed a tumor derived from 
BEAS tRNASer(Ala) cell line. 
 
 
 
 
 
 
4.4. Discussion 
In agreement with previous reports, of  Pavon and colleagues showing that mild 
overexpression of tRNAiMet is sufficient to increase metabolic activity and 
proliferation rates, we observed that increased expression of tRNASer(WT) and 
expression of a misreading tRNASer(Ala) boosted protein synthesis rates in normal 
epithelial cells, and increased cellular proliferation rates when stably expressed 12. In the 
present study, we have gone beyond previous observations and studied the effect of 
increasing the expression of WT Ser tRNA overexpression and expressing a mutant 
tRNASer(Ala) in tumorigenic initiation. Both tRNAs increased colony formation 
capacity in an anchorage-dependent colony formation assay, which is an indicator of 
increased tumorigenic ability 153. We also studied the activation of the PERK branch of 
the UPR and found that in both conditions the levels of phosphorylated eIF2α were 
Figure 4-7: Tumors developed by BEAS-2B-derived cell lines. A) Tumors derived from BEAS 
tRNASer(WT) and BEAS Mock cells inoculated in the same animal. Left panel shows an example of an 
animal that developed tumors derived from both cell lines where the size of the Mock tumor is almost 
negligible relative to the tRNASer(WT) expressing tumor; the right panel shows the tumor of an animal 
that only developed a tumor expressing the tRNASer(WT) construct. B) Tumor of the animal that only 
developed a tumor expressing the tRNASer(Ala) construct. 
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lower than the control, which has been associated to cellular transformation 125. In the 
cell line overexpressing the WT Ser tRNA, there was upregulation of GADD34, which 
explains the decrease in eIF2α-P levels, but GADD34 was not upregulated in the cell 
line expressing the misreading tRNA. In other words, those cell lines achieved the same 
eIF2α phosphorylation outcome through different molecular mechanisms. This cell line 
may instead increase CReP expression levels, an homolog of GADD34, which can also 
bind and direct PP1α towards eIF2α 154, but this hasn’t been confirmed. The reduced 
levels of eIF2α-P are also positively correlated with the increased protein synthesis rate 
observed in both cell lines. Activation of the transcription factor ATF4 was also 
increased, suggesting that transcription of GADD34 and genes that are relevant for 
adaptation under hypoxic conditions, oxidative stress and nutrient deprivation, which 
are hallmarks of tumors, were upregulated as well 155–157. Moreover, BiP was 
upregulated in the tRNASer(WT) cell line, which have been detected in head and neck 
cancer initiating cells and in lung pre-malignant lesions 158,159.  
The low number of mice used in our in vivo pilot assay and the erratic nature of 
the results prevented us to demonstrate that those tRNAs contribute to tumor initiation. 
In the mice harboring tRNASer(WT) tumors, the data indicate that overexpression of the 
tRNASer(WT) may indeed trigger formation of slow growing tumors. This experiment 
need to be repeated to clarify the role of those tRNAs in tumor initiation. 
 
4.5. Materials and Methods 
4.5.1. Cell Culture 
BEAS-2B cell line was kindly provided by Professor Maria Carmen Alpoim, 
from IBILI, University of Coimbra. BEAS-2B cells were cultured in LHC-9 medium 
(Gibco, Life Technologies) supplemented with 1% of Penicillin-Streptomycin 
(Pen/Strep) (Gibco, Life Technologies). Cells were maintained in an incubator at 37ºC 
with 5% CO2 and 95% relative humidity. To execute the following procedures, cells 
were detached using Tryple Xpress (Gibco, Life Technologies). Cells were regularly 
tested for mycoplasma contamination. 
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4.5.2. Generation of stable cell lines 
BEAS-2B stable cell lines were generated through electroporation (three 
independent times). BEAS-2B cells were seeded in 100mm dishes and cultured until 70-
90% of confluence was reached. Cells were detached and the pellet was resuspended in 
Hepes Buffered Saline (HBS) solution to improve the transfection efficiency. Then, 
4mm electroporation cuvettes were prepared with 10µg of plasmid and 0.5ml of cell 
suspension was added, mixing carefully. For each sample, the voltage applied was 
230V, with capacitance of 1500µF and resistance of 125Ω. This step was performed 
using ECM Electro Cell Manipulator (BTX, Harvard Apparatus). Immediately after the 
electroporation, 1ml of LHC-9 culture medium was added to the cuvette, cells were then 
carefully homogeneized and transferred to 60mm dishes. Stable cell lines were obtained 
by selection with 200µg/ml of G418 for three weeks. 
 
4.5.3. Extraction and Quantification of gDNA 
To ensure the plasmid did not acquire mutations when integrated in the genome, 
gDNA was extracted for Sanger sequencing. The NZY Tissue gDNA Isolation Kit was 
used following instructions recommended by the manufacturer. gDNA concentration 
was determined using a NanoDrop. 
 
4.5.4. Cellular Viability Assay 
1.5x105 cells/well (BEAS-2B and NCI-H460 derived cell lines) were seeded in a 
24-well plate. After 48h, cells were detached and equal volumes of cell suspension and 
trypan blue were mixed. Finally, cell viability (%) was obtained by counting the live 
and death cells using a TC10Tm Automated Cell Counter (Bio-Rad). This assay was 
performed with triplicates and repeated three times. 
 
4.5.5. Cellular Proliferation Assay 
To evaluate cellular proliferation, we used a colorimetric immunoassay ELISA, 
based on the measurement of BrdU incorporation during DNA synthesis (Roche, 
Cat.11647229001), following the manufacturer’s instructions. 5x103cells/well (BEAS-
2B and NCI-H460 derived cell lines) were plated in a 96-well and analysis was 
performed after 48h. 
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4.5.6. Anchorage-Dependent Colony Formation Assay 
300 cells per condition were seeded in 60mm dishes and maintained in culture 
for two weeks (BEAS-2B derived cell lines) or 9 days (NCI-H460 derived cell lines). 
The colonies were then fixed using ice cold methanol and incubated at -30ºC for 30min. 
Methanol was removed and a solution of 0.1% crystal violet in 20% methanol was 
added and the plates were incubated at room temperature for 30min. Plates were washed 
with H2O milliQ to remove excess dye and the colonies were counted. This assay was 
performed in triplicates and repeated four times.  
 
4.5.7. Protein synthesis rate determination 
To determine protein synthesis rate, we used a non-reactive fluorescence-
activated cell sorting-based assay called SUnSET, with few modifications. 1x106cells 
were plated in 60mm petri dishes and after 48h, 10% v/v puromycin (Sigma Aldrich) 
was added to each plate. Cells were then incubated for 15 min. Total protein lysates 
were obtained from cells with Lysis Buffer (0.5% Triton X-100, 50mM HEPES, 
250mM NaCl, 1mM DTT, 1mM NaF, 2mM EDTA, 1mM EGTA, 1mM PMSF, 1mM 
Na3VO4 supplemented with a cocktail of protease inhibitors (Roche). Cells were 
sonicated with a probe sonicator in 5 pulses of 5 seconds. After centrifugation at 16000g 
for 30min, protein in the supernatants was quantified using the BCA assay (Thermo 
Fisher Scientific). 100 µg of protein was denaturated with loading buffer (6x) at 95ºC 
for 5 min, resolved in 10% SDS-PAGE and blotted onto nitrocellulose membranes 
(0.2µm) (GE Healthcare Life Sciences). Anti-puromycin, clone 12D10 (kindly given by 
Philippe Pierre) was used (1:2500) to detect the incorporation of puromycin in proteins. 
IRDye800 goat anti-mouse secondary antibody (Li-cor Biosciences, Cat.400-33) was 
used (1:10000 dilution) and detected in an Odyssey Infrared Imaging System (Licor 
Biosciences). Membranes were also probed with Anti-GAPDH (Santa Cruz 
Biotechnology) (1:1000) as a loading control. 
 
4.5.8. Immunoblots 
Total protein lysates were obtained with the same extraction method used with 
the SUnSET assay. 40µg of protein were immunoblotted onto nitrocellulose membranes 
with antibodies  against eIF2α (1:1000; Cell signalling); phospho-eIF2α (1:1000; 
Abcam); ATF6 (1:400; Stressgen); GADD34 (1:1000 ThermoFisher Scientific); 
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phospho-ATF4 (1:1000; tebu-bio); ATF4 (1:1000; tebu-bio) and β-tubulin (1:1000; 
Invitrogen). IRDye680 goat anti-rabbit or IRDye800 goat anti-mouse secondary 
antibodies (1:10000, Li-cor Biosciences) were used and the signal was detected using an 
Odyssey Infrared Imaging system (Li-cor Biosciences).  
 
4.5.9. Tumor induction assay 
Six-week-old male N:NIH(s)II:nu/nu nude mice were obtained previously from 
the Medical School, University of Cape Town in 1991 and then reproduced, maintained 
and housed at IPATIMUP Animal House at the Medical Faculty of the University of 
Porto, in a pathogen-free environment under controlled conditions of light and 
humidity. Male nude mice, aged 6-8 weeks, were used for in vivo experiments. Animal 
experiments were carried out in accordance with the Guidelines for the Care and Use of 
Laboratory Animals, directive 2010/63/EU.  To measure tumorigenic potential in vivo, 
BEAS-2B cell lines harboring the empty vector (Mock), the tRNASer(WT) and the 
misreading tRNASer(Ala) were subcutaneously injected in the dorsal flanks using a 25-
gauge needle with  4.5x106 (BEAS-2B) of each cell line. A total of 4 mice per group 
were used.  Each mouse was injected in the left flank with the Mock variant and in the 
right flank with the cells misexpressing the WT or the misreading variants of each 
previously described clone. Mice were weighed, and tumor width and length were 
measured with calipers three times per week. Tumor volumes were calculated assuming 
ellipsoid growth patterns. Mice were humanely euthanized when tumors reached a 
median volume of 2000mm3 or whenever any signs of disease were detected. Tumors 
and lungs, were collected, fixed in 10% buffered formalin, paraffin embedded and then 
sectioned for histological examination. A part of each tumor was frozen in liquid 
nitrogen and stored at –80ºC until used. 
 
4.5.10. Statistical analysis  
For all the assays, except for the in vivo experiments, our data represents 3 
independent biological replicates and 3-4 independent experiments. Average values are 
usually shown and error bars represent the standard error of the mean (SEM).  Statistical 
significance was determined using One-way ANOVA with Dunnet’s post-test; Kruskal-
Walis with Dunnet’s post-test or Two-Way ANOVA for the in vivo experiments.  
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5.1. Abstract 
Overexpression of certain tRNAs has been associated with increased migration 
potential and metastization, through differential translation of mRNAs enriched in 
specific codon sets. However, overexpression of some tRNAs may cause amino acid 
misincorporation into proteins, creating high proteome heterogeneity, whose 
consequences for cancer biology are poorly understood. In previous works, we observed 
that elevated expression of Wild Type (WT) Ser tRNAs or misincorporation of Ser at 
Ala codon sites influence tumor behavior. To further clarify the role of this phenomena 
in tumor biology, we expressed these tRNAs in Non-Small Cell Lung Cancer (NSCLC) 
cells and characterized their potential to modulate cell migration, invasion and 
metastization. Upregulation of tRNASer(WT) but not expression of tRNASer(Ala) 
increased cell proliferation in vitro. Both tRNA constructs accelerated tumor growth 
kinetics, however tRNASer(Ala) expressing tumors grew slightly faster than 
tRNASer(WT) expressing tumors, which can partially be explained by reduced levels of 
eIF2α-P and upregulation of GADD34. Also, tumors expressing both tRNA constructs 
showed upregulation of BiP and activation of ATF4, which has been correlated with 
high grade NSCLC tumors. Expression of the misreading tRNASer(Ala) increased cell 
migration potential, whereas overexpression of tRNASer(WT) impaired cell migration 
potential, showing that these tRNA constructs may have different impacts on cell 
biology. Despite the fact that both tRNA constructs increased the local invasion 
potential of H460 cells, the results obtained in the in vivo metastization assay were 
inconclusive due to high dispersion of data. 
 
5.2. Introduction 
Deregulation of tRNAs in tumors or tumor-support cells imposes important 
cellular reprogramming events that  sustain tumor growth and disease progression 13,15. 
This has been associated with increased translation of specific transcripts which are 
enriched in codons matching the anticodons of such tRNAs 13. For instance, 
tRNAGluUUC and tRNAArgCCG upregulation occurs in metastatic breast cancer cell 
lines relatively to their non-metastatic counterparts. The upregulation of these tRNAs 
increase the translational efficiency of disease-promoting transcripts, shifting the 
proteome towards a pro-metastatic state 13. Also, upregulation of tRNAiMet in support 
or tumor cells can favor disease progression through different molecular mechanisms. In 
support fibroblasts, the upregulation of this tRNA induces secretion of collagen type II, 
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which favors endothelial cell migration, angiogenesis and tumor growth 14, whereas its 
upregulation in melanoma cells promotes cell migration, invasion and increased 
metastatic potential without affecting proliferation and growth of the primary tumor 15. 
 The upregulation of Ser tRNAs has been associated with poor prognosis in 
several types of cancer (YM500v3 database)9, suggesting that such tRNAs are 
important to achieve disease progression. The over-representation of some tRNAs can 
induce near-cognate codon misreading,  originating  protein missense errors 
(mistranslation) 51 that increased in tumor samples relative to normal tissue (Chapter 3). 
Interestingly, misincorporation of Ser at Ala protein sites is one of the most abundant 
missense errors in the proteome of tumor cells (Chapter 3). Such mistranslation can 
result in the accumulation of aberrant misfolded proteins, which in turn activate the 
proteome quality control (PQC) system, increasing protein refolding capacity, protein 
degradation or protein delivery to distinct quality control compartments that sequester 
potentially harmful misfolded species 137. Accumulation of misfolded proteins in the 
Endoplasmic Reticulum (ER) they sequester the molecular chaperone BiP (or GRP78) 
138, activating the Unfolded Protein Response (UPR) effectors PERK, ATF6 and IRE1α 
113, and inducing a pro-survival signaling program that can be used by cancer cells 
cancer cells to survive and thrive 139–142. The PERK branch of the UPR is specially 
interesting because it can modulate protein synthesis rate, induce the transcription of 
stress response genes and activate protein degradation systems, such as the proteasome 
or autophagy 144,145,150,160,161. Increased ability to degrade misfolded proteins is essential 
for tumor initiation and maintenance. This involves the upregulation of the proteasome 
through PERK-dependent Nrf2 activation 150,160. Furthermore, ATF4 activation through 
phosphorylation of eIF2α, activates autophagy 161.  This transcription factor induces the 
transcription of various autophagy genes, including Atg16l1, Map1lc3B, Atg12, Atg3, 
Atg7, Becn1, Gabarapl2. The latter alone or in combination with one of its targets, 
CHOP, also induces the transcription of p62, Nbr1 and Atg7 161. Autophagy is essential 
for cancer cells to recycle damaged organelles, macromolecules and protein aggregates 
that may originate from misfolded proteins 162. However, its role in cancer is highly 
context dependent, as it is required for Ras-mediated tumorigenesis, but it can delay 
disease onset in a pancreatic cancer model 163,164.  In pancreatic cancer it is instead 
required for tumor maintenance and progression 164.  Autophagy regulates the 
metastization process from its initial steps (cell migration and local invasion) and also 
promotes the survival of disseminating tumor cells in circulation, as well as the survival 
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of stem-like subpopulations of tumor cells, which drive the colonization at distant sites 
165–167. Hence, we can conclude that the PERK branch of the UPR is relevant for disease 
progression. 
In this work, we tried to clarify the role of deregulating a WT Ser-tRNA and 
inducing Ser misincorporation at Ala codons in tumor progression and also studied the 
contribution of the PERK branch of the UPR in this context. To do so, we increased the 
expression of a WT Ser tRNA and also expressed a mutant Ser tRNA that misreads Ala 
codons in a large cell carcinoma cell line, NCI-H460. We found that elevated 
expression of the WT Ser-tRNA increased cellular proliferation in vitro, which did not 
happen in cells expressing the misreading tRNASer(Ala). Both tRNAs increased tumor 
growth kinetics in vivo, but presented differential modulation of the PERK branch of the 
UPR. tRNA misreading showed positive impact on cell migration and local invasion, 
but the results from the metastization assay were inconclusive.  
 
5.3. Results 
5.3.1. Deregulation of the tRNA pool increases cell proliferation  
Our previous results showed that tRNAs are involved in tumor growth, and 
possibly in tumor initiation, but their effect on tumor progression was not clarified. For 
this, we expressed the misreading tRNASer(Ala), and overexpressed the Ser tRNA in a 
cell line derived from a large cell carcinoma, NCI-H460 (henceforth H460). To exclude 
transfection specific effects, we established three independent stable cell lines for each 
condition (Fig.5-1A,B).  
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Expression of the WT Ser tRNA was increased by 2.63-fold in H460 
tRNASer(WT) cell line when comparing to the Mock cell line (Fig.5-1C). The 
expression of the WT Ser tRNA expression was also increased in the H460 
tRNASer(Ala) cell line, suggesting that the expression of a specific tRNA can affect the 
expression levels of the others (Fig.5-1C). The misreading tRNASer(Ala) was also 
successfully expressed in H460 cells and its expression levels are similar to that of the 
WT Ser tRNA in the Mock cell line (Fig.5-1C). Similarly to other published results, the 
viability of H460 cell lines stably expressing the recombinant tRNAs was not altered 
(Fig.5-2).  
Elevated expression of the WT Ser tRNA increased cellular proliferation rates 
by 1.34-fold (p<0.05), but expression of the misreading tRNASer(Ala) had no impact on 
cellular proliferation (Fig.5-3A). Since overexpression of the WT Ser tRNA increased 
cell proliferation, we checked if protein synthesis rate was also upregulated, but no 
difference was observed, suggesting that other mechanisms may be involved in this 
phenotype (Fig.5-3B,C).  
 
 
 
Figure 5-1: Integration of the pIRES2-DsRed and recombinant tRNA genes in the cell lines. (A) 
Agarose gel (1%) of the PCR product obtained by amplification of genomic DNA from cell lines across 
the fragment of pIRES2-DsRed plasmid containing the tRNA gene insert. Legend: M – Molecular 
Marker; 1, 2, 3 – H460 Mock 1, 2 and 3, respectively; 4, 5, 6 – H460 tRNASer(WT) 1, 2 and 3, 
respectively; 7, 8 and 9 H460 tRNASer(Ala)  1, 2 and 3, respectively. (B) Sanger sequencing of the PCR 
products showing the WT anticodon of the tRNA (AGA) in tRNASer(WT) cell lines and the mutated 
anticodon (AGC) in the tRNASer(Ala) cell lines, indicated by the red arrow. (C) Quantification of tRNA 
expression by Snapshot sequencing. tRNAs were quantified based on a primer extension assay and values 
were normalized for the expression of GAPDH. tRNASer(WT) expression increased 2.63-fold respective 
to the Mock cell line, and the expression of tRNASer(Ala) was also detected. Interestingly expression of 
the WT Ser tRNA also increased in the tRNASer(Ala) cell line by 4-fold. Graphic depict average ± SEM 
(n=3). Data was analysed with unpaired, two-tailed Student´s t-test with Welch correction and significant 
p-values are shown (*p<0.05). 
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Figure 5-2: Stable expression of recombinant tRNAs do not impact on cell viability. Cells were 
grown for 48h and then stained with trypan blue (0.4%). Cell viability of H460 derived cell lines (n=3, 
with 4 technical replicates) did not change in the three conditions tested. Graphics depict the percentage 
of viable cells ±SEM. Data was analyzed with One-way ANOVA and Holm Sidak’s post-test (p>0.05). 
 
Figure 5-03: Expression of tRNASer(WT) increases cell proliferation without altering protein 
synthesis rate. (A) To evaluate cellular proliferation, 5x103cells/well were plated in a 96-well plate and 
BrdU incorporation during DNA synthesis was measured using a colorimetric immunoassay after 48h of 
incubation. Relative proliferation of H460 derived cell lines – Only expression of tRNASer(WT) increased 
proliferation of a tumorigenic cell line in vitro. (B) Expression of recombinant tRNAs did not influence 
protein synthesis rate in H460-derived cell lines (C) Protein synthesis rate was estimated by immunoblot 
against puromycin. From left to right, H460 Mock, H460 tRNASer(WT) and H460 tRNASer(Ala). GAPDH 
was used as a protein loading control. Graphics depict average ±SEM of n=3, with 3 technical replicates. 
Data was analyzed with One-way ANOVA and Holm Sidak’s post-test  and significant p values are 
shown (*p<0.05). 
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5.3.2. Recombinant tRNA expression did not alter in vitro transformation ability of 
H460-derived cell lines  
Regarding modulation of transformation ability in vitro, no changes were 
observed in the H460-derived cell lines expressing the recombinant tRNAs. This may 
be explained by the fact that this cell line is already tumorigenic and has high colony 
formation efficiency (Fig.5-4).   
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.3. Recombinant tRNAs accelerate tumor growth kinetics in an already 
tumorigenic cell line 
To clarify whether the recombinant tRNAs influenced tumor growth kinetics in a 
tumorigenic cell line, we inoculated H460-derived cell lines expressing our tRNA genes 
in the right dorsal flank of nude mice. Four mice were injected in the left flank with the 
Mock variant and in the right flank with cells overexpressing the WT or the misreading 
tRNA variants. Three mice were double inoculated with the same cell line in both flanks 
to rule out influence of one tumor over the other. Both tRNA constructs accelerated 
tumor growth kinetics (Fig.5-5A) and the experiment was humanely terminated 14 days 
after inoculation, since the combined volume of both tumors in most mice had reach 
2000mm3. tRNASer(Ala) expressing tumors started growing sooner that the other tumors 
and were the most homogeneous group of tumors of the experiment. At the end of the 
experiment these tumors were 1.7-fold bigger than the Mock tumors (p<0.001). Also, at 
Figure 5-4: Expression of recombinant tRNAs did not produce any effects on colony formation on 
H460-derived cell lines. Graphic depict average ±SEM of n=3, with 3 technical replicates. Data was 
analyzed with One-way ANOVA and Holm Sidak’s post-test (p>0.05). 
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day 14 tRNASer(WT) expressing tumors were 1.35-fold bigger than the Mock tumors 
and (p<0.05) (Fig.5-5A,B).  
Figure 5-5: Impact of mistranslation on tumor growth kinetics in vivo. A) Kinetics of tumor growth 
determined after inoculation of cells expressing Mock plasmid, the tRNASer(WT) and tRNASer(Ala) 
constructs. At day 14 post-inoculation both tRNA constructs increased tumor kinetics of a tumorigenic 
cell line. In the graphic each point represents the volume of an individual tumor and the error bar depicts 
the average ± SEM. Data was analyzed by Two-way ANOVA and significant p values are shown (n=7-
11) (*p˂0.05; **p<0.01) B) Representative photographs of paired tumors derived from the same animal. 
C) Photographs of representative Ki67 staining (40x amplification) from each condition.  
 
Histological analysis revealed that the tumors from each condition are very 
similar with epithelial-like cell morphology, present rare vascular invasion and have 
identical mitotic indexes. Ki67 staining demonstrated that the tumors are very 
proliferative in all conditions, with more than 95% of the cells being labeled (Fig.5-5C). 
Neither condition produced distant metastasis, which may be related to the short 
duration of the experiment. Therefore, both tRNA deregulation and mistranslation can 
influence tumor cell behavior in vivo, producing tumors that grow faster than those 
produced by the control cells. 
 
5.3.4. Tumors expressing heterologous tRNAs show differences in UPR activation 
Our previous studies showed that tumors derived from a near-normal cell line 
expressing the same heterologous tRNAs differentially activated the UPR. Here, we 
assessed the expression levels of BiP in these tumors and observed a 2-fold increase in 
both the tumors expressing the tRNASer(WT) and the tRNASer(Ala) constructs (p<0.05) 
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(Fig.5-6A). Similarly to previous results, the levels of eIF2α-P decreased by 24% 
(p<0.05), only in the tumors harboring the tRNASer(Ala) construct relative to Mock 
tumors (Fig.5-6B,E). We hypothesized that the differences in the phosphorylation of 
eIF2α observed in the different tumors could be due to differential activation of the 
ATF4 transcription factor or its downstream targets. The ATF4 transcription factor was 
activated by 1.23- and 1.29-fold in tRNASer(WT) and tRNASer(Ala) expressing tumors 
(p<0.05), respectively, relative to the Mock tumors (Fig.5-6C,E). Since ATF4 was 
activated in tumors expressing both tRNA constructs, we studied the expression of 
GADD34, the regulatory subunit of PP1α, and direct target of ATF4. Its expression was 
increased in tRNASer(Ala) expressing tumors by 5.34-fold relative to Mock tumors 
(p<0.01) (Fig.5-6D,E), supporting the results for the results obtained for eIF2α 
phosphorylation observed in these tumors (Fig.5-6B,E). 
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5.3.5. Local invasion is affected by heterologous tRNA expression  
Since expression of certain tRNAs induces cell migration, we wanted to clarify 
if this phenotype was induced by mistranslation or by tRNA upregulation. We evaluated 
the migration potential of these cells with a wound healing assay and determined the 
area covered by cells in 12h intervals up to 48h after removing the wound insert. For the 
tRNASer(Ala) expressing cell line, we observed an increase in cell migration from 12h 
after the insert was removed until the end of the assay (p<0.001) (Fig.5-7A,B). 
However, upregulation of the tRNASer(WT) reduced the migration potential of H460 
cells after 24h (p<0.01) (Fig.5-7A,B), showing a clear difference between the 
misreading tRNA and the upregulation of the WT tRNA. Concerning the extracellular 
matrix invasion, there was increased invasion potential in both cell lines, with 2.88- and 
5.58-fold increase in tRNASer(WT) (p<0.01) and tRNASer(Ala) (p<0.001)  expressing 
cell lines, respectively (Fig.5-7C,D).  
Figure 5-6: UPR modulation in H460 tumors. (A) Expression of tRNASer(WT) and tRNASer(Ala) 
increases BiP expression on H460 tumors. (B) Levels of eIF2α-P were reduced in tRNASer(Ala) 
expressing tumors. (C) tRNASer(WT) and tRNASer(Ala) expression in H460 tumors increased the 
activation of ATF4 transcription factor. (D) Expression of GADD34 was only increased in H460 
tRNASer(Ala) tumors. (E) Immunoblots against BiP, eIF2α-P, eIF2α, ATF4-P, ATF4 and GADD34. β-tub 
served as protein loading control. Graphics depict average ± SEM (n=3), with 3 technical replicates. Data 
was analyzed with One-way ANOVA and Holm Sidak’s post-test and significant p values are shown 
(*p<0.05; **p<0.01). 
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To clarify if our tRNAs affected disease progression, we performed a classic 
metastization assay by injecting 1x106 cells in the tail vein of 5 nude mice per cell line. 
After 5 weeks the mice were humanely euthanized and lungs, lymph nodes and liver 
samples were collected for histological analysis. The lung data was highly dispersed for 
all the groups, with some mice having high metastization area and others showing little 
metastization in the lungs, among the mice from the same group (Fig.5-8). Therefore, 
this experiment needs to be repeated with higher number of mice and analysis of the 
liver and lymph nodes which were recovered from these mice.  
 
 
 
 
 
Figure 5-7: Expression of recombinant tRNAs increase local invasion potential of H460 cells. (A) 
Migration potential of cells was assessed by a Wound healing assay. The area covered by cells was 
evaluated at 12h intervals. Cell lines expressing tRNASer(Ala) show increased migration potential, 
whereas cells expressing tRNASer(WT) have decreased migration potential. Graph depicts average ± SEM 
of n=3, with 3 technical replicates. Data was analyzed by Two-way ANOVA and significant p values are 
shown  (**p˂0.01; ***p<0.001).  (B) Representative pictures of the wounds at time of removal of the 
insert and 48h later for all cell lines (10x amplification). (C) The extracellular invasion capacity of the 
cell lines was evaluated by their capacity to invade matrigel-coated transwell inserts. Cells on the bottom 
of the insert were stained with DAPI and counted. Both tRNASer(WT) and tRNASer(Ala) constructs 
increased the invasion potential of H460 cells. (D) Representative photos of areas of the insert (20x 
magnification). Graph depict average ± SEM (n=3), with 2-3 technical replicates. Data was analyzed with 
One-way ANOVA and Holm Sidak’s post-test and significant p values are shown (**p˂0.01; 
***p<0.001). 
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5.4. Discussion 
Our data show that deregulation of a WT Ser tRNA and expression of a 
misreading tRNA, increases tumor growth kinetics in vivo. The tumors expressing the 
misreading tRNASer(Ala) appeared earlier and grew faster than tRNASer(WT) tumors, 
likely due to dephosphorylation of the initiation factor eIF2α. As NIH3T3 cells 
expressing the same tRNAs, when inoculated in mice presented a similar behavior, we 
hypothesized that this may be caused by overexpression of GADD34 regulatory subunit 
(Chapter 3). The data presented in this chapter confirm this hypothesis since H460-
derived tumors expressing tRNASer(Ala), overexpressed GADD34 (5-fold 
upregulation), relative to the Mock tumors. The upregulation of the BiP chaperone was 
observed in tumors expressing the tRNA constructs and this was correlated in other 
studies with high grade NSCLC tumors 168, implying that tumors expressing the tRNA 
constructs may have a more aggressive phenotype.  Additionally, activation of ATF4 
suggests that autophagy is increased in tumors harboring both tRNA constructs 161. 
Autophagy has been shown to be important not only for tumor maintenance, but also for 
disease progression 164,165.  
Figure 5-8 Impact of tRNA upregulation and misreading in tumor progression. (Upper panel) 
Graph depicts the area of the lung with metastasis. Each dot represents one animal. Box and whiskers 
represents min to max distribution and median is also represented in the box (n=3-5). Data was analysed 
with the Kruskal Wallis assay with Dunnett’s post-test (p>0.05). (Lower Panel) Representative pictures 
of the lungs of the mice in each group. 
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We studied the early stages of the metastization process and observed that cells 
expressing the misreading tRNASer(Ala) had increased migration and local invasion 
potential, relative to Mock cells. On the other hand, tRNASer(WT) expressing cells 
showed impaired migration ability, but increased invasion potential, showing that these 
tRNAs induce different phenotypes in H460 cells. There are also similar phenotypes, 
but the pathways involved in these phenotypic alterations may be distinct and need to be 
clarified in future studies. The differences that we observed in cell migration also need 
to be clarified, but it is likely that they are related with differences in the transcripts that 
are decoded by these tRNAs. Indeed, upregulation of some tRNAs increases translation 
of transcripts that are enriched in their matching codons 13. In other words, transcripts 
enriched in TCT codons, matching the AGA anticodon in the tRNASer(WT), may be 
translated more efficiently, leading to alterations in cell migration. 
Alanine residues mimic non-phosphorylated status of proteins 169. Although 
phosphorylation is context specific 170, the insertion of Ser at Ala sites has the potential 
to activate signaling pathways that were otherwise silent and may affect cell migration 
ability. Interestingly, both tRNA constructs were able to increase extracellular matrix 
invasion in these cells. To clarify these mechanisms we will have to identify the 
proteins that contain amino acid misincorporations and map them to specific biological 
processes. Ribosome profiling coupled with ribo-seq may also provide clues about the 
fraction of the translatome that is affected in these cells. Potential targets will then be 
validated by decreasing their expression with siRNAs. Additionally, other branches of 
the UPR should also be monitored since IRE1α has also been implicated in cell invasion 
and its activation may help to further characterize our cell models 171. The proteasome 
activity and autophagy are likely altered and should also be monitored in future studies. 
 
5.5. Materials and Methods 
5.5.1. Cell Culture 
NCI-H460 were obtained from the American Type Culture Collection (ATCC) 
and were cultured in RPMI 1640 medium (Gibco, Life Technologies), supplemented 
with 10% Fetal Bovine Serum (FBS) (Sigma) and 1% Pen/Strep. Cells were maintained 
in an incubator at 37ºC with 5% CO2 and 95% relative humidity. To execute the 
following procedures, cells were detached using Tryple Xpress (Gibco, Life 
Technologies). Cells were regularly tested for the presence of mycoplasma. 
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5.5.2. Generation of stable cell lines 
5.0 x 104 NCI-H460 cells were plated in MW24 plates, incubated for 48h and 
then were transfected using 1.5µg of plasmid DNA and 0.75µL of Lipofectamine® 
3000 (Invitrogen). Three independent transfections were carried out for the empty 
vector (Mock), the plasmid containing an extra copy of the wild WT tRNASerAGA(WT) 
or the misreading tRNASerAGC(Ala). Stably transfected cells were obtained after three 
weeks of selection in 800µg/ml of G418.  
 
5.5.3. Extraction and Quantification of gDNA 
To ensure the plasmid did not acquire mutations when integrated in the genome, 
gDNA was extracted and Sanger sequenced. For that, the NZY Tissue gDNA Isolation 
Kit was used, following the recommended instructions. gDNA concentration was 
determined using the NanoDrop. 
 
5.5.4. Cellular Viability Assay 
1.5x105 cells/well were seeded in a 24-well plate. After 48h, cells were detached 
and equal volumes of cell suspension and trypan blue were mixed. Finally, cell viability 
(%) was obtained by counting the live and death cells using a TC10Tm Automated Cell 
Counter (Bio-Rad). This assay was performed in triplicates and repeated three times. 
 
5.5.5. Cellular Proliferation Assay 
To evaluate cellular proliferation, we used a colorimetric immunoassay ELISA, 
based on the measurement of BrdU incorporation during DNA synthesis (Roche, 
Cat.11647229001), following manufacturer’s instructions. 5x103cells/well were plated 
in a 96-well and analysis was performed 48h later. 
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5.5.6. Anchorage-Dependent Colony Formation Assay 
300 cells per condition were seeded in 60mm dishes and maintained in culture 
for 9 days. The colonies were then fixed using ice cold methanol and incubated at -30ºC 
for 30min. Methanol was removed and a solution of 0.1% crystal violet in 20% 
methanol was added and the plates were incubated at room temperature for 30min. 
Plates were washed with milliQ H2O to remove excess dye and the colonies were 
counted. This assay was performed with triplicates and repeated four times.  
 
5.5.7. Determination of Protein synthesis rate  
To determine protein synthesis rate, we used a non-reactive fluorescence-
activated cell sorting-based assay, called SUnSET with few modifications. 1x106cells 
were plated in 60mm petri dishes and after 48h, 10% v/v puromycin (Sigma Aldrich) 
was added to each plate. Cells were then incubated for 15 min. Total protein lysates 
were obtained from cells with Lysis Buffer (0.5% Triton X-100, 50mM HEPES, 
250mM NaCl, 1mM DTT, 1mM NaF, 2mM EDTA, 1mM EGTA, 1mM PMSF, 1mM 
Na3VO4) supplemented with a cocktail of protease inhibitors (Roche). Cells were 
sonicated with a probe sonicator in 5 pulses of 5 seconds. After centrifugation at 16000g 
for 30min, protein in the supernatants was quantified using the BCA assay (Thermo 
Fisher Scientific). 100 µg of protein was denaturated with loading buffer (6x) at 95ºC 
for 5 min, resolved in 10% SDS-PAGE and blotted onto nitrocellulose membranes 
(0.2µm) (GE Healthcare Life Sciences). Anti-puromycin, clone 12D10 (kindly given by 
Philippe Pierre) was used (1:2500) to detect the incorporation of puromycin in proteins. 
IRDye800 goat anti-mouse secondary antibody (Li-cor Biosciences, Cat.400-33) was 
used (1:10000 dilution) and detected in an Odyssey Infrared Imaging System (Licor 
Biosciences). Membranes were also probed with Anti-GAPDH (Santa Cruz 
Biotechnology) (1:1000) as a loading control. 
 
5.5.8. Immunoblots 
Total protein lysates were obtained with the same extraction method used with 
the SUnSET assay. 40µg of protein were immunoblotted onto nitrocellulose membranes 
with antibodies  against eIF2α (1:1000; Cell signalling); phospho-eIF2α (1:1000; 
Abcam); ATF6 (1:400; Stressgen); GADD34 (1:1000 ThermoFisher Scientific); 
phospho-ATF4 (1:1000; tebu-bio); ATF4 (1:1000; tebu-bio) and β-tubulin (1:1000; 
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Invitrogen). IRDye680 goat anti-rabbit or IRDye800 goat anti-mouse secondary 
antibodies (1:10000, Li-cor Biosciences) were used and the signal was detected using an 
Odyssey Infrared Imaging system (Li-cor Biosciences).  
 
5.5.9. Tumor induction assay 
Six-week-old male N:NIH(s)II:nu/nu nude mice were previously obtained from 
the Medical School, University of Cape Town in 1991 and then reproduced, maintained 
and housed at IPATIMUP Animal House, at the Medical Faculty of the University of 
Porto, in a pathogen-free environment under controlled conditions of light and 
humidity. Male nude mice, aged 6-8 weeks, were used in the in vivo experiments. 
Animal experiments were carried out in accordance with the Guidelines for the Care 
and Use of Laboratory Animals, directive 2010/63/EU.  To measure tumorigenic 
potential in vivo, H460 cell lines harboring the empty vector (Mock), the tRNASer(WT) 
and the misreading tRNASer(Ala) were subcutaneously injected with 1x106 cells in the 
dorsal flanks using a 25-gauge needle. A total of 7 mice per group were used.  Four 
mice were injected in the left flank with the Mock variant and in the right flank with the 
cells misexpressing the WT or the misreading variants of each previously described 
clone. Three mice were double inoculated with the same cell line in both flanks to rule 
out influence of one tumor over the other. Mice were weighed, and tumor width and 
length were measured with calipers three times per week. Tumor volumes were 
calculated assuming ellipsoid growth patterns. Mice were humanely euthanized when 
tumors reached a median volume of 2000mm3 or whenever any signs of disease were 
detected. Tumors and lungs, were collected, fixed in 10% buffered formalin, paraffin 
embedded and then sectioned for histological examination. A part of each tumor was 
frozen in liquid nitrogen and stored at –80ºC until used. 
 
5.5.10. Ki67 immunohistochemistry 
Tumor sections obtained from mice tumors were de-paraffinized, re-hydrated 
with graded ethanol and washed in distilled water followed by PBS.  Heat induced 
antigen retrieval was performed using 0.01M citrate buffer, pH 6.0, for 40 min. To 
block endogenous peroxidase activity, slides were treated with 0.5% H2O2 in methanol, 
for 20 min at room temperature (RT). To block non-specific binding, slides were 
exposed to large volume of ultra V block solution (LabVision), for 30 min at RT. Slides 
5. tRNA deregulation modulates cell migration and increases cell invasion potential 
95 
 
were subsequently incubated with rabbit monoclonal antibody against Ki67 (clone SP6; 
Thermo Scientific) at 1:400 in large volume ultra Ab dilution (Lab Vision), for 2h at 
RT. After washing, sections were incubated with the Envision detection system 
peroxidase/DAB (Dako) followed by hematoxilin staining using the standard protocol. 
 
5.5.11. Wound Healing Assay 
2 well Culture-inserts (ibidi) were fixed in the bottom surface of 24-well plates. 
A cell suspension of 2.5 x105/ml was added to each well and after 24h, when cells were 
forming a confluent monolayer, the insert was removed leaving a gap of approximately 
500µM between the cells. Fresh medium was added and photos were taken every 12h to 
monitor cell migration. 
 
5.5.12. Invasion Assay 
1x105 cells were ressuspended in RPMI 1640 without supplements and then 
seeded on top of a transwell insert (8µM pores, Corning) coated with Matrigel. Media 
supplemented with 10% FBS was added to the bottom of the transwell insert to act as 
chemoattractant. After 24h the matrigel and the cells on top of the membrane were 
removed with a cotton swab. The cells on the bottom of the membrane were fixed with 
methanol and the nuclei were stained with DAPI. The number of cells present in 5 
fields/chamber were then counted in a fluorenscence microscope. 
 
5.5.13. in vivo Metastization 
1x106 cells of H460-derived cell lines were injected in the tail vein of six-week-
old male N:NIH(s)II:nu/nu nude mice. A total of 5 five mice were randomized and used 
in each group in a total of 3 groups. Each group was injected with a different cell line 
(H460 Mock, H460 tRNASer(WT) or H460 tRNASer(Ala)). We monitored the weight of 
the animals at least twice a week and after 5 weeks we humanely euthanized the 
animals. Lungs, liver and lymph nodes were collected, fixed in 10% buffered formalin, 
paraffin embedded and then sectioned for histological analysis where the total 
metastization area was evaluated. 
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5.5.14. Statistical analysis  
For all the assays, except for the in vivo experiments, our data represents 3 
independent biological replicates and 3-4 independent experiments. Average values are 
usually shown and error bars represent the standard error of the mean (SEM).  Statistical 
significance was determined using One-way ANOVA with Holm’s Sidak post-test; 
Kruskal-Wallis with Dunnet’s post-test or Two-Way ANOVA for the in vivo 
experiments.  
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6.1. Abstract 
Non-Small Cell Lung Cancer is responsible for many cancer-related deaths 
worldwide, due to late stage diagnosis and disease recurrence after therapy. Although 
novel therapies have been developed recently, patients are normally treated with 
platinum-based drugs. The resistance mechanisms to cisplatin involve several non-
overlapping molecular pathways that allow cancer cells to reduce the amount of drug in 
the cell, inhibit apoptosis, and upregulate pro-survival pathways, such as the Akt-
pathway. Alterations in the unfolded-protein response (UPR), levels of molecular 
chaperones and autophagy mediators, also reduce tumor cell sensitivity to cisplatin 
effects. Mistranslation is a phenotype that has been associated with cellular adaptation 
to stressful environments, as well as antibiotic and antifungal resistance in Candida 
albicans and Mycobacteria, raising the hypothesis that it may also play a role in cancer 
therapy resistance.  In the previous chapters of this thesis, we observed that a non-small 
cell lung cancer cell line (H460), known to be resistant to conventional chemotherapy, 
displayed UPR deregulation (Chapter 5) and increased misincorporation of Serine at 
Alanine sites (Chapter 3), suggesting that resistance to cisplatin (CDDP) may be 
correlated with UPR dysfunction, amino acid misincorporation or tRNA-pool 
deregulation. In fact, the mistranslating cells (expressing tRNASer(Ala)) showed reduced 
sensitivity to both cisplatin and carboplatin in vitro, while cells with upregulation of the 
tRNASer(WT) were only resistant do carboplatin, relative to Mock control cells. Our in 
vivo data demonstrate that tumors overexpressing the tRNASer(WT) were more resistant 
to CDDP in vivo than Mock tumors, and that tRNASer(Ala) expressing tumors also did 
not respond to CDDP treatment. This chapter highlights a new putative mechanism of 
CDDP resistance mechanism mediated by tRNAs. 
 
6.2. Introduction 
Cancer mortality is mainly fueled by tumor heterogeneity and by the acquisition 
of mechanisms that enable tumor cells to resist therapy over time.  The known 
mechanisms by which tumor cells acquire drug resistance are drug inactivation, drug 
target alteration, drug efflux, DNA damage repair, cell death inhibition, epithelial-
mesenchymal transition and epigenetic modifications 89. However, in the vast majority 
of the patients treated with chemotherapy, the mechanisms through which tumor cells 
develop multi-drug resistance is still unclear 172. Resistance to therapy is generally 
classified as intrinsic if the tumor does not respond to the first line of treatment, 
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indicating pre-existing resistance mechanisms in tumor cells; or acquired, if the disease 
progresses after an initial response 173.  
Non-Small Cell Lung Cancer (NSCLC) is usually diagnosed in advanced stages 
and the 5-year overall survival of the patients is just 10-15%, still being the non-gender 
specific cancer responsible for the majority of cancer-related deaths worldwide 174. 
NSCLC pathogenesis is not yet fully understood and further efforts are needed to 
characterize the disease from a molecular point of view to identify novel potential 
targets for therapy. Patients diagnosed with NSCLC normally undergo surgery to 
remove the primary tumor and receive adjuvant chemotherapy, because 30-55% of 
patients relapse after curative resection due to the presence of undetectable 
micrometastasis or circulating tumor cells 175. Cytotoxic chemotherapy regiments in 
NSCLC normally combine two different drugs: usually one platinum derived drug 
(most often cisplatin) and paclitaxel, etoposide, vinblastine, gemcitabine, pemetrexed, 
vinorelbine, or docetaxel 176–181.  
Several targeted therapies were developed to improve patient Overall Survival 
(OS), in subsets of patients which have tumors with specific mutations, most often 
mutations in the epidermal growth factor receptor (EGFR). EGFR is overexpressed in 
up to 40-80% of NSCLC and can be activated by either increased expression of the 
receptor, production of excess ligand or activating mutations of EGFR within malignant 
cells. EGFR activates the PI3K/AKT and RAS/RAF/MAPK pathways, inducing the 
expression of genes responsible for increased cell survival, proliferation, angiogenesis, 
invasion and metastasis 182,183. The activating mutations can be targeted by small 
Tyrosine Kinase Inhibitors (TKI) (gefitinib or erlotinib) or using antibodies (cetuximab) 
184. Although the tumors initially respond to these drugs, most patients will relapse 
either through secondary EGFR mutations (most common mechanism) or activation of 
EGFR-independent pathways to circumvent EGFR inhibition 185. However, 30% of the 
mechanisms which lead to resistance are still unknown 186.  
Other targeted therapies to specific gene alterations in NSCLC were also 
developed.  Rearrangements, activating point mutations or gene amplification of 
anaplastic lymphoma kinase (ALK) were identified in 2% to 7% of NCSLC, in the 
absence of KRAS and EGFR mutations and are targeted with small TKIs (crizotinib, 
ceritinib and alectinib) 187,188. The overexpression of the vascular endothelial growth 
factor (VEGFA) is related to poor prognosis and targeting this protein with a 
monoclonal antibody (Bevacizumab) improved  progression free survival in NSCLC 
Unravelling the roles of statistical proteomes in human cancer 
100 
 
patients in combination with cisplatin 182,184,189.  Also, alteration of mesenchymal-
epithelial transition factor (MET) expression is also relevant in NSCLC and has been 
targeted with small multikinase TKIs, such as crizotinib, cabozantinib and golvatinib; 
spefic TKIs like capmatinib, tepotinib and tivantinib; or monoclonal antibody therapy 
with onartuzumab and emibetuzumab 190. 
However, the most prevalent mutations in NSCLC are KRAS gene mutations, 
which are present in 20-30% of the tumors, representing 90% of all RAS mutations in 
adenocarcinomas. These mutations are common in smokers and patients that were 
exposed to asbestos, being more prevalent in women, and there is no currently approved 
targeted therapy for this set of patients 191,192. Therefore, despite the progress achieved 
in many targeted therapies that have been developed to improve disease outcomes, 
platinum-based chemotherapy still remains the therapeutic choice for most patients 193. 
Cisplatin (CDDP), the most used cytotoxic drug in NSCLC, is able to crosslink 
with the purine bases on the DNA, interfere with DNA repair mechanisms, cause DNA 
damage and induce apoptosis in cancer cells 194. Yet, only ~1% of CDDP interacts with 
DNA. The molecular mechanisms through which CDDP acts are poorly understood, but 
may involve: i) accumulation of ROS and nitric oxide (NO), which exacerbate CDDP 
genotoxicity and favour the opening of the permeability transition pore complex 
(PTPC); ii) transduction of mitochondrial outer membrane permeabilization (MOMP)-
stimulatory signal via the PTPC component voltage-dependent anion channel 1 
(VDAC1) and the pro-apoptotic BCL-2 family members BAK1 and BAX; iii) activation 
of cytoplasmic p53 which promotes MOMP via various mechanisms and iv) trigger ER 
stress response 94.  
Carboplatin is the only platinum derived drug which has some advantages over 
CDDP, as it induces fewer side effects 195. It has a bidentate dicarboxylate (CBDCA) 
ligand instead of the two chloride ligands, which are the leaving groups in cisplatin 196. 
It has lower reactivity and slower DNA binding kinetics, which limits excretion of the 
drug. The lower excretion rate of carboplatin results in higher drug availability, for a 
longer period of time, but 90% of carboplatin can be recovered in urine compared to 
50% of cisplatin 197,198. The half-lives of carboplatin and CDDP are 30h and 1.5-3.6h, 
respectively. Nevertheless, carboplatin is less effective than cisplatin and usually a four 
times higher dose is needed to achieve the same result 194. Therefore, carboplatin 
regimens are only used when patients have co-morbidities or display a high toxicity to 
cisplatin 199. 
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Although the majority of patients follow a platinum based chemotherapy, most 
patients develop resistance during sequential cycles of treatment with CDDP. CDDP-
resistant cells show decreased CDDP accumulation, and the identification of the 
proteins responsible for drug resistance is necessary to identify new therapy targets to 
circumvent or decrease CDDP resistance 200.  
Resistance to CDDP is frequently multifactorial and relies on simultaneous 
activation of multiple, non-redundant molecular pathways 94. First, the vast majority of 
CDDP is uptaken by the cells through copper transporters, namely CTR1, and is 
exported from the cell through ATP7B. Alterations in the expression level, subcellular 
localization and functionality of these transporters have already been linked to CDDP 
resistance, as they can reduce the amount of CDDP available in the cytoplasm 201,202. 
The sensitivity of cancer cells to CDDP is limited by the robustness of DNA repair 
mechanisms. The mismatch repair (MMR) machinery is mainly responsible for 
detecting the DNA adducts formed by CDDP, whereas the nucleotide excision repair 
(NER) system resolves the majority of damages caused by this drug 203. The 
upregulation of genes involved in NER are positively correlated with CDDP resistance, 
risk of progression and death 204. Interestingly, the MMR activation recognizes the 
CDDP adducts but is unable to resolve them. This triggers a cytotoxic response that 
leads to apoptosis 203. Therefore, the main effectors of the MMR pathway, MLH1 and 
MSH2 are usually downregulated or mutated in tumors that are resistant to CDDP 205–
207. CDDP can also cause single or double-strand breaks (SSB and DSB, respectively) in 
the DNA that are repaired by the base excision repair (BER) pathway and the 
homologous recombinantion (HR) system, respectively. CDDP resistant tumors seem to 
rely on these systems to survive, as they often upregulate PARP1 (BER pathway) and 
BRCA1 (HR system) and are sensitive to targeted therapies, such as the treatment with 
PARP1 inhibitors 204,208. 
Tumor cells also have to circumvent the activation of the pro-apoptotic signals 
upon CDDP-based therapy. CDDP can cause mitochondrial-DNA (mtDNA) mutations, 
which result in partial mitochondrial dysfunction and have been linked to chemotherapy 
resistance 209,210. Tumor cells often impair pro-apoptotic signal transducers, such as p53, 
to overcome CDDP cytotoxic effects 211,212, and upregulate BCL-2 anti-apoptotic 
proteins, BCL-2, Bcl-xL and MCL-1 213–215. 
The susceptibility of cancer cells to CDDP can also be limited by molecular 
pathways that are not directly activated by CDDP, but induce compensatory survival 
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signals. Tumors can activate pathways that induce strong proliferation signals, such as 
the AKT or the mTOR pathways and activate antioxidant defences to counteract ROS 
levels induced by CDDP 216–218. Finally, resistance to CDDP can also be achieved by 
upregulating the PQC system. Activation of the UPR, induced by mild ER-stress prior 
to treatment with CDDP, inhibits cancer cell sensitivity to the treatment through 
regulation of autophagy 143. Moreover, increased expression of the UPR master 
regulator, BiP, in NSCLC, is correlated with shorter OS and contributes to the optimal 
activation of the AKT pathway, leading to CDDP resistance 95,219. The heat shock 
proteins (HSPs) are not only essential to regulate posttranslational folding, stability and 
function of oncoproteins that are often mutated, but also regulate tumor development, 
progression, metastasis and drug resistance (not only CDDP), therefore their 
overexpression is an indicator of poor prognosis 54. 
Several reports indicate that protein mistranslation, which often leads to protein 
misfolding, induces growth advantages and phenotypic drug resistance to antibiotics in 
bacteria and fungi 104. In Mycobacteria, substitutions of glutamate for glutamine and 
aspartate for asparagine caused by tRNA mischarging, increase phenotypic resistance to 
rifampicin, whereas decreasing mistranslation produces increased susceptibility to the 
antibiotic 124. In Candida albicans, mistranslation is controlled by the environment and 
high levels of mistranslation correlate with phenotypic diversity and fluconazole 
resistance 119,123,220. Mistranslation can also help Mycoplasma to evade the host’s 
immune system in a manner similar to antigenic variation and in E.coli resistance to 
stress and antibiotics increases if the MetRS misacylates other tRNAs with Met 84. 
We have previously observed that deregulation of the tRNA pool and expression 
of misreading tRNASer(Ala) were beneficial to tumor growth, local invasion and 
activated the UPR. Given that UPR activation has been linked to CDDP resistance and 
that mistranslation has been associated with drug resistance, we hypothesized that 
deregulation of the tRNA pool or tRNA mischarging could also induce resistance to 
platinum-based drugs. To test this hypothesis, we exposed H460- and A549-derived cell 
lines expressing tRNASer(WT) and tRNASer(Ala) to CDDP and carboplatin both in vitro 
and in vivo. We observed that cells expressing the mistranslating tRNASer(Ala) were 
more resistant to cisplatin and carboplatin in vitro, but cells with upregulation of the 
tRNASer(WT) were only resistant to carboplatin, relative to Mock control cells. We also 
demonstrated that tumors overexpressing the tRNASer(WT) were more resistant to 
CDDP in vivo than Mock tumors, and that tRNASer(Ala) expressing tumors did not 
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respond to CDDP treatment.  This data shows that tRNA pool deregulation and tRNA 
misreading are sufficient to induce resistance to platinum-based chemotherapy.  
 
6.3. Results 
6.3.1. Mistranslating cells are more resistant to conventional therapy 
We observed in Chapter 5 that mistranslation has an impact on tumor growth 
and local invasion, indicating that the role of tRNAs in tumorigenesis goes beyond what 
was anticipated. In this chapter, we focused on the hypothesis that mistranslation could 
enhance the ability of cancer cells to resist chemotherapy, as it increases drug resistance 
in other organisms. We used our previously established H460-derived cell lines 
expressing tRNASer(WT) and tRNASer(Ala) constructs to test this hypothesis. As the 
H460 parental cell line has an activating mutation in the KRAS gene (Q61R), we chose 
to test their resistance to platinum-based drugs, which would be the therapy of choice 
for patients with this mutation 221. 
The colony formation assay assessed the ability of individualized cells exposed 
to treatment to resist the treatment itself and to proliferate and form colonies. The H460-
derived cell lines expressing the misreading tRNASer(Ala) were more resistant to CDDP 
than the control, showing an increase in colony formation of 1.48-fold (p<0.01) (Fig.6-
1). On the other hand, either cell lines expressing the misreading tRNASer(Ala) or 
overexpressing the tRNASer(WT), were resistant to the treatment with Carboplatin, with 
an increase in colony formation of 1.35-fold (p<0.05) and 1.45-fold (p<0.05), 
respectively (Fig.6-2).  
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To exclude the hypothesis that these data could be cell line-specific, we stably 
expressed our tRNA constructs in A549 cells (Lung adenocarcinoma). After verifying 
the integration (Fig.6-3, Upper panel) and sequence integrity of the plasmids (Fig.6-3, 
Lower panel) in the genome of these cells, we used them to confirm the results 
obtained with the H460-derived cell lines.  
 
 
 
Figure 6-2: In vitro resistance to carboplatin 
of H460-derived cell lines.  Expression of 
either tRNASer(WT) or misreading tRNASer(Ala) 
diminished the sensitivity of H460 cells to 
treatment with carboplatin, showing an increase 
in colony formation of 1.35-fold and 1.45-fold, 
respectively. Graph depicts average ± SEM 
(n=3). Data was analyzed with One-way 
ANOVA, with Dunnet’s post-test and signicant 
p-values are shown (*p<0.01). 
 
Figure 6-1: In vitro resistance to cisplatin of 
H460-derived cell lines.  Misreading 
tRNASer(Ala) were more resistant to CDDP 
than the control, showing an increase in colony 
formation of 1.48-fold. Graph depicts average 
± SEM (n=3). Data was analyzed with One-
way ANOVA, with Dunnet’s post-test and 
signicant p-values are shown (**p<0.01). 
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Figure 6-3: Integration of pIRES2-DsRed and recombinant tRNAs in the cell lines. (Upper panel) 
Agarose gel (1%) of the PCR product obtained by amplification of genomic DNA from cell lines across 
the fragment of pIRES2-DsRed plasmid containing the tRNA insert. NTC represents the negative control. 
(Lower panel) Sanger sequencing of the PCR products showing the AGA to AGC anticodon mutation of 
the tRNA tRNASer(WT), creating the misreading tRNASer(Ala) in the A549 cell line. 
  
 
 
 
 
 
 
 
 
 
 
The drug resistance pattern of the A549-derived cell lines was very similar to 
that of the H460-derived cell lines (Fig.6-4). Treatment of A549-derived cell lines with 
15 µM  of CDDP, showed that only cells that expressed the misreading tRNASer(Ala) 
were more resistant than the control with a 1.55-fold increase in colony formation 
(p<0.05) (Fig.6-4, Left panel). Also, upon treated with 10 µM of Carboplatin, both the 
cell lines harboring the recombinant tRNAs showed increased colony formation of 1.21-
fold (p<0.001) and 1.32-fold (p<0.001), for tRNASer(WT) and tRNASer(Ala) cell lines, 
respectively (Fig.6-4, Right panel).  
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These results confirm that both the upregulation of the WT-Ser tRNA and the 
expression of the misreading tRNASer(Ala) increase resistance of NSCLC cancer cells to 
conventional chemotherapy, independently of the parental cell line where the 
recombinant tRNAs were expressed.  
We further studied if tumors expressing these tRNAs were resistant to CDDP 
treatment in vivo. We chose CDDP for the in vivo treatments, since it was the drug that 
produced the biggest fold change in terms of colony formation in cells expressing the 
misreading tRNASer(Ala). We inoculated nude mice with H460-derived cell lines in 
their dorsal flanks and allowed them to grow until they reached ~100mm3, before 
initiating the treatment with cisplatin. We did bilateral injections in each mouse and 
randomized them in 4 groups, presented in Table 6-1. 
 
Groups Cells injected in 
the left flank 
Cells injected in 
the right flank 
Treatment 
Group 1 Mock tRNASer(WT) CDDP 
Group 2 Mock tRNASer(WT) Vehicle 
Group 3 Mock tRNASer(Ala) CDDP 
Group 4 Mock tRNASer(Ala) Vehicle 
Table 6-1: Groups of mice used in the in vivo experiment. In this table the information about the cell 
lines that were injected in each flank of the mice and the treatment that they received is represented. 
  
 
 
 
 
 
 
Figure 6-4: In vitro resistance to platinum-based drugs of H460-derived cell lines. (Left panel) 
Misreading tRNASer(Ala) were more resistant to CDDP than the control, showing an increase in colony 
formation of 1.55-fold. (Right panel) Expression of both tRNASer(WT) and misreading tRNASer(Ala) 
decreased the sensitivity of H460 cells to treatment with carboplatin, showing an increase in colony 
formation of 1.21-fold and 1.32-fold, respectively.  Graphics depicts average ± SEM (n=3). Data was 
analyzed with One-way ANOVA, with Dunnet’s post-test and signicant p-values are shown 
(*p<0.05;***p<0.001). 
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The results obtained in vivo were slightly different from those observed in vitro. 
The mice from groups 1 and 2 that harbored the Mock and tRNASer(WT) variants, 
showed similar tumor kinetics in the mice that received vehicle. When we treated the 
mice with CDDP, Mock tumors were much more sensitive to the drug after the second 
treatment. Conversely, the tumors expressing tRNASer(WT) were resistant to treatment 
and grew slightly slower than the tumors expressing the same vector that were treated 
with the vehicle (p>0.05) (Fig.6-5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
On the other hand, the Mock tumors that were paired with tRNASer(Ala) 
expressing tumors, did not grow when mice were treated with the vehicle or cisplatin 
(Fig.6-6A, B). The reasons for this phenotype are difficult to understand and the 
experiment should be repeated in the near future. In fact, tumors harboring the 
tRNASer(Ala) vector grew faster in the mice that were treated with CDDP relative to 
Mock tumors that grew on the left flank of the same mice (Fig.6-6A,C). However, the 
Mock tumors that were treated with cisplatin grew similarly to those that received the 
vehicle (Fig.6-6). Therefore, it is not clear if the tRNASer(Ala) expressing tumors are 
Figure 6-5:  tRNASer(WT) tumors resistance to cisplatin in vivo. (A) Upregulation of the 
tRNASer(WT) inhibits sensitivity of H460-derived tumors to systemic treatment with cisplatin (p<0.01, 
from day 15 post-inoculation). (B) Group 1 tumors, treated with vehicle. Tumors derived from the same 
animal are aligned vertically. Mock tumors are slightly smaller than the tumors expressing tRNASer(WT). 
(C) Group 2 tumors, treated with 4mg/kg of CDDP. Tumors derived from the same animal are aligned 
vertically. We can observe that Mock tumors are slightly smaller than the tumors expressing 
tRNASer(WT). 
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more resistant to cisplatin that the control tumors; despite the differences in growth 
kinetics. In any case, these tumors were not responsive to CDDP treatment.  
 
In conclusion, the treatment response observed in isolated cells in vitro was not 
correlated with tumor growth in vivo, when the drug is given systemically. We are 
unable to explain these differences at present, but lower drug availability in a tumor 
mass when compared to that of individualized cells in vitro, may contribute to those 
differences. 
 
6.4. Discussion 
Our data show that deregulation of the tRNA pool alone is sufficient to reduce 
tumor sensitivity to cytotoxic chemotherapy with cisplatin. Expression of a misreading 
tRNASer(Ala) also decreases the sensitivity of tumor cells to CDDP and carboplatin in 
vitro and inhibit the response to cisplatin treatment in vivo. The molecular mechanisms 
that support these phenotypes still need to be clarified, but it is likely that activation of 
the UPR by the recombinant tRNAs prior to treatment may be involved. The fact that 
Figure 6-6: tRNASer(Ala) tumors resistance to cisplatin in vivo. (A) Cisplatin treatment has little effect 
on Mock and tRNASer(Ala) expressing tumors, although the latter had faster growth kinetics (p<0.01, 
from day 15 post-inoculation) than the former. (B) Group 3 tumors, treated with vehicle. Tumors derived 
from the same animal are aligned vertically. We can observe that Mock grew very little when relative to 
tumors expressing  tRNASer(Ala). (C) Group 4 tumors, treated with 4mg/kg of CDDP. Tumors derived 
from the same animal are aligned vertically. We can observe that Mock tumors are slightly smaller than 
the tumors expressing tRNASer(Ala). 
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cells with upregulation of the tRNASer(WT) were resistant to carboplatin in vitro only, 
may be explained by the higher reactivity and faster DNA binding kinetics of cisplatin. 
Also, mistranslation in tRNASer(Ala) expressing cells is expected to increase the 
proteomic and phenotypic diversity, enhancing adaptation capacity to stress 83,85. 
Therefore, we hypothesize that cisplatin induces rapid and acute stress to cells, whereas 
the lower reactivity of carboplatin gives tRNASer(WT) expressing cells the time to adapt 
and thrive under such conditions. 
The overexpression of the Ser tRNA (chr6.tRNA5-SerAGA) has been associated 
to reduced OS in Breast invasive carcinoma, adrenocortical carcinoma, colon 
adenocarcinoma, head and neck squamous carcinoma and kidney renal clear cell 
carcinoma (YM500v3 database). Moreover, this tRNA has been associated with 
augmented risk of recurrence, which may indicate that it can influence therapy outcome 
9. Indeed, our in vivo results show that the upregulation of this tRNA is sufficient to 
increase resistance to cisplatin in NSCLC tumors. 
Considering our previous results (Chapter III), we could not anticipate that 
Mock tumors, paired with tRNASer(Ala) tumors, would not grow in vivo. To eliminate 
the hypothesis of tRNASer(Ala) tumors affecting the growth of Mock tumors and 
confirm that tRNA misreading reduces tumor sensitivity to CDDP, further experiments 
with mice injected with only one of the cell lines need to be carried out. Mice from the 
same litter were randomly distributed to different groups in our experiment, to ensure 
that each group had mice with different genetic backgrounds, ages and weights, so these 
would not be interfering factors. The subcutaneous injections were also made in no 
specific order. Therefore, it seems unlikely that the effect observed in this group of mice 
results from experimental biases that we were not aware off.  
Careful molecular profiling of the tumors should be carried out to understand the 
mechanisms through which resistance to cisplatin is achieved. One hypothesis is that 
pre-activation of the UPR in these cells reduces their sensibility to cisplatin. Our 
Chapter III data show that tumors expressing these tRNA constructs active the UPR, 
especially BiP, which has been related to decreased OS in NSCLC and resistance to 
CDDP 95,219. However, given that the UPR activation can be a double-edged sword for 
tumors, depending on the duration of the activation and factors that are still unknown 
other mechanisms cannot be excluded 143,222. For example, the level of pre-adaptive 
mutations in the genome may also increase due to proteome instability generated by the 
recombinant tRNAs 83. Therefore exome sequencing should be used to map such 
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mutations. Monitoring the translatome using ribosome profiling coupled with ribo-seq 
could also provide clues about the genes that effectively translated in those tumors 13. 
Finally, proteomic alterations should also be monitored since the misreading 
tRNASer(Ala) increases misincorporations of Ser at Ala (Chapter 3)  and some of these 
misincorporations may induce phenotypic mutations important for the establishment of 
the resistant phenotype. 
 
6.5. Materials and Methods 
6.5.1. Cell Culture 
NCI-H460 and A549 cell lines were obtained from American Type Culture 
Collection (ATCC). Both cell lines were cultured in RPMI 1640 medium (Gibco, Life 
Technologies), supplemented with 10% Fetal Bovine Serum (FBS) (Sigma) and 1% 
Pen/Strep. During the assays, cells were cultured without Pen/Strep. Cells were 
maintained in an incubator at 37ºC with 5% CO2 and 95% relative humidity. To execute 
the following procedures, cells were detached using Tryple Xpress (Gibco, Life 
Technologies). Cells were regularly tested for mycoplasma presence. 
 
6.5.2. Generation of stable cell lines 
5.0 x 104 NCI-H460 or A549 cells were plated in MW24 plates and after 48h 
were transfected using 1.5µg of plasmid DNA and 0.75µL of Lipofectamine® 3000 
(Invitrogen). NCI- H460 cells were transfected three independent times with the empty 
vector (Mock), the plasmid containing an extra copy of the wild type tRNASerAGA(WT) 
or the misreading tRNASerAGC(Ala). Stably transfected cells were obtained after three 
weeks of selection with 800µg/ml or 1000 µg/ml of G418 for NCI-H460 and A549, 
respectively.  
 
6.5.3. Extraction and Quantification of gDNA 
To ensure that the plasmid did not acquire mutations when integrated in the 
genome, gDNA was extracted and sequenced. The NZY Tissue gDNA Isolation Kit was 
used, following the recommended instructions, and gDNA concentration was quantified 
using a NanoDrop. 
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6.5.4. Anchorage-Dependent Colony Formation Assay 
300 cells per condition were seeded in 60mm dishes. 24h later, cells were treated 
with 10µM (H460) or 15µM (A549) of cisplatin for one hour or 5µM (H460) or 10µM 
(A549) of carboplatin for two hours. Drug concentration was optimized in order to 
inhibit approximately 50% of colony formation in the cells harbouring the empty 
plasmid. Other plates were also with the respective vehicles (0.9% of NaCl for cisplatin 
and DMSO for carboplatin) as controls. After the treatment, cells were washed with 1x 
PBS and fresh medium was added to each plate. After 9 days, the colonies were fixed 
using ice cold methanol and incubated at -30ºC for 30min. Methanol was removed and a 
solution of 0.1% crystal violet in 20% methanol was added and the plates were 
incubated at room temperature for 30min. Plates were washed with H2O milliQ to 
remove excess dye and colonies with more than 50 cells were counted. This assay was 
performed with triplicates and repeated three times. Data was analyzed by calculating 
the percentage of colonies that were formed in the plates that were treated either with 
cisplatin or carboplatin, when compared to the plates that were treated with the 
respective vehicles. 
 
6.5.5. Tumor induction assay 
Six-week-old male N:NIH(s)II:nu/nu nude mice were obtained previously from 
the Medical School, University of Cape Town in 1991 and then reproduced, maintained 
and housed at IPATIMUP Animal House at the Medical Faculty of the University of 
Porto, in a pathogen-free environment under controlled conditions of light and 
humidity. Male nude mice, aged 6-8 weeks, were used for in vivo experiments. Animal 
experiments were carried out in accordance with the Guidelines for the Care and Use of 
Laboratory Animals, directive 2010/63/EU and had the ethical approval of the Direcção 
Geral de Veterinária (Project: CO_2016_01).  To verify if deregulation of the tRNAs 
could result in tumors that were more resistant to treatment in vivo, H460 cell lines 
harboring the empty vector (Mock), the tRNASer(WT) and the misreading tRNASer(Ala) 
were subcutaneously injected in the dorsal flanks using a 25-gauge needle with 1x106 
(H460) of each cell line. 39 mice were randomized in four groups: Group 1 – Mice 
harboring Mock cell line in the left dorsal flank and tRNASer(WT) in the right dorsal 
flank, that were treated with 4mg/kg of cisplatin via Intraperitoneal (IP) ; Group  2 – 
Mice harboring Mock cell line in the left dorsal flank and tRNASer(WT) in the right 
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dorsal flank, that received 0.9% NaCl (vehicle) via IP;  Group 3 – Mice harboring Mock 
cell line in the left dorsal flank and tRNASer(Ala) in the right dorsal flank, that were 
treated with 4mg/kg of cisplatin via IP ; Group  4 – Mice harboring Mock cell line in 
the left dorsal flank and tRNASer(Ala) in the right dorsal flank, that received 0.9% NaCl 
(vehicle) via IP. Groups 1 and 3 had 9 mice, Group 2 had 10 mice and Group 4 was 
constituted by 11 mice.  The treatment began when tumors reached ~100mm3 and mice 
were treated 2 times per week. Before each treatment, mice were weighted, and tumor 
width and length were measured with calipers. Tumor volumes were calculated 
assuming ellipsoid growth patterns. We monitored the mice between treatments, giving 
them 500µL of 0.9% NaCl, subcutaneously, when mice presented signs of dehydration. 
Mice were humanely euthanized when tumors reached a median volume of 2000mm3 or 
whenever any signs of disease were detected. Tumors, were collected, fixed in 10% 
buffered formalin, paraffin embedded and then sectioned for histological examination. 
A part of each tumor was frozen in liquid nitrogen and stored at –80ºC. 
7. General Discussion 
113 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. General discussion 
 
 
  
Unravelling the roles of statistical proteomes in human cancer 
114 
 
7.1. Protein Synthesis Errors in cancer 
Cancer is a multifactorial disease seldom associated with the accumulation of 
DNA mutations, chromosomal aberrations, epigenetic alterations and transcriptional 
deregulation 98. Despite the remarkable efforts to characterize the molecular profile of 
tumors, the etiology of a significant percentage of tumors is still unknown 184.  
Deregulation of the tRNA pool, tRNA interacting enzymes, other translational factors, 
amino acid starvation and activation of protein quality control systems are common 
features of tumors, raising the hypothesis that protein synthesis accuracy is 
compromised in cancer 11,46,65,160,223,224. Specifically, the tRNA pool of tumors is 
different from that of normal tissue, with specific enrichment of tRNAs that stabilize 
transcripts which promote cancer hallmarks 11. tRNA deregulation may also lead to 
misreading of near-cognate codons, inducing errors in protein synthesis and 
destabilizing the proteome, however this 
has not yet been addressed in cancer 72. It is possible that mutations in proteins caused 
by errors in protein synthesis, explain the etiology of a certain fraction of human 
cancers, since proteome instability also destabilizes the genome 83. Working under the 
hypothesis that tRNA deregulation increases protein synthesis errors creating a 
phenotype that is advantageous for tumour cells, we established a method to determine 
protein synthesis error rate in the proteome of tumors and normal tissue and constructed 
cell lines to investigate the effects of the most common types of error in near-normal 
and tumor cells. 
Available methods for quantification of amino acid misincorporation in proteins 
rely on the use of radioactive amino acids, chemiluminescence and fluorescence probes, 
however these methods can only detect specific amino acid misincorporations and 
underestimate global error rates 2,83,87,119,225,226. Mass spectrometry (MS) has also been 
used to search for specific types of amino acids mutations and, at least in theory, should 
permit the determination of error rates at the proteome scale 227. However, this is 
difficult due to the low abundance of mistranslated peptides in complex proteome 
samples, but recent technology developments both in MS instruments and software are 
gradually overcoming the technical difficulties. In this thesis, we have developed a label 
free methodology for the determination of the frequency of protein synthesis errors in 
tumors and in normal tissue using a Thermo Orbitrap Fusion Lumos mass spectrometer. 
We implemented a mass spectrometry data analysis pipeline to identify peptides 
containing amino acid misincorporations (mutations) in raw data sets of normal colon, 
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colon adenocarcinoma (COAD) and xenograft tumor samples. The SPIDER tool of the 
PEAKS8 software platform allowed us to deep search the proteome of our cells and 
detect the mutant peptides that occur at very low level. The SPIDER algorithm 
calculates the probability of a mutation to occur in a given place, relative to other 
possible mutations or amino acid modifications 135, creating a database of putative 
mutated peptides.  To reduce the number of false positives, the results obtained were 
then validated by running the raw files again against modified databases containing the 
sequences of the mutated proteins. Our results show that the data analysis pipeline is 
robust, but sample preparation should be optimized to increase the number of peptides 
detected. Spike-in internal controls using synthetic peptides of known concentration 
should also be used to better infer the level of mutant peptides in our samples 85. 
Samples run on SDS-PAGE should be fractioned to increase the depth of analysis and 
detect rare amino acid misincorporation events. Regarding the samples of the CPTAC 
database that we also used in our study, the number of samples analyzed should be 
increased to improve the robustness of the statistical analysis (Fig.3-1A).  
Although the difference between COAD and normal samples was not 
statistically significant, likely due to high cell type heterogeneity in tumors 228, there 
was a clear trend for increased error levels in tumor samples. This first attempt to 
quantify global protein synthesis errors in tumors showed increased error rate for all 
amino acids, but Asn (N) in the COAD samples. The Ser-at-Ala misincorporation, 
which is likely associated with tRNA misacylation by Class II aaRS, was the most 
common misincorporation identified in our xenograft tumors. The observation that 
misincorporations that do not comply with genetic code rules were present at much 
lower level in these samples, strongly supports our methodology for detecting rare 
misincorporation events in complex proteomes.  
 
7.2. The role of frequent and rare protein synthesis errors in cancer  
In this work, we have studied the role of one frequent and one rare amino acid 
misincorporation in tumors. The SerRS recognizes specific elements in the acceptor 
stem, D-arm, extra arm and the anticodon stem of Ser tRNAs, but does not depend on 
anticodon recognition, allowing for the alteration of the anticodon without affecting the 
aminoacylation specificity 229,230. Geslain and colleagues, produced 10 mutant Ser-
tRNAs which were aminoacylated with Ser, but decoded codons complementary to the 
mutated anticodon, and successfully introduced random mutations in the proteome 118. 
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We chose the Ser-tRNA as proof of concept and mutated its anticodon to decode and 
incorporate Ser at Ala (tRNASer(Ala); frequent event) or Leu (tRNASer(Leu); infrequent 
event) codons. These mutant tRNAs were stably expressed in a Mus musculus near-
normal cell line, but relevant phenotypes were not observed in vitro, unless the cells 
were stimulated with a pro-inflammatory cytokine (Figs.3-2; 3-3). These data support 
previous results from our lab showing that mistranslation is mainly advantageous when 
cells are challenged with external stimuli 85,119,123; under physiologic conditions it is 
mainly detrimental in other model organisms. Given that cells expressing the 
misreading tRNASer(Ala) responded to TNFα treatment activating the Akt pathway also 
showed a slight increase in colony formation in vitro (Figs.3-2; 3-3), we hypothesized 
that the molecular changes induced by this mutant tRNA could impact the tumorigenic 
capacity of these cells. Supporting this hypothesis, the tRNASer(Ala) expressing tumors 
demonstrated increased angiogenesis and a tumor growth rate that was comparable to 
that of NIH3T3 cells expressing K-rasV12 (Fig.3-4). These tumors differed from Mock, 
tRNASer(WT) and tRNASer(Leu) expressing tumors, by showing concomitant activation 
of all the UPR branches and the Akt-pathway (Figs.3-6; 3-7; 3-12). Decreased 
phosphorylation of eIF2α observed in tRNASer(Ala) expressing tumors, likely 
contributed to increased protein synthesis rate and faster growth rate of these tumors 231; 
this is in line with transformation of NIH3T3 cells by modulation of eIF2α-P levels, 
which were previously described 125. Tumors expressing tRNASer(Ala) also activated the 
ATF6 and IRE1α branches of the UPR (Figs. 3-6; 3-12), which are associated with 
cellular protection and growth stimulation 115,127,128. The tRNASer(WT) expressing 
tumors only showed activation of the ATF6 UPR branch and downregulation of the p38 
MAPK, which is important to sustain tumor cell survival and proliferation 232, justifying 
the slower growth of these tumors relative to tRNASer(Ala) expressing tumors.  The 
difference in growth rate between tRNASer(Ala) and tRNASer(Leu) may be, at least in 
part, explained by the decreased activation of the ERK1/2 pathway in tumors expressing 
the mutant tRNASer(Leu) (Fig.3-13). The activation of this pathway is linked to G1/S 
cell cycle progression and tumor cell survival and its downregulation may lead to cell 
cycle arrest and decreased survival of tumor cells 233.  
Overall, we demonstrated that protein synthesis errors are increased in tumors 
and that frequent and infrequent errors trigger different molecular pathways in NIH3T3 
cells. Interestingly, the frequent Ser-at-Ala misincorporation, increased angiogenesis 
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and produced tumors that grew as fast as K-rasV12 expressing tumors, suggesting that 
frequent mistranslation events can indeed contribute to tumor development. 
To study the effect tRNA deregulation and tRNA misreading in different tumor 
stages, we expressed the tRNASer(WT) and tRNASer(Ala) in two human cell lines 
derived from the same organ, namely in cells derived from normal bronchial epithelium 
(BEAS-2B) and in cells derived from a large cell carcinoma, H460. This paired model 
has been successfully used before to prove the oncogenic role of a miRNA in NSCLC 
234. 
The expression levels of both tRNAs was higher in the H460 than in the BEAS-
2B cell lines (Figs.4-1; 5-1); this may be due to the difficulty of stably transfecting 
BEAS-2B cell line. BEAS-2B showed high sensitivity to the recombinant tRNA during 
the first week after electroporation, whereas H460 recovered shortly after transfection, 
suggesting that normal cell lines are more sensitive to changes in the tRNA pool and 
tRNA misreading than tumor cell lines. Interestingly, in the H460 tRNASer(Ala) cell 
line, the expression of the WT Ser-tRNA increased (Fig.5-1). How the former affects 
the latter is not clear, but the WT-Ser tRNA may dilute the effect of tRNASer(Ala) 
expression, which reached similar expression levels to those observed for WT Ser-
tRNA in Mock cell lines.  
The expression of both the recombinant tRNASer(WT) and the misreading 
tRNASer(Ala) in BEAS-2B increased cell proliferation, protein synthesis rate and 
decreased the levels of eIF2α-P. The PP1α regulatory subunit GADD34, which is 
responsible for eIF2α-P dephosphorylation, was also upregulated in BEAS 
tRNASer(WT) cells and was unaltered in BEAS tRNASer(Ala) cells (Fig.4-4). The low 
levels of eIF2α-P in this cell line should be clarified in the future by studying the 
activation levels of eIF2α kinases, namely PERK and GCN2, the levels of the PP1α 
phosphatase and also the expression of CReP, an homolog of GADD34 which can also 
bind and direct PP1α to eIF2α 154,235. Expression of our recombinant tRNAs increased 
colony formation in BEAS-2B, which is an indicator of increased tumorigenic ability. 
Moreover, BiP was upregulated in the BEAS cells expressing the tRNASer(WT) (Fig.4-
4), similarly to what has been observed in pre-malignant lesions of lung cancer 159. 
Therefore, the decreased levels of eIF2α-P, the overexpression of BiP and the increase 
in colony formation, suggest that expression of the recombinant Ser-tRNAs could 
influence tumor initiation. In fact, we observed an advantage of tRNASer(WT) 
expressing tumors over Mock tumors grown in the same animal (Fig.4-6;4-7): only 2/4 
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Mock minimal size tumors developed, whereas larger 4/4 tRNASer(WT) expressing 
tumors developed (Fig.4-6;4-7), indicating that overexpression of this WT-Ser tRNA 
may be sufficient to trigger tumor formation with slow growth kinetics. This experiment 
should be repeated with more animals to increase its statistical significance. 
Although expression of the recombinant tRNAs in H460 did not increase the 
number of colonies formed in vitro, it increased tumor growth kinetics in vivo. Similarly 
to what happened in the NIH3T3-derived tumors expressing the misreading 
tRNASer(Ala), the H460 tumors had lower levels of eIF2α-P, likely due to GADD34 
upregulation (Figs.3-6;5-6). Both tumors had higher BiP levels which is associated with 
increased aggressiveness in NSCLC tumors (Fig. 3-6) 168.  
The only common response observed in BEAS-2B-derived cell lines and H460-
derived tumors expressing the recombinant tRNAs, was the activation of the ATF4 
transcription factor (Figs.4-4;5-6). This transcription factor regulates the expression of 
many stress response genes, including GADD34 and autophagy-related genes 147,161. 
The role of autophagy in cancer is context dependent; in pancreatic cancer it is 
associated with late onset of tumor development, but is important for tumor 
maintenance and progression 164. Whether autophagy is relevant in our model remains 
to be clarified, but the slow growth kinetics of tumors derived from BEAS-2B cells 
expressing the recombinant tRNAs, and the increased growth kinetics of tumors derived 
from the H460 cells expressing the same tRNAs, which are already tumorigenic, 
suggest that it may be important. ATF4 activation has also been associated with high 
grade tumors and metastization in NSCLC tumors 236, further suggesting that 
deregulation of the tRNA pool and tRNA misreading may increase the metastization 
capacity of those cells.  
The metastization process is divided into various stages: local invasion, 
intravasation, survival in the circulation, extravasation, survival at a second site and 
finally outgrowth at a second site 237. We studied the early stages of metastization, by 
analysing cell migration, extracellular matrix invasion and also in vivo metastization. 
Upregulation of the Ser-tRNA reduced the migration capacity of H460 cells, while 
expression of the misreading tRNASer(Ala) increased it (Fig.5-7). Both tRNA constructs 
significantly increased extracellular matrix invasion ability, but the metastization assay 
results were inconclusive, as mice injected with the same cell line displayed high and 
low metastization areas in the lungs (Figs.5-7; 5-8). Despite this, metastization should 
not be ruled out because, other groups observed that overexpression of tRNAiMet 
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increases migration, invasion and metastization of melanoma cells 14. Also, expression 
of tRNAGluUUC and tRNAArgCCG shifts the proteome towards a pro-metastatic state in 
breast cancer cells, through the stabilization of transcripts enriched in codons matching 
their anticodons 13, suggesting that different tRNAs can drive the same phenotype in 
tumors in different tissues. Since the tRNA pool differs among tissues to fulfill its 
specific translational requirements 238, it is likely that changes in the tRNA pool may 
have distinct impacts on tumor development depending on the tissue of origin. In our 
study, upregulation of tRNASer(WT) in NSCLC cells may increase the translation 
efficiency of transcripts enriched in UCU codons (matching the AGA anticodon), which 
may impair cell migration ability without affecting extracellular matrix invasion. This 
needs to be clarified in future studies. 
Altogether our results suggest that expression of the recombinant tRNASer(WT) 
in BEAS-2B may drive tumor initiation, likely due to BiP upregulation and decreased 
levels of eIF2α-P; upregulation of ATF4 and most likely autophagy may be responsible 
for the late onset of these tumors. Additionally, expression of such tRNAs in a 
tumorigenic cell line, showed that cells expressing the misreading tRNASer(Ala) have a 
more aggressive phenotype, since the expression of this tRNA increased tumor growth 
kinetics, cell migration and extracellular matrix invasion. These phenotypes may be 
partially explained by the concomitant upregulation of BiP and ATF4. 
 
7.3. tRNA upregulation decreases tumor sensitivity to cisplatin 
The overexpression of the Ser tRNA (chr6.tRNA5-SerAGA) has been linked to 
reduced Overall Survival of patients with breast invasive carcinoma, adrenocortical 
carcinoma, colon adenocarcinoma, head and neck squamous carcinoma and kidney 
renal clear cell carcinoma (YM500v3 database). The risk of recurrence is also 
augmented, suggesting that its overexpression can influence therapy outcomes 9. This 
hypothesis is supported by the observation that protein mistranslation is beneficial in 
some microorganisms by bestowing them with growth advantages and phenotypic 
resistance to antibiotics 104. For instance, in Candida albicans, high mistranslation 
levels are associated with phenotypic diversity and fluconazole resistance 119,123,220 and 
E.coli strains that misacylate various tRNAs with Met are more resistant to stress and 
antibiotics 84. Interestingly, H460 tumors expressing the recombinant tRNASer(WT) and 
the misreading tRNASer(Ala), upregulated of BiP and activated ATF4. It is known that 
activation of the UPR, induced by mild ER-stress prior to treatment with cisplatin, 
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increases resistance to treatment through activation of autophagy 143, and that BiP 
overexpression in NSCLC is correlated with shorter overall survival and cisplatin 
resistance 95,219. These data strongly suggest that expression of the recombinant tRNAs 
may also increase resistance to platinum-based drugs.  
The in vitro results showed that only H460 cells expressing tRNASer(Ala) were 
resistant to cisplatin, whereas H460 cells expressing tRNASer(WT) and tRNASer(Ala) 
were resistant to carboplatin (Figs.6-1;6-2). We confirmed the results obtained in 
another NSCLC cell line, A549, and observed a similar phenotype (Fig.6-4). However, 
the results from the in vivo experiments were surprising. We demonstrated that tumors 
overexpressing the tRNASer(WT) were more resistant to CDDP in vivo than Mock 
expressing tumors, and that tRNASer(Ala) expressing tumors did not respond to CDDP 
treatment (Figs.6-5;6-6).  Regarding the tRNASer(Ala) branch of the experiment, we 
could not anticipate that Mock tumors, paired with tRNASer(Ala) tumors, would not 
grow (Fig.6-6). It is unlikely that we have unintentionally introduced an experimental 
bias, since the mice and the injections were randomized to ensure that genetic 
backgrounds, ages and weights would not interfere with results. Additional experiments 
with mice carrying tumors derived from only one cell line should be performed, to 
avoid cross-interactions between tumors expressing different constructs. Careful 
molecular profiling of these tumors should also be done to understand the mechanisms 
through which they achieve resistance to cisplatin. 
 
7.4. Conclusions and future work 
Our data show that tumors mistranslate at higher levels than normal tissue, but 
each type of tRNA produces different phenotypes likely due to activation of distinct 
signaling pathways. It is likely that the transcripts enriched in UCU codons, matching 
the AGA anticodon in the tRNASer(WT) expressing cell lines, are more efficiently 
translated and the different phenotypes observed among cell lines are likely due to 
differences in their genetic background. The increased expression of WT tRNAs may 
increase misreading of near-cognate codons, increasing protein mistranslation in these 
cells 51. Additionally, the transcripts enriched in GCU/GCC Ala codons are probably 
different from those enriched in UCU codons and their differential translation may 
explain in part the effects observed in cells expressing the tRNASer(Ala) and the WT-Ser 
tRNA. Additionally, Alanine is often used to mimic non-phosphorylated forms of 
proteins and this may impact phenotypic diversity 169. Although phosphorylation is 
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context specific 170, we cannot exclude that the insertion of Ser at Ala sites may activate 
some pathways that are otherwise silent.  
Upregulation of the WT Ser tRNA and expression of the misreading 
tRNASer(Ala) increased tumor cell growth rate, invasion potential, drug resistance and 
activation of the UPR. These phenotypes share several characteristics with the 
phenotypes induced by mistranslation in Saccharomyces cerevisiae and Candida 
albicans 82,83,85,87,102,119,220. Increased fitness of mistranslating yeast has been associated 
with high proteome diversity leading to population heterogeneity. Tumor heterogeneity 
is thought to arise from genetic instability and phenotypic diversity, and mistranslation 
in yeast destabilizes the genome in a rather dramatic manner and also increases 
phenotypic diversity 83,85.  
Although the phenotypes we observed need further clarification, tRNA 
deregulation and mistranslation in cancer are far more important than previously 
anticipated.  
 
Future studies should focus on the following priorities: 
1) Optimizing mass spectrometry analysis to identify higher nember 
of proteins with mutations and clarify how they may impact on the 
phenotypes observed; 
2) Quantification of the distinct types of errors that occur in these 
samples and associating errors to codons to clarify if there are error prone 
codons. 
3)  Ribosome profiling coupled with RNA-seq to identify the 
transcripts that are more efficiently translated in the engineered cell lines; 
4) Monitor in more detail the UPR to identify all the UPR branches 
that are induced in the recombinant cells; 
5) Assess differences in proteasome activity and study if autophagy 
is activated by the expression of the recombinant tRNAs in NSCLC cells; 
6) Sequence the exomes of the engineered cells to identify the 
mutations associated with resistance to cisplatin. 
Regarding the experiments that will have to be repeated:  
1) The number of mice used in the initiation and the metastization assays 
should be increased; 
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2) The number of cells used per inoculum in the initiation assay should also be 
increased; 
3) Metastization in the other organs collected in the metastization experiment 
should be analyzed.  
4) Mice should also be injected with only one type of cells to avoid cross-
influence of one tumor over the other.  
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1.1 Abstract  
 
Protein synthesis is a highly-regulated process and maintenance of its fidelity is essential 
to life. Alterations in the components of the protein synthesis machinery, namely tRNAs, 
aminoacyl-tRNA synthetases (aaRS) or tRNA modifying enzymes, increase the level of protein 
synthesis errors (PSE), and are associated with several conditions, from cancer to 
neurodegeneration. Still, the cause-effect mechanisms remain to be elucidated in many 
conditions. We hypothesized that accumulation of PSE in human cells activate different protein 
quality control (PQC) mechanisms depending on the type of error and the duration of the stress 
stimulus. To address this issue, we modified the anticodon of a human serine transfer RNA 
(tRNASer), to incorporate the amino acid serine (Ser) at various non-cognate sites and 
overexpressed the wild type (Wt) tRNASer to evaluate the effects of tRNA misexpression. Stable 
HEK293 cell lines were produced and analyzed at different time points (cells passages). As 
expected, mutant tRNAs and tRNA pool deregulation led to accumulation of misfolded proteins. 
Activation of the ubiquitin-proteasome system (UPS) and the unfolded protein response (UPR) 
fully protected these cells from proteotoxic stress, maintaining viability intact. Evolution of these 
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cell lines showed differential adaptation responses to different types of tRNAs’ misexpression. 
In some cases, adaption was mainly due to increased protein turnover, while in other cases, UPR 
activation with consequent protein synthesis inhibition was the main adaption mechanism. Our 
data provide new insight on how mammalian cells cope and adapt to proteotoxic stress induced 
by PSE. 
 
 
1.2 Introduction 
 
Tight control of protein synthesis is essential for cell functioning, nonetheless the high 
rate of ribosome decoding, which is required to maintain proteome homeostasis, affects the 
accuracy of mRNA translation and proteins are synthesized with some level of error. Indeed, 
lowering translation rate increases protein synthesis accuracy, but impacts negatively on growth 
rate and fitness [1, 2]. Protein synthesis errors (PSE) can arise during both aminoacylation of 
tRNAs and mRNA decoding by the ribosomes [3, 4]. The rate of eukaryotic protein synthesis 
error measured under normal experimental conditions, i.e., downstream of protein quality 
control (PQC) processes, is between 10-3 and 10-4 [4, 5]. Since most polypeptides containing 
erroneous amino acids are degraded, the real rate of amino acid misincorporation is much higher 
than those values, suggesting that defective PQC can have catastrophic consequences for the 
cell. Similarly, stress conditions, in particular amino acid starvation, and metabolic deregulation 
associated with pathology and aging increase error frequency [6]. In other words, a fraction of 
defective proteins is continually produced by cells making the existence of perfect proteomes an 
impossible task [7]. 
Not surprisingly, deregulation of protein synthesis factors that maintain translational 
accuracy has been associated with human diseases [8, 9]. For instance, mutations in genes 
encoding the glycyl-tRNA synthetase (GlyRS), have been found in patients with Charcot-Marie-
Tooth neuropathy [10, 11]. Mutations in mitochondrial tRNALeu are linked to mitochondrial 
encephalomyophathy, lactic acidosis, and stroke-like episodes (MELAS) [12, 13]. Deregulation 
of the tRNA pool and tRNA modifying enzymes have been observed in cancer [14–19]. In breast 
tumors there is strong upregulation (> 10 fold) of nuclear and mitochondrial encoded tRNAs 
[14]. The tRNA modifying enzyme TRMT12 (tRNA methyltransferase homolog 12, involved 
in the formation of wybutosine at position 37 on tRNAPhe) is overexpressed in various breast 
tumors [17, 19]. Despite clear association with disease, how such deregulation and mutations 
causes disease are poorly understood. One possibility is that PSE may saturate PQC, leading to 
accumulation of misfolded and aggregated proteins [20–24]. For example, molecular chaperones 
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selectively recognize misfolded proteins and promote refolding or degradation via the ubiquitin-
proteasome system (UPS) [6, 25]. Accumulation of misfolded proteins in the endoplasmic 
reticulum (ER) normally saturates ER chaperones (as GRP78/BiP), triggering the activation of 
the unfolded protein response (UPR) through its branches, namely ATF6, IRE1 or PERK [26]. 
These pathways, regulate protein synthesis, decrease ER load, increase ER folding capacity and 
increase the degradation of misfolded proteins [27]. In mice, a mutation in the editing domain of 
alanyl-tRNA synthetase (AlaRS), leads to the formation of toxic aggregates, an increase in 
protein ubiquitination, formation of autophagosomes, induction of molecular chaperones 
(members of Hsp70 family) and upregulation of the UPR (induction of BiP and CHOP). This 
ultimately leads to Purkinge cell death [21]. Some cancer cells have increased growth rate, 
regulated by signals related to proliferation, metabolism and protein synthesis, explaining the 
global upregulation of tRNAs and tRNA modifying enzymes [28]. This also induces ER stress 
and activation of UPR pathways [29, 30], suggesting that protein misfolding, and eventually 
PSE, may be prevalent in cancer. 
The objective of this study was to clarify the poorly understood consequences of PSE in 
human cells. In particular, we wanted to elucidate how these cells cope and adapte to such errors 
and whether they affect cell viability, activate the UPR and produce phenotypes that are common 
in diseases associated with deregulation of protein synthesis factors. To address these questions, 
we have created HEK293 cell lines expressing mutant tRNAs that randomly misincorporate 
serine (Ser) at alanine (Ala), leucine (Leu) and histidine (His) codon sites, on a proteome wide 
scale. A cell line expressing extra copies of the wild type (Wt) tRNAAGA
Ser was also produced to 
gain insight on the cellular consequences of tRNA imbalances; often observed in tumors. 
Cellular responses were studied at different time points (cells passages) to clarify how these 
HEK293 cells adapt to PSE.  
Our data show that immortalized cells cope relatively well with the presence of mutant 
tRNAs or overexpression of the Wt tRNASer. We observed accumulation of aggregated and 
ubiquitinated proteins and activation of the UPS and UPR, as expected. Activation of PQC 
mechanisms is differential according to the type of error introduced in proteins and to the cell 
passage. Additionally, the expression of mutant tRNAs decreased as cell passage increase, 
suggesting that human cells modulate expression of mutant tRNAs to decrease their destabilizing 
effect on the proteome. 
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1.3 Results 
1.3.1 Human cell line models of PSE 
 
Previous studies from Geslain and colleagues reported a novel approach for the induction 
of stress responses to protein aggregation, based on engineered tRNAs in HEK293 cells [24]. 
This strategy allows the introduction of mutations of increasing severity randomly in the 
proteome. The decoding sequence (anticodon) of tRNASer was altered, not influencing the 
recognition by the seryl-tRNA synthetase (SerRS). The altered tRNA is aminoacylated with Ser, 
but will be used by the ribosome to translate codons complementary to the engineered anticodon. 
tRNAs produced by Geslain were tested for their ability to restore fluorescence of a GFP 
reporter, where the essential residue serine-65 (S65) had been substituted for the codons 
recognized by the engineered tRNAs, proving that mutant tRNAs are fully functional in HEK293 
cells. Amino acid analysis of purified GFP from cells transfected with some of these tRNAs 
(tRNASer(Lys), tRNASer(His), tRNASer(Ile)) showed that the mutable residues had been replaced 
by serine [24]. 
In the current study, and to induce PSE in HEK293 cells, we mutated the anticodon of 
the human Wt tRNAAGA
Ser to produce a set of tRNAs: tRNAAGC
Ser, tRNAAAG
Ser, tRNAGTG
Ser   that 
misincorporate Ser at Ala, Leu and His codon sites, respectively (Figure 1-1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1. Representation of the human tRNAAGASerand mutant tRNAs used in the study. 
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These mutations do not interfere with serylation of the tRNAs by the SerRS, because this 
enzyme recognizes the extra-arm and discriminator base, rather than the anticodon of tRNASer 
[31, 32]. Participation of these tRNAs in protein synthesis leads to random incorporation of Ser 
at non-cognate sites, synthesis, misfolding, aggregation and degradation of the faulty proteins 
(Figure 1-2) [22, 24].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. Schematic representation of PSE incorporation by the mutant tRNAAAGSer. 
SerRS is not able to discriminate between endogenous tRNASer and mutant tRNAs and charges them equally, 
leading to Ser misincorporation at Leu codon sites. 
 
We chose these alterations in the anticodon to have a broad spectrum of amino acid 
chemical differences. Ser is polar and hydrophilic and is normally present on protein surfaces, 
whereas Ala is nonpolar, hydrophobic and is found inside or outside proteins. Leu is hydrophobic 
and is generally buried in folded proteins, while His is a basic and polar residue [33]. Therefore, 
Ser misincorporation severity should be higher in the case of misincorporation at Leu codon sites 
and much lower at Ala codon sites, depending also on the usage of those codons, the competition 
between endogenous tRNAs (tRNAAGC
Ala, tRNAAAG
Leu, tRNAGTG
His) in the ribosome, and the 
competition of endogenous tRNAAGA
Ser and mutant tRNAs for the SerRS. 
HEK293 cells were transfected with the plasmid pIRES2-DsRed containing one copy of 
each mutant tRNA. The resulting cell lines were denominated: tRNASer(A), tRNASer(L), 
tRNASer(H). Two additional cell lines were also produced: one was transfected with the empty 
plasmid; Mock (negative control) and another misexpressing the Wt tRNAAGA
Ser (tRNASer(S)). 
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To gain insight on the long-term adaptation to PSE, three time points (P1, P15 and P30, 
corresponding to the number of cell passages after transfection and selection in geneticin 
containing media) were studied. Mutant tRNA expression in these cell lines was monitored by 
Sanger sequencing during evolution in culture. After P30, some of these cell lines presented 
additional mutations in the recombinant tRNA genes, namely in the acceptor arm, and for this 
reason cells were only studied till P30. Each cell line was compared with the control (Mock) of 
each passage, and for each cell line the values of the three passages (P1, P15 and P30) were 
compared among each other. 
 
1.3.2 Expression and copy number of mutant tRNAs and tRNASer in HEK293 cells  
 
Exogenous tRNA expression was determined using a primer extension reaction 
(SNaPshot analysis), which allowed to specifically detect the tRNAs with the altered nucleotide 
in the anticodon. We were able to detect in all cell lines, both the expression of the endogenous 
tRNASer (Figure 1-3 A) and each mutant tRNA (Figure 1-3 B). In the Mock cell line the 
expression of the endogenous tRNASer did not change from P1 to P30 (values around 5 in 
arbitrary units (a.u.)), but the expression of tRNASer in the tRNASer(S) cell line (both the 
endogenous and the exogenous tRNA are detected) altered during our timeline (Figure 1-3 A). 
The expression of tRNASer increased slightly from passage P1 (8.9 a.u.) to P15 (12.7 a.u.) and 
then decreased from P15 (12.7 a.u.) to P30 (2.9 a.u.) (Figure 1-3 A), suggesting that increasing 
the levels of the Wt tRNASer may be slightly advantageous at the beginning of the evolution, but 
becomes deleterious in the long term. Expression of all mutant tRNAs decreased gradually from 
P1 to P30 (Figure 1-3 B). In P1, in tRNASer(A) the levels of tRNAAGC
Ser were 0.58 a.u. (60% of 
the endogenous tRNASer expression) and in P30 declined to 0.1 a.u. (10% of the endogenous 
tRNASer expression). The relative levels of the tRNAAAG
Ser(in tRNASer(L) cells) and 
tRNAGTG
Ser(in tRNASer(H) cells) in P1 were 0.3 a.u. (30% of the endogenous tRNASer 
expression) and declined to 0.05 a.u. and 0.03 a.u. (5% and 3% of the endogenous tRNASer 
expression) in P30, respectively (Figure 1-3 B).  
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Figure 1-3. Quantification of tRNASer and mutant tRNAs expression. A – Detection of 
tRNAAGASer expression in Mock and tRNASer(S) cell lines, assessed by the SNaPshot assay. B – Expression of 
mutant tRNAs relative to the Wt endogenous tRNAAGASer determined by SNaPshot in tRNASer(A), tRNASer(L) 
and tRNASer(H) cell lines. tRNA values were normalized to an endogenous control, GAPDH. Data represents 
Average±SEM of one biological replicate and at least two technical replicates. 
 
 
To clarify if the gradual decrease in tRNA levels observed during the P1-P30 evolution 
were caused by differences in tRNA gene copy number we have also used the SNaPshot 
technique to detect tDNA insertion into the genome of HEK293 cells (Figure 1-4). The number 
of copies of the tRNASer in the genome of Mock and tRNASer(S) cell lines was not altered from 
P1 to P30. As expected, the copy number of tRNASer was higher in tRNASer(S) cells than in the 
Mock cell line, confirming incorporation of the plasmid into the genome (Figure 1-4 A). In the 
tRNASer(A) cell line the number of copies of the tDNA decreased from P1 (0.26 a.u., 26% of 
tRNASer copies) to P30 (0.15 a.u., 15% of tRNASercopies). In tRNASer(L) and tRNASer(H) cell 
lines the number of tDNA copies was maintained.  In tRNASer(L) cells, tDNA values were 
around 0.06 a.u. (6% of tDNASer copies) and in tRNASer(H) cells, tDNA showed values around 
0.09 a.u. (9% of tDNASer copies). The tRNASer(A) cell line incorporated more copies of the 
respective tDNA, relative to tRNASer(L) and tRNASer(H) cell lines (Figure 1-4 B).  
Therefore, the expression of the tRNAs and respective tDNA copy number are well 
correlated indicating that the former may be due to transcriptional regulation by Pol III or tRNA 
degradation, rather than loss of tDNA copies during evolution. tRNASer(A) cell line, is an 
exception since the decreased mutant tRNA expression is accompanied by a decrease in the copy 
number. 
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Figure 1-4. Copy number of tRNASer and mutant tRNAs. A – tDNAAGASergenomic copy number 
in Mock and tRNASer(S) cell lines, assessed by SNaPshot. B – Genomic copy number of the mutant tDNA 
genes relative to the Wt endogenous tRNAAGASer, assessed by SNaPshot, in tRNASer(A), tRNASer(L) and 
tRNASer(H) cell lines. tRNA values were normalized to an endogenous control, GAPDH. Data represents 
Average±SEM of one biological replicate and at least two technical replicates.  
 
 
1.3.3 Phenotypic effects of PSE  
 
We have accessed cell viability, proliferation, number of anchorage-dependent colonies 
formed, protein synthesis rate and accumulation of insoluble proteins, as readouts of putative 
phenotypic effects produced by PSE emerging during evolution of our cell line models.  
We used the number of cell passages as landmark of time points during evolution. Since 
overexpression of Wt tRNASer and expression of mutant tRNAs did not affect doubling time of 
HEK293 cells (approximately 20h), we believed that all cells were approximately in the same 
generation along the experiment (Figure 1-5).  
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Figure 1-5. Doubling time of cells, assessed by cell counting with Tripan blue. Values represent 
Average±SEM of three independent experiments in triplicate. One-way ANOVA followed by Dunnett’s post-
est was used to assess differences between the Mock cell line and cells misexpressing the Wt tRNASer 
(tRNASer(S)) and expressing mutant tRNAs (tRNASer(A), tRNASer(L), tRNASer(H)) (p>0.05). 
 
 
In order to test the toxicity of mutant tRNAs and increased copies of the tRNASer, cell 
viability was assessed using Tripan blue. Overall, viability was not compromised by the 
expression of mutant tRNAs or alteration in the tRNA pool (Figure 1-6 A). However, 
tRNASer(A) and tRNASer(L) cell lines showed an increase in viable cells (5.14% and 6.08% 
respectively), relatively to the Mock in P1 (Figure 1-6 A). This was coincident with the passage 
in which these mutant tRNAs were most expressed (Figure 1-3 B). During evolution, tRNASer(A) 
and tRNASer(L) cells showed the same pattern of viability, which decreased from P1 and P15 
(93% in P1 and a 88% in P15 of viable cells), and recovered from P15 to P30, to a level of viable 
cells similar to that observed in P1 (~ 93% of viable cells) (Figure 1-6 B). 
 
A                                                                          B 
 
                                                                              
 
 
 
 
 
 
Figure 1-6. Percentage of viable cells in culture determined by cell counting with Tripan 
blue. A – Percentage of viable cells in comparison with the Mock in each passage (one-way ANOVA, 
Dunnett’s post-test,**p<0.01 ) B – Percentage of viable cells in each time point in tRNASer(A) and tRNASer(L) 
cell lines (one-way ANOVA, Bonferroni’s post-test, *p<0.05;**p<0.01;***p<0.001). Values were normalized 
to the Mock cell line of each passage and represent Average±SEM of three independent experiments in 
triplicate. 
 
 
Regarding cell proliferation, assessed with a DNA synthesis–based cell proliferation 
assay (BrdU), in P1 comparatively to the Mock, there were no alterations (Figure 1-7). In P15, 
the tRNASer(A) cell line showed higher proliferation than Mock (1.43 fold), while tRNASer(H) 
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cell line showed a decrease of proliferation (0.64 fold) relative to Mock (Figure 1-7 A). In P30, 
both tRNASer(S) and tRNASer(A) cell lines proliferated more than the Mock cell line (1.08 fold 
in both). The tRNASer(H) cell line, which showed decrease in proliferation from P1 to P15 (0.33 
fold), restored its proliferation values in P30 (1.03 fold) (Figure 1-7 B). The tRNASer(A) cell 
line, which showed an increase in proliferation from P1 to P15 (0.36 fold), in P30 recovered the 
proliferation values observed in P1 (Figure 1-7 B). 
A                                                                          B 
 
 
 
 
 
 
 
 
Figure 1-7. Relative cell proliferation determined using a BrdU ELISA Kit. A – Cell 
proliferation in comparison with Mock in each passage (one-way ANOVA, Dunnett’s post-test, 
(*p<0.05;**p<0.01) B – Relative proliferation of tRNASer(A) and tRNASer(H) cell lines (one-way ANOVA, 
Bonferroni’s post-test, *p<0.05;**p<0.01;***p<0.001).Values were normalized to the Mock cell line of each 
passage and represent Average±SEM of three independent experiments in triplicate. 
 
 
Cell proliferation and survival was also assessed using anchorage-dependent colony 
formation assay, which consists in the ability of a single cell to grow into a colony. Only 
tRNASer(H) cell line had lower colony formation capacity relative to Mock cell line in P15, with 
an average 12.87 colonies for tRNASer(H) vs. 18.44 for Mock (Figure 1-8). This was consistent 
with proliferation data, as tRNASer(H) was the only cell line that displayed decreased 
proliferation, at this same passage. 
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Figure 1-8. Number of colonies formed after 12 days in culture. Values were normalized to the 
Mock cell line of each passage and represent Average±SEM of three independent experiments in duplicate 
(one-way ANOVA, Dunnett’s post-test, *p<0.05) 
 
Since these engineered cell lines are error prone at the level of protein synthesis, we 
questioned if protein synthesis rate could be affected during the evolution of these cell lines 
along 30 passages in culture. To measure protein synthesis rate, we took advantage of the 
SunSET method, based in the detection of puromycin incorporation into proteins, as described 
in the methods section [34]. Protein synthesis rate increased in tRNASer(A) cells in P1 (1.23 fold) 
and P15 (1.48 fold) relative to Mock, but decreased in the tRNASer(L) cells in P30 (0.61 fold) 
relative to Mock (Figure 1-9 A). Despite showing increased protein synthesis rate relative to 
Mock, when we compare the three time points (P1, P15 and P30) of tRNASer(A) cell line, there 
was a decrease from 1.23 fold in P1 to 0.76 fold in P30. The same occurred in tRNASer(L) cells, 
in which protein synthesis rate decreased from 1.20 fold in P1 to 0.61 fold in P30 (Figure 1-9 
B).  
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Figure 1-9. Protein synthesis rate determined by SunSET method adapted to immunoblot 
with anti-puromycin. A – Top panel: Relative protein synthesis rate in comparison with Mock in each 
passage (one-way ANOVA, Dunnett’s post-test, *p<0.05). Mock values for each passage were considered 1 
and were not represented in the graph. Lower panel: Representative immunoblot images for each time point 
and cell line and β-tubulin. B – Relative protein synthesis rate during evolution of tRNASer(A) and tRNASer(L) 
cell lines (one-way ANOVA, Bonferroni’s post-test, **p<0.01;***p<0.001). Values were normalized to the 
Mock cell line of each passage and represent Average±SEM of at least three independent experiments in 
triplicate.  
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To test whether mutant and Wt tRNASer destabilized the proteome and lead to misfolded 
protein accumulation and aggregates formation, we have quantified the insoluble protein fraction 
in P1, P15 and P30. In P15, there was a tendency for increasing levels of insoluble proteins, but 
it was only statistically significant for the tRNASer(L) cell line (2.66 fold) (Figure 1-10). This 
protein aggregation effect was also transient, as the level of insoluble proteins returned to control 
levels at P30. This result may be explained by the lower expression levels of the mutant tRNAs 
in P30, but it may also indicate that cells counteracted protein aggregation, through activation of 
PQC mechanisms. Interestingly, the level of insoluble proteins decreased from P15 (2.1 fold) to 
P30 (0.71 fold) in the tRNASer(S) cell line that misexpresses the Wt tRNASer (Figure 1-10 B).   
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Figure 1-10. Relative insoluble protein fraction. A – Top panel: Relative insoluble fraction in 
comparison with Mock in each passage (one-way ANOVA, Dunnett’s post-test, **p<0.01). Mock values for 
each passage were considered 1 and were not represented in the graph. Lower panel: Representative 
acrylamide gel after commassie staining of each time point and cell line. B – Protein insoluble fraction during 
evolution of the tRNASer(S) cell line (one-way ANOVA, Bonferroni’s post-test, *p<0.05). Values were 
normalized to the Mock cell line of each passage and represent Average±SEM of at least three independent 
experiments in triplicate. 
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1.3.4 The impact of PSE in the ubiquitin-proteasome system and molecular 
chaperones  
 
Eukaryotic cells encompass several mechanisms of PQC to avoid protein aggregation 
and to eliminate aggregates, if they accumulate. These mechanisms include molecular 
chaperones, the ubiquitin-proteasome system (UPS), the unfolded protein response (UPR), the 
endoplasmic reticulum associated protein degradation (ERAD) and autophagy [6, 35, 36]. Since 
we did not observe significant accumulation of insoluble proteins, particularly in P30, we 
wondered if erroneous proteins could have been marked by ubiquitin for degradation by the UPS 
[37, 38]. We observed increased levels of ubiquitinated proteins in the tRNASer(H) cell line (1.43 
fold) in P1 (Figure 1-11 A). In P15, all other cell lines, tRNASer(S), tRNASer(A) and tRNASer(L), 
also showed higher levels of ubiquitinated proteins (1.36, 1.37 and 1.48 fold respectively) 
(Figure 1-11 A). In P30, the amount of ubiquitinated proteins in all cell lines was similar to Mock 
in the same passage. Importantly, from P15 to P30 the amount of ubiquitinated proteins 
decreased in all cell lines, being statistically significant in tRNASer(S) (from 1.36 fold in P15 to 
0.96 fold in P30) (Figure 1-11 B). The latter data indicates that these cells were able to somehow 
degrade all proteins targeted by ubiquitination. 
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Figure 1-11. Relative protein ubiquitination determined by immunoblot. A – Top panel: 
Relative protein ubiquitination in comparison with Mock in each passage (one-way ANOVA, Dunnett’s post-
test, *p<0.05;**p<0.01). Mock values for each passage were considered 1 and were not represented in the 
graph. Lower panel: Representative immunoblot images for each time point and cell line plus β-tubulin are 
shown. B – Relative protein ubiquitination during evolution of the RNASer(S) cell line (one-way ANOVA, 
Bonferroni’s post-test, ***p<0.001). Values were normalized to the Mock cell line of each passage and 
represent Average±SEM of at least three independent experiments in triplicate. 
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We then checked whether proteasome activity was altered in the same cell lines and time 
points, using a proteasome activity assay that measures chymotrypsin-like activity. The 
tRNASer(L) cell line showed higher proteasome activity in P1(1.27 fold) (Figure 1-12 A), while 
tRNASer(A) cell line had higher activity relative to Mock in P15 and P30 (2.17 fold and 1.66 
fold, respectively) (Figure 1-12 A). However, proteasome activity decreased in the tRNASer(L) 
cell line from 1.85 fold in P15 to 0.97 fold in P30 (Figure 1-12 B). The accumulation of 
ubiquitinated proteins and insoluble proteins in P15, particularly in this cell line, was likely 
overwhelming for the proteasome, affecting its degradative capacity. On the other hand, in the 
tRNASer(A) cell line the accumulation of ubiquitinated proteins in P15 was concomitant with 
increased proteasome activity. tRNASer(S) and tRNASer(H) cell lines did now show significant 
alterations in proteasome activity. 
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Figure 1-12. Relative proteasome activity. A – Relative proteasome activity assessed by fluorescent 
measurement of the labeled substrate Suc-LLVY-AMC (one-way ANOVA, Dunnett’s post-test, 
*p<0.05;**p<0.01). Mock values for each passage were considered 1 and were not represented in the graph. B 
– Proteasome activity of the tRNASer(L) cell line (one-way ANOVA, Bonferroni’s post-test, *p<0.05). Values 
were normalized to the Mock cell line of each passage and represent Average±SEM of at least three 
independent experiments in triplicate. 
 
 
Finally, we checked the molecular chaperones branch of the PQC system. We assessed 
the expression of those chaperones that are known to play a critical role in protein folding during 
stress, and whose expression is frequently altered in human diseases, namely Hsp70, Hsp27, 
Hsp60, Hsp90α and BiP [39, 40]. Hsp70 (heat shock protein 70) binds to a wide range of nascent 
polypeptides in stress conditions and by shielding hydrophobic regions, prevents aggregation 
and promotes proper folding. It also recruits ubiquitin ligases, such as CHIP (carboxyl terminus 
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of Hsp70-interacting proteins) to tag proteins for proteasomal degradation [41]. The expression 
of Hsp70 did not change in P1 and P15, but decreased in P30 in tRNASer(A), tRNASer(L) and 
tRNASer(H) cell lines: 0.67, 0.55 and 0.64 fold, respectively (Figure 1-13 A).   
In general, the expression of this molecular chaperone decreased during evolution until 
P30, being this decrease statistically significant in tRNASer(A) cells (from 1.02 fold in P1 to 0.67 
fold in P30) (Figure 1-13 B).  
 
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
Figure 1-13. Relative HSP70 expression. A – Relative HSP70 expression and respective immunoblots 
(one-way ANOVA, Dunnett’s post-test, *p<0.05;**p<0.01). Mock values for each passage were considered 1 
and were not represented in the graph. B – Expression in the three different time points of HSP70 in tRNASer(A) 
cell line (one-way ANOVA, Bonferroni’s post-test, *p<0.05). Values were normalized to the Mock cell line of 
each passage and represent Average±SEM of at least three independent experiments in triplicate. 
 
 
Hsp27  minimizes protein aggregation, by destabilizing aggregates, bind to proteins and 
aids in the refolding processes, favors degradation of some ubiquitinated proteins by the 
proteasome and is involved in apoptotic signaling pathways [42]. Its expression increased in 
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tRNASer(L) cells in P15 (1.69 fold) and decreased in tRNASer(L) and tRNASer(H) cells in P30; 
0.53 and 0.56 fold, respectively (Figure 1-14 A). In P15, the increase in Hsp27 levels in the 
tRNASer(L) cell line was consistent with the higher levels of insoluble proteins, which may 
indicate that Hsp27 is being recruited to destabilize aggregated proteins.  tRNASer(S) and 
tRNASer(A) cell lines showed increased Hsp27 during early evolution from P1 to P15 (from 0.75 
to 1.48 fold and from 0.74 to 1.35 fold, in tRNASer(S) and tRNASer(A) cells, respectively). 
However, from P15 to P30 the level of this chaperone decreased (from 1.49 to 0.96 fold and 
from 1.35 to 0.69 fold, in tRNASer(S) and in tRNASer(A) cells, respectively) (Figure 1-14 B). 
From P15 to P30, the decrease in the expression of Hsp27 was also statistically significant in 
tRNASer(L) (from 1.69 to 0.53 fold) and in tRNASer(H) cells (from 1.31 to 0.56 fold) (Figure 1-
14 C). These alterations in Hsp27 expression are consistent with the dynamics of increased 
protein ubiquitination in these cell lines in P15.  
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Figure 1-14. Relative Hsp27 expression.  A - Relative Hsp27 expression the respective immunoblot 
(one-way ANOVA, Dunnett’s post-test, *p<0.05). Mock values for each passage were considered 1 and were 
not represented in the graph. B and C – Hsp27 expression during evolution line (one-way ANOVA, 
Bonferroni’s post-test, (*p<0.05;**p<0.01; ***p<0.001 ).Values were normalized to the Mock cell line of each 
passage and represent Average±SEM of at least three independent experiments in triplicate. 
 
 
Hsp60 (heat shock protein 60) is a mitochondrial chaperonin involved in protein 
refolding in the mitochondrial matrix under stress conditions. In our cell lines, the expression of 
Hsp60 increased in P15 in tRNASer(H) cell line (1.48 fold) and decreased in P30 in tRNASer(L) 
(0.69 fold) and tRNASer(H) cell lines (0.76 fold) relative to Mock (Figure 1-15 A). The 
expression of Hsp60 in these two cell lines, increased from P1 to P15 (from 0.83 to 1.4 fold in 
tRNASer(L) cells and from 0.78 to 1.48 fold in tRNASer(H) cells), but decreased from P15 to P30 
(from 1.4 to 0.69 fold in tRNASer(L) cells and from 1.48 to 0.76 fold in tRNASer(H) cells) (Figure 
1-15 B), indicating that PSE may also affect protein folding in the mitochondria.   
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Figure 1-15. Relative Hsp60 expression. A - Relative Hsp60 expression the respective immunoblot 
(one-way ANOVA, Dunnett’s post-test,*p<0.05;**p<0.01; ***p<0.001). Mock values for each passage were 
considered 1 and were not represented in the graph. B – Hsp60 expression during evolution (one-way ANOVA, 
Bonferroni’s post-test, *p<0.05;**p<0.01). Values were normalized to the Mock cell line of each passage and 
represent Average±SEM of at least three independent experiments in triplicate. 
 
 
Hsp90α is a molecular chaperone involved in the refolding of specific proteins (normally 
proteins involved in signal transduction, some of which are ER transmembrane kinases that 
participate in the UPR) [43]. This protein displayed lower levels in tRNASer(L) (0.71 fold) and 
tRNASer(H) (0.69 fold) cell lines in P1, relative to Mock in the same passage (Figure 1-16). In 
tRNASer(S) cell line, Hsp90α increased in P30 (1.31 fold) (Figure 1-16).  
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Figure 1-16. Relative Hsp90α expression. Graphic and immunoblot image of Hsp90α expression. 
Values were normalized to the Mock cell line of each passage and represent Average±SEM of at least three 
independent experiments in triplicate (one-way ANOVA, Dunnett’s post-test, *p<0.05). Mock values for each 
passage were considered 1 and were not represented in the graph. 
 
 
Finally, we accessed the expression of BiP, a molecular chaperone of 70 KDa located in 
the lumen of the ER that senses ER stress and activates UPR signaling [44]. Its expression was 
low compared to Mock in tRNASer(H) cell line (0.61 fold) in P1 and higher compared to Mock 
in the tRNASer(L) cell line in P30 (1.34 fold) (Figure 1-17 A). In tRNASer(L) there was 
upregulation of this chaperone (from 0.77 to 1.34 fold) from P1 to P30 (Figure 1-17 B), 
suggesting the presence of misfolded proteins in the ER. 
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Figure 1-17. Relative BiP expression. A – BiP expression relative to Mock and the corresponding 
immunoblots (one-way ANOVA, Dunnett’s post-test,*p<0.05). Mock values for each passage were considered 
1 and were not represented in the graph. B – BiP expression during evolution in tRNASer(L) cell line (one-way 
ANOVA, Bonferroni’s post-test, *p<0.05). Values were normalized to the Mock cell line of each passage and 
represent Average±SEM of at least three independent experiments in triplicate.  
 
 
In this part of the study, we have observed accumulation of ubiquitinated proteins in all 
cell lines, but proteasome activity was only altered in tRNASer(A) and tRNASer(L) cells. While 
tRNASer(A) cells maintained high proteasome activity, tRNASer(L) cells did not. The expression 
of molecular chaperones changed depending on the cell line and throughout evolution. Hsp70 
expression tended to decrease during evolution, while expression of Hsp27 had a peak in P15, 
which could be correlated with higher levels of ubiquitinated proteins and insoluble proteins in 
some of the cell lines analyzed. Hsp60 expression was also increased in tRNASer(H) cells in P15, 
but its levels decreased in P30. Hsp90α and BiP presented a different pattern of expression as 
their expression increased from P1 to P30, in some of our cell lines.
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1.3.5 Effects of PSE in the UPR 
 
Accumulation of misfolded proteins in the ER leads to activation of the UPR, which 
consists in transcriptional activation of genes required for protein folding, ER expansion and 
ER-associated protein degradation (ERAD). Activation of UPR reduces ER stress, but 
prolonged activation leads to apoptosis and also the accumulation of reactive oxygen species 
(ROS) via UPR-regulated oxidative protein folding machinery in the ER, contributing in this 
way to cell death [45]. To clarify whether constitutive PSE could lead to activation of the 
UPR, we studied some molecular markers of the UPR branches. Activation transcription 
factor 6 (ATF6) is a transmembrane protein embedded in the ER. Following ER stress-
induced proteolysis, it functions as a nuclear transcription factor [27]. Although in P1 there 
were no alterations in the ratio of fragmented ATF6/total ATF6 among cell lines, compared 
to the Mock, tRNASer(S) cell line displayed an increase in P15 and tRNASer(A) an increase in 
P30 (1.69 fold in both cases) (Figure 1-18 A). In tRNASer(S) cell line the ratio of fragmented 
ATF6/total ATF6 increased from P1 to P15 (from 0.72 to 1.69 fold) and decreased from P15 
to P30 (from 1.69 fold to 0.67 fold) (Figure 1-18 B).  
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Figure 1-18. Relative ATF6f/ATF6t expression. A – ATF6f/ATF6t expression relative to Mock 
and the corresponding immunoblot (one-way ANOVA, Dunnett’s post-test,*p<0.05). Mock values for each 
passage were considered 1 and were not represented in the graph. B – ATF6f/ATF6t expression during 
evolution in tRNASer(S) (one-way ANOVA, Bonferroni’s post-test, **p<0.01). Values were normalized to 
the Mock cell line of each passage and represent Average±SEM of at least three independent experiments 
in triplicate.  
 
 
Another marker of UPR activation is the phosphorylation of the eukaryotic initiation 
factor 2α (eIF2α-P). In cases of ER stress, PERK phosphorylates and inactivates eIF2α, 
shutting down mRNA translation to reduce protein load in the ER [46]. Only in P30 were 
observed diffrences in the ratio eIF2α-P/total eIF2α in our cell lines. The ratio eIF2α-P/total 
eIF2α decreased in tRNASer(A) (0.53 fold) and increased in tRNASer(L) (1.6 fold), comparing 
to Mock (Figure 1-19 A). In the latter, this happened gradually throughout evolution, from 
P1 to P30 (from 0.8 to 1.6 fold) (Figure 1-19 B) and this decrease is consistent with the 
decreased protein synthesis rate in P30 (Figure 1-9). The decrease of eIF2α-P in the 
tRNASer(A) cell line made us wonder whether it was caused by downregulation of PERK, or 
upregulation of the eIF2α phosphatase PP1’s regulatory domain, GADD34. Our data showed 
an increase in GADD34 expression only in tRNASer(A), in P30 (1.71 fold) (Figure 1-20 A) 
and from P1 to P30 (from 0.98 to 1.71 fold) (Figure 1-20 B). These results confirm that 
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GADD34 plays an important role in the maintenance of protein translational rate in this 
particular cell line.  
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Figure 1-19. Relative eIF2αP/eIF2αt expression.  A – eIF2αP/ eIF2αt expression relative to 
Mock and the corresponding immunoblots (one-way ANOVA, Dunnett’s post-test,*p<0.05). Mock values 
for each passage were considered 1 and were not represented in the graph. B – eIF2αP/ eIF2αt expression 
during evoltution in tRNASer(L) cells (one-way ANOVA, Bonferroni’s post-test,*p<0.05). Values were 
normalized to the Mock cell line of each passage and represent Average±SEM of at least three 
independent experiments in triplicate. 
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Figure 1-20. Relative GADD34 expression. A – GADD34 expression relative to Mock and the 
corresponding immunoblots (one-way ANOVA, Dunnett’s post-test, **p<0.01). Mock values for each 
passage were considered 1 and were not represented in the graph. B – GADD34 expression during 
evoltution in tRNASer(A) cells (one-way ANOVA, Bonferroni’s post-test,*p<0.05). Values were 
normalized to the Mock cell line of each passage and represent Average±SEM of at least three independent 
experiments in triplicate. 
 
 
Therefore, different types of PSE activated different UPR pathways, probably due to 
differences in ER stress intensity. Indeed, in the tRNASer(A) cell line, where protein 
misfolding levels and ER stress are probably milder (Ser and Ala are chemical similar amino 
acids), there was an increase in fragmented ATF6, concomitant with increased accumulation 
of ubiquitinated proteins and proteasome activity. This is physiologically relevant since ATF6 
is also responsible for protection against ER stress-induced apoptosis and cell survival [47]. 
However, in the tRNASer(L) cell line, where the level of misfolded proteins and ER stress 
should be more intense due to bigger chemical differences between Ser and Leu, 
phosphorylation of eIF2α repressed protein synthesis. This did not happen in the tRNASer(A) 
cell line due to eIF2α dephosphorylation by GADD34, that maintained the levels of protein 
synthesis rate and allowed a balance between protein degradation and protein synthesis.  
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1.3.6 Transcriptional deregulation induced by PSE  
 
To obtain a better picture of PQC activation in our model, we have characterized our 
cell lines using cDNA microarrays. We focused our gene expression data analysis on UPR, 
UPS, autophagy, translational factors and ribosomal protein genes (Table 2-1). Regarding the 
UPR genes, ERN1(endoplasmic reticulum to nucleus signaling 1, IRE1), XBP1(X-box 
binding protein 1) and EIF2AK3 (eukaryotic translation factor 2 alpha kinase 3, PERK) were 
deregulated in our cells. In P1, ERN1 was downregulated 2.4 fold in tRNASer(S), 2.0 fold in 
tRNASer(A) and 1.8 fold in tRNASer(L) cells. On the contrary, XBP1 (wich correspondes to 
the unspliced transcript) was upregulated 1.5 fold in P1 and 1.8 fold in P15 in tRNASer(S) 
cells. ERN1 catalyzes the splicing of XBP1 mRNA. Probably, since ERN1 is downregulated 
in P1 in tRNASer(S) cells, there is an accumulation of XBP1u. The upregulation of XBP1 
mRNA in P15, in  tRNASer(S) cells, is consistent with increased fragmented ATF6. ATF6 can 
induce not only the expression of ERAD genes, but also XBP1 gene [48]. During evolution, 
EIF2AK3 expression increased from -1.2 fold in P1 to 1.1 fold in P30, relative to Mock in 
tRNASer(L) and decreased in tRNASer(H) cells from 1.3 in P1 to -1.2 in P30. EIF2AK3 
encodes the kinase responsible for eIF2α phosphorylation (PERK) and its upregulation is 
consistent with increased levels of eIF2α-P, in P30, in the tRNASer(L) cell line.  
The cDNA microarray data also confirmed activation of the UPS, as alterations in the 
expression of some ubiquitin ligases (UBE2Z, UBE2I and SMURF2) were observed over 
time. Overall, there was a tendency to increased expression in ubiquitin ligases in P15 in 
tRNASer(S), tRNASer(L) and tRNASer(H) cells, despite the values were below 1.5 fold. In 
tRNASer(S), UBE2Z expression decreased from P15 (1.3 fold) to P30 (-1.3 fold), while 
SMURF2 expression increased from P1 (-1.2 fold) to P15 (1.3 fold). For the last one, in 
tRNASer(L), there was also an increase in expression from P1 (0.8 fold) to P15 (1.1 fold). In 
tRNASer(H), the expression of UBE2I decreased from P15 (1.1 fold) to P30 (-1.1 fold). 
Deubiquitinating enzymes (USP48 and USP36) were deregulated in tRNASer(S), tRNASer(A) 
and tRNASer(L) cell lines. USP48 was upregulated in tRNASer(L) in P30 (1.6 fold). USP36 
was upregulated in tRNASer(S) in P15 (1.5 fold) and its expression decreased in tRNASer(A) 
cells from P1 (1.2 fold) to P15 (-1.0 fold). Also, the expression of PSMC1 gene (proteasome 
26S subunit, ATPase 1) suffered alterations during evolution, its expression decreased from 
P15 to P30 in tRNASer(S) (1.3 to -1.0 fold), tRNASer(A) (1.1 to -1.1 fold) and tRNASer(H) 
cells (1.2 to -1.1 fold). tRNASer(S) cell line presented more alterations in UPS genes 
comparatively to the other cell lines. We could also observe that UPS related genes tended to 
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be upregulated in P15, concomitantly with the accumulation of ubiquitinated proteins in most 
cell lines, with exception for UPS48  in tRNASer(S) (upregulated in P30, 1.6 fold).  
Regarding autophagy, the microarray data showed upregulation of ATG16L1 during 
evolution in tRNASer(S) (from -1.0 fold in P15 to 1.3 fold in P30), tRNASer(A) (-1.1 fold in 
P15 to 2.2 fold in P30) and tRNASer(H) cells (-2.2 fold in P1 to 1.6 fold in P30). ATG12 and 
ATG5 expression also increased in the tRNASer(L) cell line, from -1.0 fold in P1 to 1.3 fold 
in P15 and -1.2 fold in P1 to 1.1 fold in P15, respectively. These two genes encode proteins 
that form a complex involved in the formation of the autophagosomes and may be involved 
in the degradation of protein aggregates [49]. These results indicate that autophagy was 
probably activated in our cell lines. The increase in ATG12 and ATG5 is consistent with the 
higher levels of insoluble proteins in the tRNASer(L) cell line.  
Beyond the above mentioned deregulations, a set of translational factors, namely 
EIF4EBP1 (eukaryotic translation initiation factor 4E binding protein 1), EEF1A1 
(eukaryotic translation elongation factor 1 alpha 1) and EEF2 (eukaryotic translation 
elongation factor 2), were also deregulated during evolution. EIF4EBP1 expression decreased 
in tRNASer(A) celss from P15 (1.3 fold) to P30 (-1.1 fold). The eIF4EBP1 interacts with 
eIF4E and inhibits initiation complex assembly with consequent translation repression [50]. 
The decreased expression of EIF4EBP1 is in accordance with the translation derepression 
observed in this cell line. EEF1A1 expression decreased in tRNASer(S) and tRNASer(H) cells 
from 1.4 fold in P15 to -1.0 fold in P30 and from 1.0 fold in P1 to -1.2 fold in P15, 
respectively. Also, in tRNASer(S) cell line, EEF2 expression was downregulated from 1.0 fold 
in P15 to -1.5 fold in P30. These data suggest that translation elongation rate may also been 
affected during evolution, but our data was not able to reveal it. Also, these results may 
indicate that translation was remodeled for efficient translation of stress genes rather than for 
global translational repression. Indeed, the RPS6KL1 (ribosomal protein S6 kinase like 1) that 
encodes a member of the ribosomal S6 kinase family was upregulated during evolution from    
-1.3 fold in P15 to 1.0 fold in P30 in tRNASer(A) cell line. S6 kinases are part of the 
mammalian target of rapamycin (mTOR) pathway, which is a key regulator of cell growth 
via the regulation of protein synthesis. S6 kinases are activated by serine/threonine 
phosphorylation and phosphorylate ribosomal protein 6, increasing translation of a set of 
proteins, including ribosomal proteins [51]. 
Altogether, the expression microarrays data are in accordance with our previous 
results and supported the idea that PQC mechanisms are being activated in a time dependent 
manner, and in response to mutant tRNAs or tRNA pool deregulation alone. UPR related 
genes were upregulated (tRNASer(S) cell line), or showed increased fold change during 
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evolution (tRNASer(L) cell line). UPS related genes were also upregulated in the same cell 
lines. Variation of expression through time in UPS genes, was observed in tRNASer(S), 
tRNASer(A) and tRNASer(H) cells. These gene expression alterations are different for each 
cell line, probably depending on the need for ubiquitinating or deubiquitinating enzymes 
during each passage. Autophagy seems to play a role in the response against misfolded 
proteins in our cell lines, since there was an increase in the expression of autophagy related 
genes through their evolution from P1 to P30. Alterations in translational factors were also 
seen, as well as a tendency to decreased expression though time in tRNASer(S) and 
tRNASer(A) cells, with no implications in the overall protein synthesis rate. Finally, also the 
expression of a ribosomal protein kinase (RPS6KL1) was altered in tRNASer(A) and 
tRNASer(H) cell lines.  
 
Table 1-1. Deregulation of PQC genes induced by protein synthesis errors.  
Red color represents upregulated genes, fold change above 1.5. Green color represents dowregulated 
genes, variation below -1.5 fold. Numbers in blue highlight changes in gene expression that occurred 
during evolution.  
 
 
1.4 Discussion  
 
Our study demonstrates that HEK293 cells expressing mutant tRNAs or 
overexpressing the Wt tRNASer are highly tolerant to PSE, despite the accumulation of 
misfolded proteins over time. PQC mechanisms were activated in a time and stress dependent 
manner, allowing these cell lines to thrive, after several generations in culture. 
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PSE destabilize protein structure and cause disease by overloading chaperones and 
the proteasome and inducing autophagy, increasing protein cleaning up energetic costs, 
altering cell signaling and metabolism, producing toxic protein aggregates, repressing protein 
synthesis and inducing major genomic alterations [22, 52–54]. Kalapis and Bezerra have 
demonstrated recently that a yeast strain misincorporating Ser at Leu sites could adapt to PSE 
by up-regulating protein synthesis, protein degradation and glucose up-take [55]. 
Remarkably, clones that evolved for approximately 250 generations were able to reduce 
protein aggregates and recovered fitness to almost wild type levels, but at a high metabolic 
cost [55]. Our data are in line with those data. Indeed, protein synthesis and degradation rates 
increased during evolution in tRNASer(A) cell line. In contrast, while mistranslation had a 
major negative initial impact on yeast growth rate and viability, no consequence at all were 
seen in HEK293 cells doubling time and an increase was even observed in the viability of 
tRNASer(A) and tRNASer(L) cell lines and proliferation of tRNASer(S) and tRNASer(A) cell 
lines (Figure 1-5, Figure 1-6 and Figure 1-7). 
Also, tolerance to mutant tRNAs increased in yeast during evolution, while in human 
cells the mutant tRNAs expression was strongly repressed throughout evolution. These data 
suggest that yeast adapted to mistranslation using error mitigation mechanisms, while human 
cells preferred error prevention. 
The decrease in protein aggregation levels observed during evolution in yeast and 
HEK293 cells (namely in tRNASer(L) cell line) has implications for understanding the biology 
of protein misfolding diseases. Protein aggregation studies use cell models where expression 
of aggregation prone proteins is induced and adaptation is not evaluated [56–58]. Even in 
cases where these proteins are expressed constitutively the norm is to maintain cell passages 
as low as possible to avoid genomic instability [59]. Considering our data on adaptation 
during evolution, human cell models of Alzheimer’s, Parkinson’s and other protein 
misfolding diseases should be studied to capture the full spectrum of metabolic and 
physiological changes induced by protein aggregation. Aggregates associated with 
neurological disorders are known to block proteasome activity and activate mechanisms that 
lead to the repression of protein synthesis [8, 60], suggesting that these cells are unable to 
tolerate and adapt to them [61, 62]. However, different types of human cells cope differently 
with protein aggregation, raising the question of whether adaptation to aggregation may 
follow different routes in different cell types. Recent studies showing that suppression of 
eIF2 kinases alleviates Alzheimer’s symptoms in mice [63] support this hypothesis.  
Different amino acid misincorporations in the proteome activated different cellular 
responses and led to differential adaption routes during the evolution of our cell lines. 
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Interestingly, increased expression of the Wt tRNAAGA
Ser had phenotypic consequences that 
were clearly distinct from the Mock (control), suggesting that human cells are highly sensitive 
to tRNA gene copy number alterations and expression levels. It is known that increased 
expression of Wt tRNAs (which is common in cancer) alters translation rate, enhances 
expression of oncogenes and may also increase the level of protein errors, leading to 
accumulation of misfolded proteins [14, 64]. In P15, we observed accumulation of 
ubiquitinated proteins, UPS and UPR activation (Figure 1-21) confirming the hypothesis that 
misexpression of Wt tRNAs may have major physiological consequences due to activation 
of the stress response and translational deregulation of gene expression [65].  
In the tRNASer(A) cell line there was an initial (P1 to P15) increase in protein 
synthesis rate, followed by increased proteasome activity (P15 to P30), in other words 
increased protein synthesis and turnover, as occurred in yeast (Figure 1-21) [55]. Previous 
studies show that short-living proteins have on average higher aggregation propensity and 
fewer chaperone interactions than long-living proteins and high protein turnover seems to be 
sufficient to prevent aggregation [66]. Therefore, the Ser-to-Ala misincorporation model may 
be relevant to address the biology of PSE for instance in cancer, where PQC mechanisms are 
highly activated [67], but generalized protein aggregation is not commonly observed. Indeed, 
PSE have not yet been quantified in a systematic manner in cancer, and it is unclear whether 
it plays a relevant role, however chaperones are often uperegulated in tumors [68], suggesting 
high demand for protein folding/refolding, which is a hallmark of PSE.  
The tRNASer(L) cell line had higher proteasome activity (P1), but accumulation of 
aggregated proteins was also visible (P15) (Figure 1-21). Adaptation of this cell line to mutant 
tRNA expression and protein aggregation was more dependent on UPR activation, namely 
phosphorylation of eIF2α, and consequent inhibition of protein synthesis rate in order to 
alleviate ER stress, than other cell lines. At the protein synthesis level, phosphorylation of 
eIF2α promotes polysome disassembly resulting in the accumulation of untranslated 
messenger ribonucleoprotein particles (mRPs) that can form stress granules, and are 
responsible for reprogramming mRNA metabolism and contribute to cell survival [69, 70]. 
Together with the decrease in protein synthesis rate, also dilution by cell division and 
autophagy may have contributed to the decrease in protein aggregates observed in P30, in 
this cell line.  
tRNASer(H) activated mainly PQC mechanisms in P1 and P15, while in P30, a 
decrease in molecular chaperones occurred (Figure 1-21). With exception of Hsp90α and BiP, 
there was a general decrease in molecular chaperones expression in our cell lines (Figure 1-
21). Decrease in chaperones with aging have been already reported in several studies [71–
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74]. Molecular chaperones are, usually, the first line of defense against misfolded proteins, 
and probably, other mechanisms can be more efficient to remove these proteins after 
prolonged proteotoxic stress.  
 
 
 
Figure 1-21. Summary of the PQC alterations identified in the different cell lines. Mutant 
tRNAs and misexpression of tRNASer led to accumulation of ubiquitinated proteins, suggesting increased 
levels of misfolded proteins.  PQC mechanisms were recruited in an error type and time dependent manner 
to counteract proteotoxic stress. Increase in protein turnover and decrease in protein synthesis seem to be 
two important mechanisms that cells used to thrive in culture after several generations accumulating errors 
in proteins. 
 
 
1.5 Conclusion 
 
PSE have been extensively studied in E. coli and yeast, but little is known about their 
biology in human cells. We show here that experimental evolution provides an important tool 
to study such errors in human cells, although they have only been applied to microorganisms.  
HEK293 cells activated PQC mechanisms in order to respond to the accumulation of 
misfolded proteins caused by the introduction of mutant tRNAs or tRNA pool deregulation. 
As we expected, this activation depends on the cell passage and the type of proteome 
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destabilization that we are creating. With evolution of the cell lines, we observed that there 
was a decrease in protein ubiquitination and in some cases protein aggregates with 
concomitant increase in UPR activation or protein degradation.  
Clearly, and in contrast to models of protein misfolding diseases, we did not observe 
significant effects on cell viability or proteasome inhibition suggesting that human cells cope 
better with PSE than with protein aggregation associated with Alzheimer’s, Parkinson’s and 
other neuropathies. Adaptation to PSE and protein aggregation may also suggest that protein 
synthesis and degradation rates are more relevant to mitigate and erase aggregates than 
chaperones or autophagy. In fact, expression of molecular chaperones was unchanged or 
decreased during evolution, an effect also observed in yeast, where chaperones expression 
increases initially but decreases gradually or is even repressed in some cases.  
 
 
1.6 Materials and Methods  
 
1.6.1 Cell culture 
 
Human embryonic kidney 293 (HEK293) cells were purchased from American Type 
Culture Collection (ATCC®CRL-1573). Cells were grown in Minimum Essential Medium 
(Gibco, Cat.41090-028) supplemented with 10% fetal bovine serum (FBS) (Sigma, 
Cat.F1051), 1% of Pen/Strep (Gibco, Cat.15070-063) and 1% of non-essential amino acids 
(Gibco, Cat.11140-050) in a humidified atmosphere at 37ºC in the presence of 5% CO2.  
 
 
1.6.2 Construction of mutant tRNA plasmids  
 
A DNA fragment of 248kb, corresponding to part of the gene encoding human wild 
type tRNAAGA
Ser (Chr6 tRNA#5) and its flanking region, was amplified by PCR. The primers 
used were the following: forward 5’- 
GCCGAATTCAGCTATTATTAAATCCCTAATAAAAGG-3’ and reverse 5’-
CGCCTCGAGTTGTAAAAGATCGAAAGCCTTTTTA-3’. The region amplified has the 
following sequence: 5’-
AGCTATTATTAAATCCCTAATAAAAGGAGTACAATATGTGATGTATGGAAACAT
GTAAGACATTTAATAAGGTTTTTGGTATCTGTAGTCGTGGCCGAGTGGTTAAGG
CGATGGACTAGAAATCCATTGGGGTCTCCCCGCGCAGGTTCGAATCCTGCCGAC
TACGGCAGTGGGTTTTTGCATCTTCAAGCAGGTTTCATCCGACCGATCGATATTT
CACGTGTAAAAAGGCTTTCGATCTTTTACAA-3’. This region was cloned into the 
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modified vector pIRES2-DsRed with new multiple cloning sites, using the enzymes EcoRI 
(Thermo Scientific, Cat.ER0271), XhoI (Thermo Scientific, Cat.ER0691) and T4 DNA ligase 
(Thermo Scientific, Cat.EL0011). To change the anticodon of the tRNAAGA
Ser, to other 
anticodons, we performed site-directed mutagenesis. The primers used were the following: 
forward to tRNAAGC
Ser (A) 5’-
GTTAAGGCGATGGACTAGCAATCCATTGGGGTCTCCC-3’; reverse to tRNAAGC
Ser 
(A) 5’-GGGAGACCCCAATGGATTGCTAGTCCATCGCCTTAAC-3’;forward to 
tRNAAAG
Ser (L) 5’-GGTTAAGGCGATGGACTAAGAATCCATTGGGGTCTCCC-3’; 
reverse to tRNAAAG
Ser (L) 5’-
GGGAGACCCCAATGGATTCTTAGTCCATCGCCTTAACC-3’;forward to  tRNAGTG
Ser 
(H) 5’-GGTTAAGGCGATGGACTGTGATCCATTGGGGTCTCC-3’; reverse to 
tRNAGTG
Ser (H) 5’-GGAGACCCCAATGGATTCACAGTCCATCGCCTTAACC-3’. 
Contruction of mutant tRNA plasmids was done by Patrícia Pereira in the RNA 
Biology Laboratory, Aveiro, Portugal, in 2007.  
 
 
1.6.3 Generation of mistranslating cell lines 
 
HEK293 cells with approximately 60% of confluency were transfected with 1µg of 
plasmid DNA using Lipofectamine2000 (Invitrogen, Cat.11668019), following 
manufacturer’s instructions. Cells were transfected with an empty vector (Mock), and with 
the plasmid carrying tRNAAGA
Ser(S), tRNAAGC
Ser(A), tRNAAAG
Ser(L) or tRNAGTG
Ser(H) genes. 
To establish stable cell lines, 72h after transfection, geneticin (Formedium, Cat.G4185) was 
added to the medium at a concentration of 800µg/ml and selection lasted for 1 month. Cells 
were kept in low concentration of geneticin (100µg/ml) after selection and during evolution 
in culture. Geneticin was not added to the medium when cells were plated for the experiments.  
  
 
1.6.4 Evolution of cells in culture  
 
After transfection with the plasmids and selection, cells were kept in culture dishes 
(60mm) and subcultured ever 3 days using the same dilution (1/6) until passage 30. Cell 
culture conditions were the same during evolution. In P1, P15 and P30 cells were plated in 
100mm culture dishes, to have enough cells to perform the experiments and extract DNA, 
RNA and protein.  
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1.6.5 Total RNA extraction  
 
RNA was extracted using Trizol®Reagent (Thermo Fisher Scientific, Cat.15596026). 
The content of one well from a 6 well plate, with around 5x105 cells, was collected for each 
experimental condition. Purification of RNA was done using DNaseI, Amplification Grade 
kit (Invitrogen, Cat.18068015), following manufacturer’s instructions. RNA was then 
precipitated with a standard Phenol/Chlorophorm/Isoamylalchohol (25:24:1) (Acros 
Organics, Cat.327111000) extraction protocol and conserved at -80ºC. RNA concentration 
was determined using NanoDrop1000 (Thermo Scientific). RNA quality was verified using 
Agilent 2100 Bioanalyser.  
 
 
1.6.6 Quantification of tRNA expression and tDNA copy number 
 
The expression of the tRNAs was quantified by extracting total RNA from the 
transfected cell lines. 200ng of total RNA were used for cDNA convertion using NCode™ 
VILO™ miRNA cDNA Synthesis Kit (Invitrogen, Cat.A11193050), following 
manufacturer’s instructions. To determine the copy number of the Wt tDNASer and the mutant 
tDNA genes, genomic DNA was extracted using Wizard® Genomic DNA Purification Kit 
(Promega, Cat.TM050), following the manufacturer’s instructions. Amplification of the Wt 
and mutant tRNAs from cDNA (2µL) or DNA (200ng) was done by PCR using the following 
primers: forward 5’-CGTAGTCGGCAGGATTCGAA-3’ and reverse 5'-GTA GTC GTG 
GCC GAG TGG TT-3'. As an internal control, GAPDH was also amplified in the same PCR 
reaction, using the following primers: forward 5´-CTC CTG TTC GAC AGT CAG CC -3' 
and reverse 5'-CCC ACT TGA TTT TGG AGG GA-3'.  
PCR conditions for DNA amplification were: 95ºC for 15min, (95ºC for 30 sec, 62ºC 
for 1 min and 30 sec, 72ºC for 1 min and 30 sec, 3 cycles); (95ºC for 30 sec, 60ºC for 1 min 
and 30 sec, 72ºC for 1 min and 30 sec, 3 cycles); (95ºC for 30 sec, 58ºC for 1 min and 30 sec, 
72ºC for 1 min and 30 sec, 30 cycles) and a final step of extension at 72°C for 10 min. 8µL 
of the PCR product was run on a 2% agarose gel to confirm the amplification of the two bands 
(Figure 1-23 A).  
PCR conditions for cDNA amplification were: 95ºC for 15min, (95ºC for 30 sec, 62ºC 
for 1 min and 30 sec, 72ºC for 1 min and 30 sec, 3 cycles); (95ºC for 30 sec, 60ºC for 1 min 
and 30 sec, 72ºC for 1 min and 30 sec, 3 cycles); (95ºC for 30 sec, 58ºC for 1 min and 30 sec, 
72ºC for 1 min and 30 sec, 30 cycles) and a final step of extension at 72°C for 10 min. 5µL 
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of PCR product were purified with 1µL of ExoI (Thermo Fisher Scientific, Cat.EN0581) and 
1µL of FastAp (Thermo Fisher Scientific, Cat.EF0654) for 60min at 37ºC followed by 15min 
at 85ºC. 2µL of purified PCR product were reamplified. PCR conditions were the same, with 
the exception of the number of cycles in the last amplification step (cycle 25). 8µL of the 
PCR product were run on a 2% agarose gel to confirm the amplification of the two DNA 
fragments (Figure 1-23 B).  
5µL of PCR products (from DNA or cDNA) were purified using 1µL of ExoI (Thermo Fisher 
Scientific, Cat.EN0581) and 1µL of FastAp (Thermo Fisher Scientific, Cat.EF0654) for 
60min at 37ºC followed by 15min at 85ºC.  
SNaPshot reaction was performed using the following primers: 5’-
GGGAGACCCCAATGGATT-3’ for tRNAs and 5'-CCC ACT TGA TTT TGG AGG GA-3' 
for GAPDH and a SNaPshot Multiplex Ready Reaction Mix (Applied Biosystems, 
Cat.4323163). Reaction cycles for tRNAs were: 96ºC for 10 sec, 54ºC for 5 seconds and 60ºC 
for 30 sec, 25 cycles. Reaction cycles for GAPDH were: 96ºC for 10 sec, 64ºC for 5 seconds 
and 60ºC for 30 sec, 10cycles. SNaPshot products were purified with 1µL of FastAp (Thermo 
Fisher Scientific, Cat.EF0654) for 60min at 37ºC, followed by 15min at 85ºC. Samples were 
then sequenced and analyzed with Peak Scanner software (Applied Biosystems). The peak 
area corresponding to each mutant tRNA and Wt tRNASer was determined and a ratio 
calculated. GAPDH was quantified and used as a internal control to normalize tRNA 
expression levels [75, 76].  
 
 
 
1.6.7 Cell fitness assessment 
 
To measure cells doubling time, 3x104cells/well were plated in 6-well plates. After 
72h, cells were detached and counted in a Neubauer chamber with Tripan blue 0.4% (Lonza, 
Cat.17-942E). Population doubling time was calculated using the formula: Doubling 
time=duration*log(2)/(log(final concentration)-log(initial concentration)) [77]. For viability 
assays, the number of viable cells in culture was determined with Tripan blue exclusion assay. 
3x104cells/well were plated in 6-well plates. After 72h, cells were counted in a Neubauer 
chamber using Tripan Blue 0.4% (Lonza, Cat.17-942E). For the quantification of cell 
proliferation, we used a colorimetric immunoassay ELISA, based on the measurement of 
BrdU incorporation during DNA synthesis (Roche, Cat.11647229001), following 
manufacturer’s instructions. 1x105cells/well were plated in a 96-well and analysis was 
performed after 48h. To access the ability of a single cell to grow into a colony we performed 
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an anchorage-dependent colony formation assay. 100cells/well were plated in 6-well plates. 
The medium was renewed every 3 days. After 12 days, cells were fixed in ice-cold methanol 
and stained with 1% cristal violet (Sigma Aldrich, Cat.C6158) in 20% methanol to count the 
foci.  
 
 
1.6.8 Protein synthesis determination  
 
In order to determine protein synthesis rate, we took advantage of a non-reactive 
fluorescence-activated cell sorting-based assay, called SUnSET [34] with few modifications. 
2x105cells/well were plated in 6-well plates and after 48h, puromycin (Sigma Aldrich, Cat. 
07635) was added to each well in a final concentration of 10%. Cells were kept in the 
incubator for 10 min, washed twice with 1%PBS and returned to the incubator for 50 min. 
After protein extraction with Lysis Buffer (0.5% Triton X-100, 50mM HEPES, 250mM NaCl, 
1mM DTT, 1mM NaF, 2mM EDTA, 1mM EGTA, 1mM PMSF, 1mM Na3VO4 supplemented 
with a cocktail of protease inhibitors (Complete, EDTA-free, Roche, Cat. 11873580001); as 
recommended by the manufacturer) and denaturation, 100 µg of protein were resolved in 10% 
SDS-PAGE and blotted onto nitrocellulose membranes (0.2µm) (GE Healthcare Life 
Sciences). Anti-puromycin, clone 12D10 (kindly given by Philippe Pierre) was used (1:5000 
dilution) to detect the incorporation of puromycin into proteins. IRDye800 goat anti-mouse 
secondary antibody (Li-cor Biosciences, Cat.400-33) was used (1:10000 dilution) and 
detected in an Odyssey Infrared Imaging System (Licor Biosciences). Membranes were also 
probed with Anti-β-tubulin (Invitrogen, Cat.32-2600) (1:1000 dilution) as a loading control. 
 
 
1.6.9 Quantification of the insoluble protein fraction  
 
To quantify the insoluble protein fraction, 2x105cells/well were plated in 6-well 
plates. After 48h cells were detached and 100µL of Lysis Buffer (0.5% Triton X-100, 50mM 
HEPES, 250mM NaCl, 1mM DTT, 1mM NaF, 2mM EDTA, 1mM EGTA, 1mM PMSF, 
1mM Na3VO4 supplemented with a cocktail of protease inhibitors (Complete, EDTA-free, 
Roche, Cat. 11873580001) as recommended by the manufacturer) was added to the cells’ 
pellet. Cells were sonicated with a probe sonicator in 5 pulses of 5 seconds, incubated on ice 
for 30min and centrifuged at 5000rpm for 15min at 4ºC. 10µL of the supernatant (total protein 
fraction) were stored to measure protein concentration with bicinchoninic acid (BCA) assay 
(Thermo Fisher Scientific, Cat. 23225). 80µL of supernatant were centrifuged again at 
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12000rpm for 20min at 4ºC. The pellet (insoluble fraction) was then washed with 160µL of 
LB and 40µL of 10%Triton X-100 (Sigma-Aldrich, Cat.X100) and centrifuged at 15000g for 
20min at 4ºC. The pellet was solubilized in 50µL of LB. 15µL of samples were denaturated 
with loading buffer (6x) (0.375M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6M DTT, 0.06% 
bromophenol blue) at 95ºC for 5 min and resolved in a 10% SDS-PAGE. The gel was stained 
with 0.1% Comassie Brilliant Blue G solution (Sigma-Aldrich, Cat.B0770) for at least 2h. 
After destaining with a solution of 10% ethanol and 7.5% acetic acid, gels were scanned using 
Odyssey Infrared Imaging System (Licor Biosciences). Lane signals corresponding to each 
sample were quantified and normalized to the total amount of protein determined with BCA 
assay.  
 
 
1.6.10 Quantification of proteasome activity  
 
In order to test the activity of the proteasome, 2x105cells/well were plated in 6-well 
plates. After 48h cells were washed with 1%PBS and resuspended in 100µL of Lysis Buffer 
(1mM EDTA, 10mM Tris-HCl pH 7.5; 20% glycerol; 4mM DTT; 2mM ATP). Cells were 
sonicated with a probe sonicator in 5 pulses of 5 seconds, and centrifuged at 13000rpm for 
10min at 4ºC. The supernatant was diluted (1:20) and protein content was quantified using 
Bradford method (Sigma-Aldrich, Cat.B6916). 20µg of protein in Lysis Buffer were 
incubated with the substrate suc-LLVY-MCA (50µM) (Sigma-Aldrich, Cat.S4939) in the 
presence or in the absence of the proteasome inhibitor MG132 (10µM) (Sigma-Aldrich, 
Cat.SML1135) in a medium containing 1mM EDTA, 10mM Tris-HCl pH 7.5; 2mM ATP 
(final volume 100µL). Substrate degradation was monitored every 5min during 1h at 37ºC in 
a fluorescence-luminescence detector Synergy™ HT Multi-Mode Microplate Reader 
(Biotek), set to 380 and 460nm, excitation and emission wavelengths, respectively.  Specific 
proteasome activity was determined by subtracting the values for each sample without 
MG132 to the values with MG132. Final activity was calculated as fluorescence emission at 
0 min subtracted from fluorescence after 1h relative to control (Mock).  
 
 
1.6.11 Immunoblots  
 
2x105 cells were plated in 6-well plates. After 48h, cells were washed with 1%PBS 
and then lysed with protein Lysis Buffer (0.5% Triton X-100, 50mM HEPES, 250mM NaCl, 
1mM DTT, 1mM NaF, 2mM EDTA, 1mM EGTA, 1mM PMSF, 1mM Na3VO4 supplemented 
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with a cocktail of protease inhibitors (Complete, EDTA-free, Roche, Cat. 11873580001) as 
recommended by the manufacturer). Cells were sonicated with a probe sonicator in 5 pulses 
of 5 seconds. After centrifugation, 16000g for 30min, protein in the supernatants was 
quantified using the BCA assay (Thermo Fisher Scientific, Cat. 23225). Samples were 
denaturated with loading buffer (6x) at 95ºC for 5 min.  
Protein samples were separated by SDS-PAGE in 10% polyacrylamide gels (or 8% 
for molecular chaperones and ATF6), transferred to nitrocellulose membranes (0.2µm) and 
immunobloted. Membranes were incubated with primary antibodies overnight (4ºC), washed 
and incubated with secondary antibodies (1:10000 dilution, 2h at room temperature), 
IRDye800 goat anti-mouse (Li-cor Biosciences, Cat.400-33) or IRDye680 goat anti-rabbit 
(Li-cor Biosciences, Cat.925-68070). Secondary antibodies were detected using an Odyssey 
Infrared Imaging System (Licor Biosciences). The following primary antibodies were used: 
anti-ubiquitin (1:1000 dilution) (Sigma-Aldrich, Cat.U0508), anti-Hsp70 (1:1000 dilution) 
(Stress Marq Biosciences, Cat.SMC-100B), anti-Hsp27 (0.5µg/ml dilution) (Stress Marq 
Biosciences, Cat.SMC-161A), anti-Hsp60 (1:1000 dilution) (Stress Marq Biosciences, 
Cat.SPC-105), anti-Hsp90α (1:1000 dilution) (Stress Marq Biosciences, Cat.SMC-147), anti-
BiP (1:1000 dilution) (Stress Marq Biosciences, Cat.SPC-180), anti-ATF6 (1:400 dilution) 
(Stressgen, Cat.70B1413.1), anti-eIF2α (1:1000 dilution) (Cell Signalling, Cat.9722), anti-
phosphorylated eIF2α (1:400 dilution) (Abcam, Cat.ab4837), anti-GADD34 (1:500 dilution) 
(Thermo Fisher Scientific, Cat.PA1-12376), anti-β-tubulin (Invitrogen, Cat.32-2600). β-
tubulin was used in all the immunoblots as a loading control. 
 
 
1.6.12 Gene expression microarrays 
 
Gene expression microarrays profiling was performed using the Agilent protocol for 
One-Color Microarray Based Gene Expression Analysis Low Input Quick Amp Labeling 
v6.9 (Agilent Technologies). RNA quality determination was performed using 2100 
Bioanalyser (Agilent Technologies) and the kit Agilent RNA 6000 Nano kit (Agilent 
Technologies, Cat.5067-1512). 100ng of total RNA were used to synthesize labeled cDNA 
(with Cyanine 3-CTP) using Agilent T7 Promoter Primer and T7 RNA polymerase Blend 
(Agilent Technologies, Cat.5190-2305). cDNA was purified with RNAeasy mini spin 
columns (Quiagen, Cat.74104). Dye incorporation was quantified using Nanodrop 1000 
Spectophotometer. 600ng of labeled cDNA were hybridized in Sure Print G3 Human Gene 
Expression 8x60k v2 microarrays (Agilent Technologies, Cat.G4851B). Hybridizations were 
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carried out using Agilent gasket slides in a rotating oven for 17h at 65ºC. Slides were then 
washed following manufacturer’s instructions and scanned in an Agilent G2565AA 
microarrays scanner.  
Probes signal values were extracted using Agilent Feature Extraction Software. Data 
were normalized using median centering of signal distribution with Biometric Research 
Branch BRB-Array tools v3.4.o software [78, 79]. Microarrays statistical analysis was carried 
out using Mev software (TM4 Microarray Software Suite) [80, 81]. T-test was performed to 
identify genes that showed differences in expression between control (Mock) and samples. 
Significant genes that present a fold change above 1.5 or bellow -1.5 were considered for 
downstream analysis.  
The microarray raw data was submitted to the GEO database and has been given the 
following accession number: GSE93854.  
 
 
1.6.13 Statistical analysis  
 
For all assays, our data represent at least 3 independent experiments and 3 replicates. 
Statistical analysis was performed using One-way ANOVA analysis of variance followed by 
the Dunnett’s or Bonferroni’s post-tests, as indicated in the figures. In all cases, p-
values<0.05 were considered statistically significant.  
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1.7 Supplementary Figures  
 
Figure 1-22. tRNA amplification with primers for the plasmid and Sanger sequencing. 
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Figure 1-23. SNaPshot analysis – Agarose gels representative of the amplification of 
tRNA and GAPDH. A – Amplification from DNA of mistranslating cells; B – Amplification from 
cDNA of mistranslating cells.  
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Figure 1-24. SNaPshot peaks of the endogenous tRNASer, mutant tRNAs and the 
respective control, GAPDH. Sequenced samples correspond to cDNA from P1. The primer 
extension (SNaPshot) reaction utilizes a multiplex kit that contains a reaction mix of four differentially 
fluorescently labeled ddNTPs, allowing the detection of the incorporated base correspondent to the last 
base of anticodons. In the case of tRNASer(S) cell line, expressing tRNAAGASer, the peak corresponds to the 
incorporation of T (red peak). For tRNASer(A) cells (expressing tRNAAGCSer), the peak corresponds to the 
incorporation of G (blue peak). For tRNASer(L) (expressing tRNAAAGSer) and tRNASer(H) (expressing 
tRNAGTGSer) cells, the peak corresponds to the incorporation of C (black peak). In tRNASer(A), tRNASer(L) 
and tRNASer(H) cell lines, the Wt tRNASer and mutant tRNAs were detected (upper panel). The peak area 
corresponding to each mutant tRNA and Wt tRNASer was determined for each cell line and a ratio was 
calculated. Amplification of GAPDH was used as an internal control to normalize the values (lower panel).   
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Figure 1-25. SNaPshot peaks of the endogenous tRNASer, mutant tRNAs and the 
respective control, GAPDH. Sequenced samples correspond to cDNA from P15. For 
tRNASer(S) cell line (expressing tRNAAGASer), the peak corresponds to the incorporation of T (red peak). 
For tRNASer(A) cells (expressing tRNAAGCSer), the peak corresponds to the incorporation of G (blue peak). 
For tRNASer(L) (expressing tRNAAAGSer) and tRNASer(H) (expressing tRNAGTGSer) cells, the peak 
corresponds to the incorporation of C (black peak). In tRNASer(A), tRNASer(L) and tRNASer(H) cell lines, 
the Wt tRNASer and mutant tRNAs were detected (upper panel). The peak area corresponding to each 
mutant tRNA and Wt tRNASer was determined for each cell line and a ratio was calculated. Amplification 
of GAPDH was used as an internal control to normalize the values (lower panel).   
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Figure 1-26. SNaPshot peak of the endogenous tRNASer, mutant tRNAs and the 
respective control, GAPDH. Sequenced samples correspond to cDNA from P30. For 
tRNASer(S) cell line (expressing tRNAAGASer), the peak corresponds to the incorporation of T (red peak). 
For tRNASer(A) cells (expressing tRNAAGCSer), the peak corresponds to the incorporation of G (blue peak). 
For tRNASer(L) (expressing tRNAAAGSer) and tRNASer(H) (expressing tRNAGTGSer) cells, the peak 
corresponds to the incorporation of C (black peak). In tRNASer(A), tRNASer(L) and tRNASer(H) cell lines, 
the Wt tRNASer and mutant tRNAs were detected (upper panel). The peak area corresponding to each 
mutant tRNA and Wt tRNASer was determined for each cell line and a ratio was calculated. Amplification 
of GAPDH was used as an internal control to normalize the values (lower panel).   
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Figure 1-27. SNaPshot peaks of the endogenous tRNASer, mutant tRNAs and the 
respective control, GAPDH.  Sequenced samples correspond to DNA from P1. For 
tRNASer(S) cell line (expressing tRNAAGASer), the peak corresponds to the incorporation of T (red peak). 
For tRNASer(A) cells (expressing tRNAAGCSer), the peak corresponds to the incorporation of G (blue peak). 
For tRNASer(L) (expressing tRNAAAGSer) and tRNASer(H) (expressing tRNAGTGSer) cells, the peak 
corresponds to the incorporation of C (black peak). In tRNASer(A), tRNASer(L) and tRNASer(H) cell lines, 
the Wt tRNASer and mutant tRNAs were detected (upper panel). The peak area corresponding to each 
mutant tRNA and Wt tRNASer was determined for each cell line and a ratio was calculated. Amplification 
of GAPDH was used as an internal control to normalize the values (lower panel).   
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Figure 1-28. SNaPshot peaks of the endogenous tRNASer, mutant tRNAs and the 
respective control, GAPDH.  Sequenced samples correspond to DNA from P15. For 
tRNASer(S) cell line (expressing tRNAAGASer), the peak corresponds to the incorporation of T (red peak). 
For tRNASer(A) cells (expressing tRNAAGCSer), the peak corresponds to the incorporation of G (blue peak). 
For tRNASer(L) (expressing tRNAAAGSer) and tRNASer(H) (expressing tRNAGTGSer) cells, the peak 
corresponds to the incorporation of C (black peak). In tRNASer(A), tRNASer(L) and tRNASer(H) cell lines, 
the Wt tRNASer and mutant tRNAs were detected (upper panel). The peak area corresponding to each 
mutant tRNA and Wt tRNASer was determined for each cell line and a ratio was calculated. Amplification 
of GAPDH was used as an internal control to normalize the values (lower panel).   
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Figure 1-29. SNaPshot peaks of the endogenous tRNASer, mutant tRNAs and the 
respective control, GAPDH. Sequenced samples correspond to DNA from P30. For 
tRNASer(S) cell line (expressing tRNAAGASer), the peak corresponds to the incorporation of T (red peak). 
For tRNASer(A) cells (expressing tRNAAGCSer), the peak corresponds to the incorporation of G (blue peak). 
For tRNASer(L) (expressing tRNAAAGSer) and tRNASer(H) (expressing tRNAGTGSer) cells, the peak 
corresponds to the incorporation of C (black peak). In tRNASer(A), tRNASer(L) and tRNASer(H) cell lines, 
the Wt tRNASer and mutant tRNAs were detected (upper panel). The peak area corresponding to each 
mutant tRNA and Wt tRNASer was determined for each cell line and a ratio was calculated.  Amplification 
of GAPDH was used as an internal control to normalize the values (lower panel).   
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de controlo de qualidade proteica, tumorigénese. 
 
Resumo 
 
 
Os tecidos humanos exibem diferentes padrões de expressão de 
tRNAs que se correlacionam com o codon usage de genes altamente 
expressos, o que pode representar um controlo ao nível da tradução tendo 
em conta que os tRNAs são intervenientes importantes durante a síntese 
proteica. Nas células cancerígenas é observada a desregulação de 
componentes do processo de tradução, nomeadamente elevados níveis 
de tRNAs específicos estão correlacionados com a expressão 
preferencial de genes relacionados com o cancro. Assim, a desregulação 
da pool de tRNAs pode aumentar a eficiência de tradução desses genes, 
promovendo a transformação maligna. 
O processo tumorigénico é acompanhado por aumento do conteúdo 
proteico celular. A evasão à apoptose, a instabilidade do genoma e as 
mutações frequentes são também observadas em células cancerígenas. 
Isto pode promover a acumulação de proteínas mutantes que 
desencadeia o stress proteotóxico e a produção elevada de HSPs, de 
forma a contrariar a instabilidade proteica. Para além disso, elevados 
níveis de proteínas incorretamente enoveladas, derivadas da elevada 
taxa de síntese proteica, induzem outras vias de controlo de qualidade 
proteica que auxiliam a ação dos chaperons: a resposta das proteínas não 
enoveladas e o sistema de degradação associado ao retículo 
endoplasmático. 
Este estudo teve como objetivo avaliar a influência da desregulação 
da pool de tRNAs na aquisição do fenótipo maligno e a contribuição das 
vias de controlo de qualidade proteica na transformação celular. 
Globalmente, os resultados mostraram que a desregulação da pool de 
tRNAs induzida pela sobre expressão do tRNASer leva à aquisição de um 
fenótipo intermédio entre as células normais e as células cancerígenas. 
Assim, concluímos que esta desregulação pode representar um promotor 
da aquisição da malignidade celular. 
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quality control pathways, tumorigenesis 
 
Abstract 
 
Human tissues display different tRNA expression patterns correlated 
with the codon usage of highly-expressed genes, which may represents a 
translational control since tRNAs are critical players during protein 
synthesis. In cancer cells it is observed misregulation of components of 
translational machinery, namely elevated levels of tRNAs in a specific 
fashion, correlated with a preferential expression of cancer-related genes. 
Therefore, misregulation of tRNA pool may enhance the translational 
efficiency of these genes, promoting the malignant transformation. 
The tumorigenic process is accompanied by increasing cellular protein 
load. Evasion of apoptosis, genome instability and frequent mutations are 
also observed in cancer cells. This may promote accumulation of mutated 
proteins that leads to proteotoxic stress and high production of HSPs, in 
order to counteract protein instability. Furthermore, high levels of 
misfolded proteins derived from the high rate of protein synthesis induce 
other protein quality control pathways to support the action of chaperones: 
the unfolded protein response and the endoplasmic reticulum-associated 
degradation system.  
This study aimed to evaluate the influence of tRNA pool deregulation 
in the acquisition of a malignant phenotype and the contribution of protein 
quality control pathways in cell transformation. In general, the results 
showed that the deregulation of tRNA pool prompted by tRNASer 
overexpression leads to the acquisition of an intermediary phenotype 
between normal cells and cancer cells. Therefore, we concluded that this 
deregulation may be a driven force for cellular malignancy.  
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V. Introduction 
1.1.The Genetic Code 
The central dogma of molecular biology states that the genetic information is coded in 
DNA molecules confined to the nucleus, which are transcribed in messenger RNA (mRNA) 
molecules that, in turn, will originate proteins in a process called translation. Translation is 
the last step of gene expression and it occurs according with the rules established by the 
genetic code, proposed by F. Crick in 1968.1,2  
The mRNA is composed by codons that are non-overlapping nucleotide triplets, among 
adenosine (A), guanosine (G), cytosine (C) and uridine (U). Despite the 64 possible 
combinations between the ribonucleotides only 20 amino acids are coded, demonstrating the 
degenerative character of the genetic code (Figure 1).3 The number of possible codons for each 
amino acid is variable, known as synonymous codons, but only one exists to start the 
translation of all proteins, the start codon methionine (AUG) and 3 stop codons (UAA, UAG, 
UGA) in eukaryotes to ensure the translation termination.3–5 However, the universal genetic 
code is flexible since deviations to the canonical genetic code are described both in 
eukaryotes and bacteria, suggesting that it is still evolving.6  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1. The genetic code. Clancy, S. and Brown, W. 2008 
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Amino acids are transported by transfer RNAs (tRNAs) that recognize the corresponding 
codon through interactions with its anticodon. The interaction between the first and second 
position of mRNA with tRNA is based on the canonical Watson-Crick pairing rules, by 
which an A or a G (purines) pairs an U or a C (pyrimidines), respectively. Furthermore, in 
1996, F. Crick proposed that the third position, also known as the wobble position, could 
pair with the perfectly matched tRNA anticodon or adopt a non-canonical interaction to 
allow the same tRNA to recognize more than one codon, giving rise to the “Wobble 
Hypothesis”.7,8 
 
1.2.Codon Usage 
The genetic code degeneracy allows a choice between different codons for the same 
amino acid in the transcriptome, which will affect the efficiency and accuracy of translation. 
This is known as codon usage. The codon usage has a close relation with the cellular 
availability in tRNAs (tRNA pool), that is regulated at several levels such as transcription, 
posttranscriptional processing, amino acid loading and degradation. The balance between 
these two factors affects protein production levels and the cellular fitness in a global view.9–
11 Non-optimal codon usage derived from poor correlation between codon usage and the 
tRNA pool may result in incorrect allocation of resources, namely the increase of ribosomes 
sequestration due to translation speed decrease, reducing the global cellular fitness.12–14  
Highly expressed genes are often codon optimized to match the tRNA pool so they can 
be translated more efficiently. These genes are under a higher pressure for translational 
efficiency and accuracy, in particular the speed by which they are recognized by the 
ribosome and the corresponding tRNA selection. Thus, codon usage has a crucial role in 
modelling gene expression and can increase the expression of a gene more than 1000-fold. 
Moreover, alternative nucleotide sequences arising from synonymous codons may have a 
direct influence in protein folding and stability of secondary structures.9–12,15 
The transcriptome’s codon usage and the cellular tRNA pool are dynamic and adapted 
to biological conditions and tissue requirements, allowing different translation patterns 
accordingly with the cellular microenvironment.12,15 Recently, Gingold et al. verified that 
cells’ content in tRNAs and the respective codons in the transcriptome have approximately 
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the same gene copy numbers, suggesting that changes in tRNA’s basal levels are required to 
restore the balance between codon usage and tRNA pool when the first is altered.15 
 
1.3.Eukaryotic Translation 
Translation is the process whereby information encoded in mRNAs is converted in 
polypeptide chains. This process is carried out in the core of ribosomes, where the interaction 
between mRNA codons and acylated-tRNA anticodons is allowed.16 Ribosomes are 
ribonucleoproteins, complexes with several proteins and ribosomal RNAs (rRNAs), 
comprising a large and a small subunit, known as the 60S and 40S in respect with its 
sedimentation rate. In their inactive state, ribosomal subunits are apart and they only form 
complexes in the presence of mRNA transcripts that need to be translated, acquiring distinct 
functions. The small subunit offers the suitable environment for interaction between tRNAs 
and mRNA codons, while in the large subunit occurs the formation of peptide bonds between 
the recently added amino acids.16  
The ribosome moves along the mRNA transcript by reading the nucleotide triplets from 
its 5’ end to 3’ end, giving rise to the polypeptide chain from the N-terminal to the C-
terminal. The ribosome has one binding site for mRNA chains and three binding sites for 
tRNAs, which are the A-site, the P-site and the E-site, allowing amino acid adding in three 
major steps: tRNA binding, peptide bond formation and large and small subunits 
translocation, in a processes fully described below.16,17 
 
a. Initiation 
The initiation of translation requires several eukaryotic initiation factors (eIFs) and their 
isoforms. Generally in eukaryotes and for most cellular mRNAs, initiation occurs in a CAP-
dependent manner, with the start codon AUG being recognized through scanning of the 
mRNA transcript.18,19 The ternary complex is the major player in the scanning process and 
is fundamental in CAP-dependent translation, comprising the eIF2-GTP (guanosine-5'-
triphosphate) and the initiator tRNAi
Met.20–23 The α-subunit of eIF2 (eIF2α) is crucial for 
translation regulation during initiation. Its phosphorylation at Ser51 prevents GDP 
(guanosine-5’-diphosphate) recycling triggered by eIF2B, hindering the interaction of eIF2 
with the additional ternary complex components and consequent inhibition of protein 
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synthesis. This inhibition usually occurs during stress conditions to reduce protein synthesis 
rate and to enhance the translation of mRNAs that allow the adaptation to stress and the 
recovery of translation.23   
Anyhow, translation initiation only occurs in the presence of the 43S preinitiation 
complex (PIC) that comprises the ternary complex, the 40S ribosomal subunit and the factors 
eIF3, eIF1, eIF1A and probably eIF5. The mRNA 5’ CAP is recognized by the multimeric 
eIF4F complex, composed by eIF4E, the CAP-binding protein stabilized by the ATP-
dependent RNA helicase eIF4A, and the eIF4G, a scaffold protein that links the mRNA and 
the ribosome using the eIF3. This complex unwinds the structures in the 5’ untranslated 
region (5’ UTR) and, together with eIF3 and poly(A) binding protein (PABP), attaches the 
3’-poly(A) tail allowing the PIC to scan mRNAs for the initiation codon.20–23 When the 
initiation codon, localized in a favorable context as Kozak sequence, is recognized in the P-
site by the anticodon of the Met-tRNAi
Met in the ternary complex, the scanning is arrested 
and GTP is irreversible hydrolyzed by the GTPase-activating protein (GAP) eIF5, 
consequentially releasing the eIF2-GDP and other eIFs. At this point, the eIF5B-GTP 
promotes the association between the 60S ribosomal subunit and the complex formed by the 
40S small subunit, the initiation aminoacyl-tRNA and the mRNA chain. When GTP is 
hydrolyzed, the eIF5B is released from the ribosome, dictating the final of the initiation.21–
23 
However, CAP-independent translation represents an alternative to CAP-dependent 
translation both under normal and stress conditions, such as endoplasmic reticulum (ER) 
stress, hypoxia, nutrient deprivation, mitosis and cell differentiation and it is used not only 
by eukaryotic cells but also by virus that infect them as a strategy to express their mRNAs. 
At stress conditions, CAP-dependent translation is compromised leading to a significant 
increase in cellular Internal Ribosome Entry Sites (IRES)-mediated translation that recruits 
both canonical and non-canonical initiation factors, IRES trans-acting factors (ITAFs) and 
40S ribosomal subunits.24,25 
 
b. Elongation 
Translation elongation is conserved among Eukarya, Bacteria and Archaea and it follows 
the initiation process.21 In the beginning of elongation the P-site is occupied by the Met-
tRNAi
Met and the A-site is empty. Then, the aminoacyl-tRNA whose anticodon complements 
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the second codon, or the cognate aminoacyl-tRNA, is added to the A-site due to the 
formation of another tertiary complex comprising the cognate aa-tRNA and the eEF1A-GTP. 
The interaction between this tRNA and the mRNA codon involves conformational changes 
in the decoding center of the 40S ribosomal subunit and the GTP hydrolysis ensures the 
presence of the cognate tRNA. If the complementarity is assured, the eEF1A-GTPase 
becomes activated. Then, eEF1A-GDP is released and the aminoacyl tRNA is 
accommodated in the A-site.17,21,26,27 
The next step is the peptide bond formation between Met and the recently added amino 
acid, in the peptidyl transferase center (PTC) located in the large ribosomal subunit. The Met 
accommodated in the P-site moves to the A-site of this center and a peptide bond can be 
made with the second amino acid still attached to its cognate tRNA, in a peptidyl transferase 
induced reaction. Then, the P-site is occupied with a deacylated tRNA connecting the mRNA 
in the small subunit and the 3’ CCA in the E-site of the large subunit. Also, the peptidyl 
tRNA is in a hybrid state as its acceptor arm is in the P-site and the anticodon arm forming 
a mRNA-tRNA duplex in the A-site of the small subunit.21,26,27 The eEF2-GTP is required 
to restore the canonical positions in the A and P-sites, in a process named translocation. GTP 
hydrolysis turns the ribosome free to move temporarily three codons towards the mRNA 3’ 
end. Posttraslocation state accounts for a deacylated tRNA in the E-site, a peptidyl-tRNA in 
the P-site and a new codon in the A-site to be decoded. At this point, a new codon can be 
read and this cyclic mechanism is repeated until a stop codon is detected.21,27 
 
c. Termination 
When the ribosome detects a stop codon in the A-site a signal to finish the translation 
and to release the polypeptide chain is recognized.  Stop codon recognition can be made by 
the ribosome, by external factors that interact with the ribosome and by the combined action 
of both.17,28  This signal activates the eukaryotic release factor 1 (eRF1), a class I release 
factor that binds the ribosome at the A-site. It is responsible for high-fidelity stop codon 
recognition and peptidyl-tRNA hydrolysis, promoting the addition of a water molecule to 
the peptide chain.27  eRF1 may also open a channel that triggers the incoming of water 
molecules into the ribosome; engender conformational changes in the ribosome so the water 
molecule can reach the active center; activate the water molecule and the ester bond so 
peptidyl-tRNA hydrolysis can occur.21 This step destroys the attachment of the carboxyl end 
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to the ribosome, and the recently synthetized polypeptide is finally released. eRF1 activity 
and connection with the ribosome is supported by a class II release factor, the eRF3-GTPase 
whose hydrolysis removes eRF1 from the ribosome.17,21,28 
 
d. Recycling 
The ribosomal subunits have to be recycled after the synthesis of a newly polypeptide 
chain, so another translational cycle could be performed. Therefore, the mRNA chain and 
the deacylated-tRNA have to be released as well as the ribosomal subunits have to be 
separated in a process called recycling, a mechanism that lacks fully explanation in the 
eukaryotic model.27 
Nevertheless, partial dissociation of ribosomes is also observed in a mechanism termed 
reinitiation. In these cases, the ribosome translates further Open-Reading Frames (ORFs) in 
the same mRNA without complete recycling of the ribosomal machinery. In this way, 
translation of the same ORF can be done, through incomplete recycling potentially taking 
place in the stop codon, allowing scanning along the 3’ UTR and triggering the 40S 
transference to the 5’ UTR. Although interactions involved in this process are not completely 
known, there is a potential hypothesis based on the role of PABP, eRF3, eIF4E and eIF4G 
in a mechanism that potentiate a close proximity between the mRNA 5’ and 3’ ends.21,27 
The eIF3 has an active role in the recycling process in higher eukaryotic translation, since 
it directly binds to and induces conformational changes in the 40S small subunit surface 
avoiding its reconnection with the 60S large subunit until a new mRNA emerge to be 
translated.20,21,27  
 
1.4.Transfer RNAs 
Transfer RNAs (tRNAs) are universally conserved small and ubiquitous RNA molecules 
that are the interface between the genetic information encoded in mRNA transcripts and the 
proteins. 29,30 The secondary structure of tRNA (Figure 2) has a cloverleaf shape derived from 
a single nucleotide chain with 73 to 90 nucleotides in length and 4 domains organized in 
unpaired and paired regions: acceptor arm, D arm, anticodon arm and TΨC arm. The 
acceptor arm has a 3’ CCA tail that links covalently the cognate amino acid, and the 
anticodon arm has a three nucleotide sequence in the unpaired region, the anticodon loop, 
 9 
 
that interacts with the mRNA codon. Unpaired regions also mold loops in the D and the TΨC 
arms and an unpaired region between the anticodon and the TΨC arms represents the 
variable arm, also known as extra arm. 16,29–31 The size of the variable arm can range from 3 
to 21 bases and dictates tRNA grouping in class I or II. The first includes the majority of 
tRNA molecules and is characterized by small extra arms, while class II tRNAs, comprising 
Leucine (Leu), Serine (Ser) and Tyrosine (Tyr), have larger variable arms and a R13-R22 base 
pair (bp) in the D-loop.16,32  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Functional and mature tRNAs acquire a L-shape tertiary structure through the stacking 
between acceptor stem and TΨC arm and between D-arm and anticodon arm, both stacks 
forming a continuous A-helix. Thus, functional tRNAs are characterized by an amino acid 
accepting branch where cognate amino acid covalently links an adenosine in 3’ CCA tail 
and an anticodon branch that connects with the codons in mRNAs. This highly stable 
structure is obtained from the interaction between conserved and semi conserved nucleotides 
in the tRNA chain and it is substantially altered according to its functional state.29–31,33 
Figure 2. tRNA secondary structure. Adapted from Zvelebil, M. and Baum, J. O. 2007 
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tRNAs are codified by 506 genes [Genomic tRNA Database] that are transcribed by the RNA 
polymerase III, whose activation is regulated by cellular nutrient availability and other 
environmental features. To become functional, tRNA transcripts should be processed to get 
the standard length and be posttranscriptionally modified (Figure 3). Still in the nucleus, the 
ribonucleoprotein RNase P performs endonucleolytic cleavage of the 5’ ladder sequence in 
precursor tRNA. Then, endonucleases (such as RNase E and RNase III) cleave the 3’ trailer 
extensional sequence and exonucleases (such as RNase T and RNase PH) cleave the residual 
trailer sequence. In some cases where CCA tail is absent, it is added by the CCA-adding 
enzyme following the discriminator base N73. Next, the splicing of remaining introns occurs, 
as well as modification of several nucleotide residues. 
 
 
 
 
 
 
 
 
 
 
These posttranscriptional modifications are divided in two types, according to its target: 
modifications in the loops of D and TΨC arms have the purpose to stabilize the tertiary L-
shape structure, while modifications in the anticodon loop promote precise codon pairing 
and accurate recognition by the cognate aminoacyl tRNA synthetase (aaRS).33,34 
In spite of tRNAs being mainly associated with its role during translation, these 
molecules also participate actively in other cellular functions, both in prokaryotic and 
eukaryotic cells. Uncharged tRNAs act as signaling molecules that activate cellular stress 
responses in the presence of nutritional stress, to stimulate the expression of genes related to 
amino acid synthesis and their uptake and to aminoacyl-tRNA synthetases, thus contributing 
to cell survival.29,31 Additionally, tRNAs are mediators in non-ribosomal processes, as the 
peptide bond formation between peptidoglycans in bacterial cell wall biosynthesis and in the 
modification of phospholipids that form the cell membrane.35 These molecules can also label 
Figure 3. tRNA processing. Nakanishi, K and Nureki, O. 2005 
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proteins for degradation, participate in the regulation of apoptosis and in antibiotic 
biosynthesis.31,36  
Recently, tRNA-derived fragments (tRFs), resulting from tRNA degradation, were also 
found to be functional forms that can actively participate in regulation of gene expression at 
translational level under stress conditions and in gene silencing.31,37,38 
Since tRNAs can have a variety of functions, it is not surprising that their biosynthesis 
occurs under several control pathways, which recognize and degrade misfolded or 
hypomodified forms. Also, tRNAs account for more than 15% of total RNA amount and 
comprise one of the most abundant transcripts in the cells.29 
 
1.5.Aminoacyl-tRNA Synthetases 
Aminoacyl-tRNA synthetases (aaRSs) are a highly conserved enzyme family that 
catalyzes tRNA aminoacylation with the cognate amino acid. The aminoacylation reaction 
occurs in two steps, illustrated in Figure 4. From the first step results a stable complex between 
the active site of aaRS and the cognate amino acid, in an ATP dependent reaction. In this 
way, a firmly bounded aminoacyl-adenylate is formed, releasing a pyrophosphate (PPi). In 
the second step, the tRNA binds the amino acid by the 3’ end adenosine in the acceptor stem, 
releasing AMP and esterifying the tRNA at 3’ end.39 
 
 
 
  
 
 
 
 
The recognition of tRNAs by its cognate aaRSs is based on the interaction with specific 
elements, as the discriminator base N73, the acceptor stem and the anticodon region. Less 
often, interactions with elements in the extra arm, the D stem, the core of the tRNA tertiary 
Figure 4. Schematic representation of aminoacylation reaction. AS, active site; aa, amino acid; 
PPi, pyrophosphate. Jiqiang Ling, J. et al. 2009 
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structure and the phosphate backbone or with modified nucleotides and the wobble base can 
occur.39 
To avoid inaccuracy derived from tRNA charging with the incorrect amino acid, aaRSs 
have an editing capacity encoded by a different active site. The double-sieve model suggests 
that the editing capacity allows aaRSs to discriminate amino acids with similar properties, 
and it can occur before or after amino acid transference to the tRNA, the pretransfer editing 
and posttransfer editing, respectively. Pretransfer editing is based on the hydrolysis of amino 
acids incorrectly activated before transference to the tRNA, while posttransfer editing 
requires the interaction between the tRNA 3’ CCA tail with the aaRS editing site. Trans 
editing was recently proposed and relies on the capacity of other proteins to recognize and 
hydrolyze incorrectly charged tRNAs.40–42 Moreover, the editing capacity is wider and it can 
act through discrimination between tRNAs by direct interaction, recognition of the acceptor 
stem nucleotide sequence and by contact with key nucleotides in the tRNA.17,41 This editing 
capacity is essential to avoid protein synthesis errors and its disturbance can be associated 
with various pathologies, which severity varies inversely with the editing capacity.40 
 
1.6.Protein Folding and Misfolding 
Proteins are the most structurally and functionally complex molecules, thus its activation 
requires more than its translation. After leaving the ribosome, the polypeptide chain has to 
be modified to get its unique three-dimensional conformation. Protein-modifying enzymes 
bind small-molecule cofactors essential for protein activity or assemble proteins with other 
protein subunits.17,43  
The information necessary for these modifications is encoded by the amino acid 
sequence itself and its biochemical properties. The interaction between amino acids from 
different regions of the polypeptide occurs by weak non-covalent bonds that taken together 
determine the protein folding stability. Also, folding is influenced by the hydrophobic 
character of the side chains, as the non-polar tend to cluster in the interior of the molecules 
forming a hydrophobic core, while polar amino acids are exposed and form hydrogen bonds 
with other molecules. These interactions result in a three dimensional structure that lacks the 
conformation of lowest free energy, without losing the flexibility to interact with other 
molecules that may influence protein function.16,17,43  
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Incorrect folding results in misfolded and nonfunctional proteins characterized by 
exposed hydrophobic amino acids. Alterations in cell homeostasis caused by stochastic 
fluctuations, destabilizing mutations, stress conditions or metabolic alterations resulting 
from processes such as cancer and aging, trigger wrong interactions, unfolding or denaturing 
of proteins and inhibit interactions between subunits of larger protein complexes. These 
alterations can be dangerous for the cell because misfolded/unfolded proteins can aggregate 
in toxic forms and give rise to several human diseases. Thereby, cells account with several 
mechanisms to maintain the stability of the proteome, ensuring misfolded proteins refolding, 
degradation or sequestration.17,44–46 
 
1.7.Proteotoxic Stress and Protein Quality Control Pathways 
The endoplasmic reticulum (ER) is the cellular compartment responsible for structural 
maturation of one-third of all eukaryotic proteins. Proteins remaining in the cytoplasm and 
mitochondria are under constant vigilance of chaperones responsible for its maturation. 
Proteins matured in the ER, when leaving this compartment, no longer need the assistance 
of chaperones, meaning that only correctly folded proteins leave the ER. In this way, highly 
sophisticated and robust quality control systems are required to avoid release of aberrant 
proteins to perform their functions.43,47  However, as a result of errors during transcription 
and translation, aberrant proteins are produced and their accumulation leads to homeostatic 
perturbations and proteotoxic stress.2,48,49 
To counteract the proteotoxic stress, several quality control responses are activated to 
promote the refolding of misfolded proteins or, if not possible, its degradation. The 
activation of these pathways aims to restore homeostasis and to avoid apoptosis induction. 
Homeostasis is achieved by upregulation of the ER folding capacity, increasing chaperones 
availability and foldases as well as ER size; through downregulation of biosynthetic load, 
inhibiting protein synthesis at transcriptional and translational levels; and increasing 
elimination of unfolded proteins through upregulation of Endoplasmic Reticulum 
Associated Degradation (ERAD) protein clearance mechanism.2,45–47,49 It is estimated that 
30% to 70% of proteins do not pass the quality control mechanisms and end up being 
degraded.50 
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If cells are unable to activate these control pathways or if these pathways become 
overloaded, waste of nutrients occurs and misfolded and nonfunctional proteins that can 
aggregate in toxic forms are produced, dictating cell death as the final fate.2 
 
a. Chaperones and Heat Shock Response 
Molecular chaperones are proteins that assist noncovalent folding of newly synthesized 
polypeptides, assembly of protein subunits, preventing or reversing incorrect folding. This 
large protein family, first discovered in 1978 by Laskey et al., recognizes and binds reactive 
surfaces exposed in the client protein, avoiding incorrect interactions. Still, chaperones assist 
oligomeric structures synthesis in the transport of proteins through membranes, by 
preventing the three-dimensional folding that can be a hitch in the membrane crossing, 
maintaining the protein in an unfolded and more flexible status. Chaperones can also signal 
the protein for degradation.16,46,51 
A significant number of chaperones are designated heat shock proteins (HSPs), term that 
derives from its overexpression in cells exposed to higher temperatures. While chaperones 
have the folding as their major role during normal metabolism, stress conditions induce 
higher levels of HSPs that assist the refolding and repair of damaged proteins, to prevent 
protein denaturation and aggregation. HSPs derive from the transcription of distinct gene 
families and they are classified according to their approximate relative molecular mass in 
five main HSP families: Hsp70, Hsp90, Hsp60, small HSP and large HSP families. The 
genes encoding chaperones have three differently regulated classes: constitutively expressed 
chaperones, during growth and development; constitutively and induced chaperones and 
strictly induced chaperones.51–54 
Regarding their action, HSPs can be classified, not exclusively, in holding and folding 
proteins. The first group comprises HSP70 and HSP90 families and they recognize and bind 
exposed hydrophobic domains in unfolded polypeptides. They can act during mRNA 
translation to prevent premature self-association of nascent polypeptide chains; during heat 
shock response through interaction with totally or partially unfolded proteins and 
constitutively to bind unstable tertiary structures. In this process a large complex is formed, 
comprising five core proteins that accounts for Hsp90, the scaffold protein Hop, the p23 
protein as mediator of substrate selection and the complex HSP70/HSP40 to mediate the 
interaction between HSP90 and the client protein. These complexes interact with many 
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accessory proteins, also known as co-chaperones, to facilitate substrate selection and cycles 
of association and dissociation from the client protein. Once the correct folding is achieved, 
HSPs are released from proteins in an ATP-dependent mechanism.  
Folding activity can be performed individually by Hsp70, Hsp40 or co-chaperone GrpE 
or in a chaperonin system comprising a large oligomeric assembly that lodges unfolded 
proteins and promotes a suitable environment for their folding. Also, Hsp90 together with 
Hsp70 acts directly with specific classes of proteins involved in signal transduction, thereby 
maintaining the target in an appropriate function until it is stabilized through the interaction 
with other components of the pathway.16,44,54 
The transcription of HSPs is dependent on heat shock factor 1 (HSF1) transcription factor 
that binds the promoters of HSP genes, inducing HSP mRNA transcription. Activation of 
HSF1 is still under investigation but some explanations were proposed. HSF1 is inhibited 
by its products, which in stress conditions may be sequestrated in protein aggregates, thus 
de-repressing HSF1. Another mechanism for HSF1 activation relies on the heat-induced 
binding to large non-coding RNAs, which are known to be involved in the regulation of a 
wide range of genes, complexed with eEF1A. Besides, during stress conditions, a rapid 
phosphorylation of serine 326 in the HSF1 occurs, correlated with the onset of HSF gene 
transcription, suggesting that this serine has a role in stress response regulation prompted by 
HSF1: the heat shock response (HSR).52,53 
The HSR is a cellular mechanism activated in the presence of a wide range of stress 
conditions that triggers protein inactivation. This response is based on a combination of 
events called thermotolerance, a condition directly related with the coordinated synthesis of 
HSPs. 44,52,53 
 
b. Unfolded Protein Response 
The UPR relies on the activation of different but complementary signal pathways 
triggered by three ER transmembrane proteins: the inositol requiring kinase 1 (IRE1α), the 
double-stranded RNA-activated protein kinase (PKR)-like endoplasmic reticulum kinase 
(PERK) and the activating transcription factor 6 (ATF6), schematically represented in Figure 
5. During homeostatic conditions these proteins are inactivated by formation of stable 
complexes with the ER stress sensor GPR78, also known as binding immunoglobulin protein 
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(BiP). However, presence of unfolded proteins leads to a competition for BiP, derepressing 
the signal pathways.45,55,56 
 
 
 
 
 
 
 
 
 
 
 
 
 
When IRE1α is dissociated from BiP, it undergoes dimerization and 
autophosphorylation, activating its endonuclease activity for mRNA processing. IRE1α 
activates the X-box binding protein 1 (XBP1), through splicing of its mRNA transcript. 
When active, XBP1 upregulates the expression of genes encoding proteins that have roles in 
protein folding, insurance of its quality and ERAD activation.45,55–57 
After being released from BiP, PERK becomes activated through dimerization and 
autophosphorylation, activating its kinase activity. PERK activation prompts global protein 
synthesis inhibition through inhibitory phosphorylation of eIF2α, to reduce the influx of 
newly synthetized proteins into the ER. The downregulation of translation upregulates the 
activating transcription factor 4 (ATF4) that promotes cell survival since it regulates genes 
involved in oxidative stress, amino acid synthesis, protein folding and cell differentiation. 
45,55–57 
Finally, ATF6 is released from BiP and translocated to the Golgi compartment. There, 
ATF6 is cleaved by the site-1 and site-2 proteases releasing its N-terminal fragment, the 
cytoplasmic domain, which acts as a transcription factor. In the nucleus, ATF6 fragment 
promotes upregulation of UPR target genes, such as XBP1, and ERAD associated 
proteins.45,55–57 
Figure 5. Schematic representation of the unfolded protein response. Adapted from Claudio Hetz et al. 2013 
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c. Endoplasmic Reticulum Associated Degradation Response 
ERAD is fundamental to eliminate misfolded proteins, maintaining the equilibrium 
between protein synthesis and degradation, in a demand to prevent proteotoxicity, ER stress 
and subsequent apoptosis.57 
The ERAD response promotes degradation of aberrant proteins by the Ubiquitin-
Proteasome System (UPS), the major eukaryotic proteolytic pathway. This process is 
initiated with the recognition of substrate and its translocation across the ER lipid bilayer to 
the cytoplasm. In the cytoplasm, proteins are polyubiquitinated, signaling for degradation by 
the 26S proteasome subunit.46,58  
 
d. Autophagy 
Autophagy is an evolutionarily conserved protein and organelle degradation mechanism 
with a complex molecular background, missing full explanation. Autophagy can be 
characterized into three different types: macroautophagy, microautophagy and chaperones-
mediated autophagy (CMA). All end up with the delivery of the target, the cargo, into the 
lysosome where it occurs protein unfolding and degradation by the action of proteases.59  
Regarding the protein quality control, the autophagic process represents an important 
mechanism to eliminate aggregation prone proteins. It functions as a backup of ERAD since 
its impairment leads to an upregulation of autophagy, as a strategy to recognize and degrade 
protein aggregates.46,60 Also, autophagy has a role during stress caused by nutrient and 
oxygen deprivation, and biosynthetic and homeostatic functions. Examples are the 
degradation of mitochondria, known as mitophagy, as an approach to control their reliability 
and to avoid the production of reactive oxygen species (ROS), or the degradation of 
peroxisomes that are no longer needed, the pexophagy. 59,61 
 
 
 
1.8.Tumorigenesis 
 18 
 
The tumorigenic process starts with a normal cell that becomes transformed by 
acquisition of autonomous proliferation features driven by accumulation of genetic 
alterations, leading to immortalization. Acquisition of malignancy is the result of tumour 
progression rather than transformation. During tumour progression, cancer cells lose their 
original shape and polarity. Finally, they acquire the capacity to invade nearby tissues and 
metastasize to distant locations through the blood or lymphatic system.62,63 
Variability is an intrinsic characteristic of tumors that promotes functional and 
phenotypic heterogeneity in tumors established in the same organ, known as intertumoral 
heterogeneity, and even within individual tumors, the intratumoral heterogeneity.62 The 
intertumoral heterogeneity is associated with different genetic and epigenetic mutations, 
distinct cells in the origin of tumor, different molecular profiling characterization, different 
specific markers expression and different morphological features.62  
Intratumoral heterogeneity can be explained by the cancer stem cell (CSC) and the 
clonal-evolution models.62 The first proposes that the tumor has its origin in normal self-
renewing stem cell or downstream progenitor with limited or no self-renewal. Considering 
that the expansion of the progenitor cell may originate downstream cells which accumulate 
different mutations, CSCs can originate different clones within the same tumor, thus 
contributing to its heterogeneity.64,65 In turn, the clonal evolution model suggests that a single 
cell accumulates mutations that are hereditarily transmitted through successive generations 
and the most advantageous for the tumor are selected through natural selection.64 The genetic 
and epigenetic changes which provide the cell with the more aggressive, invasive and drug-
resistant phenotype are those prevailing. However, these models cannot be applied in a 
mutually exclusive characterization since all the events interact to define the tumor 
histopathology and behavior.62,64,65 
In a global view, cancer cells can be characterized based on traits that enable them with 
distinct but complementary capabilities. These features allow tumor growth and metastatic 
dissemination and they are known as the hallmarks of cancer (Figure 6). The acquisition and 
development of these hallmarks are possible due to genome instability, product of several 
random and particular genetic mutations and chromosomal rearrangements, and the 
inflammatory state of established or premalignant lesions that is supported by immunologic 
cells.66 
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Cancer cells present deregulation of growth-promoting signals, leading to sustained 
proliferative signaling. Moreover, cancer cells are also able to evade growth suppressors that 
could inhibit its proliferation.66,67  
The programmed cell death is essential to prevent cancer development. The most 
relevant player in responses to stress, damage and regulation of apoptosis is the p53. In 
cancer cells, mutations in TP53 gene or in its upstream or downstream effectors are frequent, 
allowing apoptosis evasion, invasion, metastasis, proliferation and cell survival.66,68,69  
Proliferation of normal cells is limited by a number of successive division cycles in a 
process controlled by the size of telomeres, which triggers cell death when they become too 
short to protect the chromosomes. In cancer cells, the DNA telomerase is highly expressed, 
opposing to what happens in normal cells, which is correlated with resistance to senescence 
and acquisition of replicative immortality.66 
Cancer cells are also associated with the capacity to induce angiogenesis, in a process 
triggered by deregulated proangiogenic signals that give rise to aberrant neovascularization. 
Considering that tumor microenvironment is characterized by hypoxia, nutrient deprivation 
and low pH, angiogenesis may be induced as an alternative to obtain nutrients and oxygen 
and to discard metabolic wastes and carbon dioxide.66  
Lastly, malignant cells have the capacity to invade, to avoid apoptosis and to disseminate, 
in a process called metastization, closely related to the regulatory program “epithelial-
mesenchymal transition” (EMT). The reprogramming of energy metabolism and the capacity 
Figure 6. The hallmarks of cancer and enabling characteristics. Adapted from Hanahan, D. and 
Weinberg, R, 2011 
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of tumor cells to avoid immune surveillance are now emerging as new hallmarks of cancer, 
as major evidences are emerging to prove its crucial role in cancer development.66,70 
 
1.9.Lung Cancer and Non-Small Cell Lung Cancer 
Cancer is the leading cause of death in the world with a continuous increase in the 
number of cases, particularly in developing countries, estimated at over 20 million per year 
at 2025.71 Lung cancer represents the main cancer related death and it is associated to 
cigarettes active smoking, followed by passive smoking and occupational exposure to 
chemical and physical carcinogenic agents as nickel, asbestos, arsenic, radiation and air 
pollution. Susceptibility to lung cancer is also allied with individual inherent susceptibility 
to these agents and familiar history of lung cancer, without overlooking lifestyle factors as 
diet and physical inactivity, established diagnosis of acquire lung diseases and HIV related 
infections.72 The stage and degree of tobacco epidemic have a close relationship with 
countries socioeconomic development. Countries that had its smoking peak in the middle of 
20th century are currently detecting a decrease in lung cancer rates; instead, countries where 
tobacco consumption epidemic was established recently are handling increasing rates. Yet, 
as the rate of smokers decreases it is observed a greater frequency of lung cancer among 
passive smokers. Another bequest of socioeconomic development is the increase in smoking 
habit among women, resulting in 50% of cancer related death in this gender and 80% in 
men.72–74 
Lung cancer is classified in two major subtypes based on histological features and 
response to conventional therapies: small cell lung cancer (SCLC) and non-small cell lung 
cancer (NSCLC), the last accounting for 85% of all lung cancers. SCLC type can be also 
divided in classical small cell carcinoma, large cell neuroendocrine and combined, while 
NSCLC comprises adenocarcinoma, squamous cell carcinoma and large cell carcinoma.74–
76 
Lung cancer has a 5-years survival rate of 15%, as result of late diagnosis of advanced 
tumors.74,75 Diagnosis of lung cancer is achieved by analysis of complete medical history 
and physical examination that can reveal suggestive signs and symptoms of lung disease, 
such as alterations in expectoration quantity, amount and presence of blood, shortness of 
breathing, wheezing, chest pain and frequent respiratory infections. Then the physician 
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should proceed with more conclusive and chest located tests as radiography and also 
computed tomography and magnetic resonance imaging, which can identify metastatic 
episodes and support a differential diagnosis. Adenocarcinoma and large cell carcinoma 
have preferential localization in the periphery of lung, lining the small airways while 
squamous cell carcinoma and SCLC have their origin in epithelial cells that line the larger 
airways in the central area of chest. At the cellular level, cytological analysis can be made 
after expectoration collection, being enough to diagnose 80% of lung tumors. To improve 
diagnostic capacity and precision, a bronchoscopy and fine-needle biopsy of lung and 
metastatic lesion or lymph node may be done.75,77   
NSCLC has a complex molecular character underlying his pathogenesis that is not fully 
understood. However, it is crucial to understand and characterize diagnostic and prognostic 
biomarkers and therapeutic targets so worry rates associated to lung cancer can be 
weakened.78 The epidermal growth factor receptor (EGFR) is responsible for the activation 
of phosphoinositide 3-kinase (PI3K)/AKT and RAS/RAF/MAPK pathways that ultimately 
lead to the active transcription of genes involved in cell survival, proliferation, angiogenesis, 
invasion and metastasis. Mutations in EGFR are presented in 10% of NSCLC cases and are 
closely related with tobacco consumption, being inversely proportional to the degree of 
smoking.76,79 Mutations on the V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-
ras) gene are present in 20-30% of NSCLCs, with influence on cell proliferation and 
apoptosis via MAPK and on cell survival responses via PI3K. These represents 90% of all 
ras mutations in adenocarcinomas and they are common in smokers and patients that were 
exposed to asbestos, being more prevalent in women.76,79,80  
Despite those factors are markedly involved in the carcinogenic process of NSCLC, 
others have been identified. The vascular endothelial growth factor (VEGF) is highly 
expressed in NCSLC and it is critical in physiologic and pathologic angiogenesis, through 
promotion of survival and tumor growth. Its overexpression relates to poor prognosis.76 
Similarly, overexpression, amplification or gain-of-function of the mesenchymal-epithelial 
transition factor (c-MET) are evident in lung adenocarcinoma, participating in tumor growth, 
differentiation and metastasis and thus contributing to a poor prognosis.77,81,82  
The rearrangement of the anaplastic lymphoma kinase (ALK) gene derived from the 
fusion with the echinoderm microtubule-associated protein-like 4 (EML4) gene was 
classified as a gain of fusion mutation. EML4-ALK fusion was identified in 2% to 7% of 
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NCSLC, in the absence of KRAS and EGFR mutations, with a positive influence in 
neoplastic transformation and cell survival.76,83  
 
1.10. tRNA Pool Deregulation in Cancer 
The deregulation of protein synthesis machinery and tRNA pool, in particular, are 
observed in a wide range of tumors, suggesting that misregulation of translation components 
are involved in malignant transformation.84  
Pavon-Eternod et al. observed a significant overexpression of tRNAs in breast cancer 
cell lines and tumor tissues when compared with non-cancer-derived breast epithelial cell 
lines and normal breast tissues.85 In particular, tRNASer, tRNATyr and tRNAThr were the most 
expressed and its overexpression seems to favor the codon usage of cancer-related genes, 
important in tumor initiation and progression, but not the house-keeping genes and cell-line 
specific genes. Also, the overexpressed tRNAs carry polar amino acids that are targets of 
protein kinases and phosphatases, demonstrating a possible mechanism for potentiating 
posttranslational regulation of proteins involved in signal transduction.85 Notably, the 
overexpression of tRNAs in cancer cells is accompanied by altered metabolic activity and 
unregulated growth.86 
Differential expression of tRNAs regulates the efficiency of translation through the 
codon usage of specific genes and it is possible that during active cell growth there is a 
correlation between the tRNA pool and the codon usage of highly translated genes.85 So, 
deregulation of the tRNA pool in cancer may be responsible for the quantitative and 
qualitative alterations in protein expression, since this deregulation leads to preferential 
expression of key proteins in tumor progression and development, such as growth factors, 
cell-cycle promoters and oncoproteins, particularly c-Myc and VEGF, the last known to be 
upregulated in NSCLC tumors.76,85,86 
The deregulation of RNA polymerase III is also observed in several tumors, explained 
by the releasing of pol III-specific transcription factor TFIIIB from the inhibitory effect 
provided by RB (retinoblastoma protein) and p53, which are often mutated in cancer 
cells.84,85 Also, TFIIIB is activated by the upregulation of c-Myc and mutations in KRAS, 
alterations observed in NSCLC cells.80,87 Must be noted that tRNA transcription via pol III 
is globally regulated by environmental signals, as nutrient availability, and the transcription 
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of tRNA genes is coordinately regulated by common transcription factors that act in highly 
related promoter sequences.86  
Cellular stress leads to an alteration in the codon usage of demanded genes and so the 
request for tRNAs by certain codons increases and the availability in tRNAs for other codons 
decreases. It is also known that codons that became preferentially expressed under these 
conditions corresponded to tRNAs that are represented by the lowest gene copy number.15  
In another study, Pavon-Eternod et al. verified that induction of the elongator tRNAe
Met 
does not alter significantly its levels but punctual changes in levels of several other tRNAs 
not induced experimentally are observed. This can be explained by a regulatory feedback 
mechanism related with overexpression of tRNAi
Met.86  
Nonetheless, the knowledge available about effects derived from overexpression of 
tRNAs and the mechanisms of response from cells to these perturbations is very limited 
yet.86  
 
1.11. Proteotoxic Stress in Cancer 
The process of malignant transformation is accompanied by increased protein load. 
Likewise, evasion of apoptosis, genome instability and frequent mutations are observed in 
cancer cells, which may promote accumulation of mutated proteins and sustained activation 
of proliferation signals.88 Qualitative and quantitative alterations of the proteome induce 
cellular proteotoxic stress that is faced by the induction of HSPs as an attempt to repair and 
refold aberrant products. In cancer cells, an increase in HSF1 levels is observed through a 
process not yet understood but that may be related with increased transcription and 
translation as well as epigenetic regulation.53,88 
The relation between increased chaperoning capacity and tumorigenesis can be 
explained by the “addiction to chaperones” hypothesis. This assumption is based on the 
increased necessity for chaperoning the larger protein load due to rising in mRNA translation 
derived from highly metabolic and proliferative rates and the polyploidy observed in several 
cancer cells. The instability created in the proteome is supported by chaperones in an 
addictive process since high protein expression and gene mutations are driven forces of 
tumor growth and progression. Interestingly, in studies where the Hsp90 chaperone is 
inhibited  downregulation of several oncogenes is observed, probably because the instability 
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of mutant and aberrant proteins is not counteracted and they are eliminated by quality control 
pathways.53  
Moreover, HSPs activity in cancer cells supported by HSF1 seems to affect a wide range 
of pathways that are essential to sustain the malignant phenotype. Evidences exist to prove 
their role in the acquisition of cancer hallmarks, excluding the evasion of growth suppressors 
where the role of chaperones is still inconclusive.53 Hsp90 seems to be the main chaperone 
in tumorigenesis, acting to maintain the active conformation of mutant and signal proteins 
as an approach for faster information flux in response to extracellular signals, essential to 
development and cell renewal.53,54 Hsp90 and Hsp70 overexpression in cancer allows to 
stabilize precancerous proteins, such as growth factor receptors, survival-signaling kinases, 
oncogenes and mutated proteins, supported by Hsp27 that is known to be upregulated in 
many cancers.53,89 In the NSCLC context, low levels of HSP90 are correlated with better 
prognosis and pharmaceutical inhibitors of Hsp90 also impair EGFR activity, useful when 
no KRAS mutations are present.90 
Cancer cells grow in an environmental context that differs from normal cells as it is 
hypoxic and with lower pH and nutrient availability, as a result of low vascularization. The 
higher tumor growth rate outdoes new blood supply, although in an inefficiently manner 
because the synthesis of new vessels is aberrant and the blood flow dynamics are altered.57,91 
The low nutritional availability directly influences protein glycosylation and ATP 
production, which triggers synthesis of misfolded proteins, an event also supported by the 
lack of oxygen that is crucial for disulfide bond formations in proper protein folding. These 
perturbations lead to ER stress with consequent activation of quality control pathways, at 
which cancer cells can adapt and so escape to apoptosis.57,92 
Cancer cells have high activation of the UPR and take advantage from activation of 
characteristic signal pathways, in a chronic manner. BiP is known to be increased in 
aggressive malignant forms, including lung cancer and it seems to promote cell survival, 
tumor progression, metastasis and resistance to therapeutics.57,93 This is possible since 
overexpression of BiP has a crucial role in pro-survival and cytoprotective responses in 
malignant cells, by diverse mechanisms such as inactivation of caspase-7.57 
Despite its role in tumorigenesis is not entirely explained, IRE1α inhibition appears to 
prompt reduction in tumor growth, in angiogenesis and in blood perfusion of tumor. It is 
known that IRE1α induces cellular proliferation through XBP1 splicing and the axis IRE1α-
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XBP1 seems to be regulated by the pro-apoptotic proteins BAX and BAK, suggesting a close 
relation between the UPR and the apoptotic pathway. Deletion of Xbp1 increases sensitivity 
to hypoxia-induced cell death and consequent decrease in tumor formation capacity, since it 
is a major transcription factor in the adaptive response to ER stress, solid tumor growth and 
survival under hypoxic conditions. The activation of such related factors promotes induction 
of proangiogenic factors like VEGF, highlighting its role in angiogenesis and proposing as 
possible therapeutic targets.57,92 
PERK can have an active role in tumor growth and proliferation through limitation of 
oxidative stress derived from ATF4 activation, which also stimulates transcription of pro-
survival genes and upregulation of  adhesion proteins, VEGF and type 1 collagen inducible 
protein, important factors for angiogenesis.92,94 Furthermore, ATF4 expression triggers cell 
survival by negative regulation of genes related with cellular senescence.57 Moreover, the 
upregulation of the autophagosomal membrane LC3B by ATF4 allows lysosomal 
degradation of unnecessary cellular components and thereby cell survival. In a global view, 
inhibition of PERK remarkably reduces cells adaptation and survival under hypoxic 
conditions.57 Recently, Fan et al. detected an active form of ATF4 phosphorylated at Ser 245 
highly expressed in NSCLC tumors that may contribute to its progression, particularly in 
metastasis, since it promotes adaptive response to ER stress and triggers stress-induced 
angiogenesis. However, the mechanism involved in its upregulation is still unclear.57,94 
Although few studies have been conducted, it is know that ATF6 is required to malignant 
transformation. Its functionally active form improves tumor survival by activating the 
mammalian target of rapamycin (mTOR) signaling pathway, which has been associated with 
malignant transformation, taking into account its influence in cell growth and 
proliferation.59,97 Particularly in NSCLC, the mTOR activation, AKT-dependent or 
independent, has been correlated with the proliferative character of cancer cells.82,100 
Regarding the ERAD system, its regulation is also visible in cancer cells as a way to 
evade apoptosis and to reduce the accumulation of misfolded proteins that may be toxic for 
the cell. The valosin containing protein (VCP), an AAA ATPase molecular chaperone, is 
upregulated in several tumors. VCP controls ubiquitin mediated degradation of misfolded 
proteins and it is involved in protein folding, cell cycle control and apoptosis.57 Valle et al. 
demonstrated that the inhibition of VCP in cells from a NSCLC suppresses tumor growth 
and induces apoptosis in vitro and in xenograft murine models.96  
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Autophagy can act both as tumor suppressive and as oncogenic player. As tumor 
suppressive, autophagy intervenes in cell cycle arrestment, strives for maintenance of 
genome and organelle integrity and promotes inhibition of necrosis and inflammation. On 
the other hand, autophagy promotes cell survival under the conditions of metabolic stress 
created by the tumor microenvironment, through elimination of damaged mitochondria, 
ROS and protein aggregates, which cause DNA damage and activation of tumorigenesis.59,97  
 
 
VI. Aim of Study 
The deregulation of tRNA pool has been reported in different tumors and correlated with 
the expression of cancer-related genes.85,86 However, a major question remains: is tRNA 
pool deregulation a cause or a consequence in the acquisition of a malignant phenotype?  
In order to contribute to the clarification of this issue, this study proposed to evaluate the 
influence of tRNA deregulation in the acquisition of a malignant phenotype and the 
contribution of protein quality control pathways in cell transformation. Therefore, the 
following cellular mechanisms were evaluated: 
 Phenotypic profiling; 
 Transformation ability in vitro; 
 Induction of proteotoxic stress; 
 Activation of protein quality control mechanisms; 
 Insoluble protein expression profile. 
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VII. Experimental Design  
To assess the effects of tRNA overexpression for the acquisition of a malignant 
phenotype, a comparative study was performed between a normal human cell line derived 
from the bronchial epithelium (BEAS-2B cell line) and a NSCLC cell line (NCI-H460 cell 
line) derived from a large cell lung carcinoma. Since Pavon-Eternod et al. observed a 
particular overexpression of tRNASer in breast cancer cell lines and breast tumor tissues.85 
Therefore, BEAS-2B cells were stably transfected with a pIRES2-DsRED plasmid 
containing tRNASer to induce tRNASer overexpression and so promote deregulation of the 
cellular tRNA pool. This transfection created BEAS-2B tRNASer cell line. Also, BEAS-2B 
cells and NCI-H460 cells were stably transfected with the empty pIRES2-DsRED plasmid, 
given rise to the BEAS-2B Mock cell line and NCI-H460 Mock cell line, respectively. 
BEAS-2B Mock cell line is the control in the assays performed.  
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VIII. Material and Methods 
2.1.pIRES2-DsRED plasmid  
To induce overexpression of tRNASer in a stable cell line we used the pIRES2 DsRed-
Express2 vector, a bicistronic expression vector (Figure 7) that allows simultaneously the 
expression of the tRNASer coding sequence and the Ds-Red Express2 fluorescent protein, 
useful to identify cells expressing the tRNASer gene through fluorescence microscopy. Also, 
this vector contains a kanamycin/neomycin resistance gene, suitable for selection of 
Escherichia Coli (E. Coli) competent cells with the plasmid using kanamycin, and for the 
selection of stably transfected mammalian cells using geneticin (G418) (FormediumTm). 
Previously co-workers inserted the coding sequence for the tRNASer using EcoRI and XhoI 
restriction enzymes into the vector. A pIRES2 DsRed-Express2 vector without the tRNASer 
coding sequence was used to normalize the effect of plasmid insertion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. pIRES-DsRed containg the tRNASer(AGA) coding sequence. 
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2.2.Escherichia Coli Competent Cells 
E. Coli cells were grown to obtain enough amount of plasmids to create our cell lines. 
Previously, co-workers transformed these cells with the pIRES2-DsRED containing the 
tRNASer and the empty pIRES2-DsRED plasmid and stored at -20ºC. To cultivate the E. Coli 
cells, Lysogeny Broth (LB) medium was supplemented with kanamycin. After 
homogenization, 20µl of transformed E. Coli cells were added to the medium and maintained 
overnight in a shaking incubator at 37ºC.  
 
2.3.Extraction and Quantification of pDNA 
Plasmid DNA (pDNA) from transformed E. Coli was extracted with MiniPrep Nzytech 
Kit, according with the manufacturer's instructions. After extraction, the pDNA 
concentration was quantified with the NanoDrop spectrophotometry (ThermoScientific). 
The system was calibrated using 1.5µl of miliQ H2O and purity values were calculated 
through the ratios 260nm/280nm and 260nm/230nm.  
 
2.4.Polymerase Chain Reaction  
To verify if the E. Coli selected carried our plasmid without alterations, we amplified 
the tRNA region of our plasmid by PCR using 50ng of pDNA. The reagents were acquire to 
Invitrogen (Thermo Scientific) and primers’ sequences are represented in Table I. Note that 
primers are the same for the amplification of pIRES2-DsRED containing the tRNASer and 
the empty pIRES2-DsRED plasmid since the flaking regions are equivalent. The PCR 
reaction comprised 35 cycles and occurred in the MyCycler™ Thermal Cycler (Bio-Rad). 
 
Table I. Primers used and respective sequences 
 
 
 
 
 
 
Primer Sequence 
Primer Forward  CAATACGCCCGCGTTTCTT 
Primer Reverse TTATCCAAAAAGGATCTTCACCTAGA 
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2.5.Agarose Gel Electrophoresis 
PCR amplification products were analyzed by performing an agarose gel electrophoresis, 
a technique that allows the separation of DNA fragments, according with their molecular 
size, under an electric field.98 Five µl of PCR products were run in 1% agarose with 0.01% 
ethidium bromide (EtBr) at 80V and in an electrophoretic thank containing 1X Tris-Acetate-
EDTA (TAE) (GRiSP). After electrophoresis, gels were scanned in the UV-Transilluminator 
(Bio-Rad) and results were visualized with Quantity One 4.2.1 software. 
 
2.6.Purification of PCR products 
PCR purification was performed using the QIAquick PCR Purification Kit (Qiagen), 
following the manufacturer’s instructions. After the purification, DNA concentration was 
evaluated in the NanoDrop, as described in 2.3. 
 
2.7.DNA Sequencing 
To confirm the nucleotide sequences of the pIRES2-DsRED containing the tRNASer and 
the empty plasmid, purified PCR products were prepared to be sequenced by GATC Biotech. 
For that, microtubes with 5µl of 80ng/µl of amplified DNA were prepared for each sample 
as well as microtubes with the forward and reverse primers with 5µl of 5µM, according to 
the recommendations of the LIGHTRUN sequencing kit. Results were analyzed using the 
FinchTV v.04 software (Geospiza Inc). 
 
2.8.Cell Culture 
BEAS-2B cell line was kindly provided by Professor Maria Carmen Alpoim, from IBILI, 
University of Coimbra and NCI-H460 were obtained from IPATIMUP’s Cell Bank. BEAS-
2B cells were cultured in LHC-9 medium (Gibco, Life Technologies) supplemented with 
1% of Penicillin-Streptomycin (Pen/Strep) (Gibco, Life Technologies). NCI-H460 cells 
were cultured in RPMI 1640 medium (Gibco, Life Technologies), supplemented with 10% 
Fetal Bovine Serum (FBS) (Sigma) and 1% Pen/Strep. Cells were maintained in an incubator 
at 37ºC with 5% CO2 and 95% relative humidity. 
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To execute the following procedures, cells were detached using trypsin (Sigma). Then, 
BEAS-2B cells were resuspended in trypsin neutralizer solution [0.5% FBS in 1X Phosphate 
Buffered Saline (PBS)] while NCI-H460 cells were resuspended in complete RPMI 1640 
medium. Cells were then centrifuged at room temperature (RT) and ressuspended in 
complete medium or 1X PBS, depending on the following procedure.  
2.9.Lipotransfection 
Lipotransfection is a procedure that uses cationic lipids formulations to deliver the 
foreign genetic material into eukaryotic cells. 99 
Transfection protocols using Lipofectamine® 3000 Transfection Kit (Invitrogen), for 
BEAS-2B and NCI-H460, were carefully optimized to reach close to 100% transfection 
efficiency. 1.0 x 105 BEAS-2B cells and 5.0 x 104 NCI-H460 cells were plated in MW24 
plates and after 48h cells were transfected with small alterations to manufacturer’s protocol. 
BEAS-2B were transfected using 1µg of plasmid DNA and 1µL of Lipofectamine® 3000, 
whereas NCI-H460 were transfected using 1.5µg of plasmid DNA and 0.75µL of 
Lipofectamine® 3000. In this transfection, while a set of BEAS-2B cells were transfected 
with the pIRES2-DsRED containing the tRNASer another set of BEAS-2B cells were 
transfected with the empty pIRES2-DsRED plasmid. NCI-H460 cells were transfected with 
the empty pIRES2-DsRED plasmid. 
Since the goal was the integration of the plasmid in the genome and the expansion of 
these cells, cell lines were on culture for three weeks and under the selection of G418 in a 
concentration of 200µg/ml in BEAS-2B cells culture and 800µg/ml in NCI-H460 cells 
culture (concentrations previously optimized through a death curve). 
Despite this methodology allowed the creation of a stable NCI-H460 Mock cell line, 
BEAS-2B Mock cell line or BEAS-2B tRNASer cell line were not successfully created since 
these cells lost the plasmid during selection and died. 
 
2.10. Electroporation 
As an alternative to create stable BEAS-2B derived cell lines, we used electroporation, 
which is a technique that relies in the use of electric pulses to transiently alter the cell 
membrane permeability, allowing the DNA to enter the cell.99 To perform the 
electroporation, BEAS-2B cells were seeded in 100mm dishes and cultured until 70-90% of 
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confluence was reached. Cells were detached as described in 4.8 and the pellet was 
resuspended in Hepes Buffered Saline (HBS) solution (Appendix) to improve the transfection 
efficiency. Then, 4mm electroporation cuvettes were prepared with 10µg of plasmid and 
0.5ml of cell suspension was added, mixing carefully. For each sample, two conditions were 
tested differing in the voltage applied, 230V and 260V, both with capacitance of 1500µF 
and resistance of 125Ω. This step was performed using ECM Electro Cell Manipulator 
(BTX, Harvard Apparatus). Immediately after the electroporation, 1ml of LHC-9 culture 
medium was added, homogenizing carefully, and the mixture was transferred to 60mm 
dishes, already prepared with 3ml of LHC-9 culture medium.  
The stable cell lines BEAS-2B Mock and BEAS-2B tRNASer were obtained by selection 
with G418 in a concentration of 200µg/ml for three weeks, as in the lipotransfection. 
 
2.11. Fluorescence Microscopy 
pIRES2-DsRED plasmid codifies for the red fluorescent protein DsRed-Express2, which 
allows to validate its integration in the cell genome through fluorescence microscopy. For 
that, a coated coverslip (Corning™) was placed in the well or culture dish of each culture 
cell line in the moment of transfection, so the cells could adhere and grown into it. 48h later, 
the culture medium was removed and the well/culture dish was washed ten times with 1X 
PBS. Then, enough volume of Hoechst dye (1µg/ml) was added to the coverslip and 
incubated during 15min at RT, protected from the light. The coverslip was washed five times 
with 1X PBS, the excess was removed and it was transferred to a microscope slide containing 
the Fluoroshield mounting medium (Sigma), leaving to dry for 15min. Fluorescence was 
detected in the Zeiss MC80 Axioplan 2 Light microscope with the filter set HE38. 
Photographs were taken using an AxionCam HRc camera. 
2.12. Extraction and Quantification of gDNA 
To ensure the plasmid did not acquire mutations when integrated in the genome, gDNA 
was extracted to be sequenced as described in 2.7. For that, it was used the NZY Tissue 
gDNA Isolation Kit, following the recommended instructions, and gDNA concentration was 
quantified in the NanoDrop, as described in 2.3. 
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2.13. Cellular Viability Assay 
To perform this assay 1.5 x 105 cells/well of BEAS-2B Mock cells, BEAS-2B tRNASer 
cells and NCI-H460 Mock cells were seeded in a 24-well plate. After two days in culture, 
cells were detached and equal volumes of cell suspension and trypan blue were mixed. 
Finally, cell viability (%) was obtained by counting the live and death cells using a TC10Tm 
Automated Cell Counter (Bio-Rad). This assay was performed with triplicates and repeated 
three times. 
 
2.14. Cellular Proliferation Assay 
To evaluate cellular proliferation, 5.0 x 104 cells/well of BEAS-2B Mock cells, BEAS-
2B tRNASer cells and NCI-H460 Mock cells were seeded into four 24-well treated culture 
plates, so cell counting could be performed before the first cellular division (0h) and over 
the next three days (24h, 48h, 72h). Cells were detached and equal volumes of cell 
suspensions and trypan blue were mixed and viable cells were counted in a Neubauer 
chamber at each time point. The procedure accounted with triplicates and it was repeated 
three times. 
 
2.15. Anchorage-Dependent Colony Formation Assay 
To access the tumorigenic ability of our cell lines in vitro we performed an anchorage-
dependent colony formation assay. This assay requires well individualized cells, so 
suspensions of 300 cells of BEAS-2B Mock cells, BEAS-2B tRNASer cells and NCI-H460 
Mock cells were seeded in 60mm dishes and maintained on culture during two weeks. After, 
the colonies were fixed using ice cooled methanol and maintained at -30ºC during 30min. 
Methanol was removed and a solution of 0.1% crystal violet in methanol was added and the 
plates were laid on stirring at least for 30min. When colonies were stained, each well was 
washed with H2O milliQ to remove excess dye and the colonies were counted. This assay 
was performed with triplicates and repeated four times. 
 
2.16. Total Protein Extraction 
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To obtain total protein from the three cell lines, BEAS-2B Mock cells, BEAS-2B 
tRNASer cells and NCI-H460 Mock cells were seeded on 60mm dishes and maintained on 
culture until they reached about 90% confluence. At that time, the culture medium was 
removed and the plates were washed with 1X PBS. Cells were detached and pelleted as 
described in 2.8. 
The next step was to lyse cellular membranes to release their content, by resuspending 
the pellet in lysis buffer (Appendix) (volume was adjusted regarding the size of the cell pellet) 
and incubating during 30min. From this point, sample manipulation should be performed on 
ice to avoid proteases activity. During the incubation with lysis buffer, each sample was 
sonicated in a Branson Sonifier S-250A (Fisher Scientific) and centrifuged at 4ºC and 
16000g for 30min in a Centrifuge 5415R (Eppendorf®). Finally, the supernatants were 
collected and the samples were concentrated in a DNA 120 SpeedVac System (Thermo 
Scientific) until a volume of 50µl was reached. 
Protein quantification was accessed through the Pierce BCA Protein Kit (Thermo 
Scientific), according to the recommendations of the manufacturer. Absorbance at the 
575nm wavelength was obtained using a microplate reader (iMark™ Microplate Reader, 
Bio-Rad), and results were analyzed in the Microplate Manager Software v6.3 (Bio-Rad 
Laboratories, Inc.). 
 
2.17. Western Blot 
Western blot is a technique that separates proteins based on its molecular weight under 
an electric field, which are then transferred to a solid supported and identified using specific 
and labeled antibodies.100 Proteins were separated by sodium dodecylsulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE), which allows proteins to migrate according to their 
molecular weight. Accordingly with the molecular weight of proteins in study, 8% and 10% 
polyacrylamide gels (Appendix) were prepared. 
Protein quantity was optimized for each protein studied (ranging from 30µg to 60µg of 
protein) and protein samples preparation required addition of 6X SDS Protein Loading 
Buffer (Appendix). Proteins were denatured at 95ºC for 5min in the Thermomixer Comfort 
(Eppendorf®). The denatured proteins were then loaded into gels in an electrophoretic thank 
filled with 1X running buffer (Appendix), under a voltage of 80V when running in the stacking 
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gel and 100V during migration in the running gel. After their separation, proteins were 
transferred from gels to 0.2µm nitrocellulose membranes (GE Healthcare Life Sciences) in 
a transference system filled with cold transfer buffer (Appendix) under the constant voltage of 
100V, for 1h30min at 4ºC. As a transference quality control, the membranes were stained 
with 0.1% (m/v) Ponceau S (Sigma-Aldrich) in 5% (m/v) acetic acid during 1min at RT and 
excess dye was removed with distilled H2O (dH2O). Staining was removed by washing the 
membranes with Tris-Buffered Saline – Tween (TBS-T) (Appendix). 
To avoid antibody unspecific hybridization, membranes were incubated with blocking 
solution [5% BSA in TBS-T] for 1h at RT and then washed three times with TBS-T for 5 
min each. At this point, the membranes were ready for hybridization with the primary 
antibodies: anti-Hsp27, anti-Hsp70, anti-Hsp90α, anti-BiP and anti-ubiquitin (StressMarq, 
Biosciences Inc.) prepared in blocking solution with 1:1000 dilution factor. Their 
hybridization occurred overnight at 4ºC. After the incubation, membranes were washed three 
times with TBS-T for 5 min each. 
The secondary antibodies goat anti-mouse IgG and goat anti-rabbit IgG (Odyssey, LI-
COR) diluted 1:10000 in blocking solution were incubated by 2h at RT, protected from the 
light. Anti-β tubulin (StressMarq, Biosciences Inc.) was used as internal control and its 
hybridization occurred for 2h at RT and also 2h with the secondary antibody goat anti-mouse 
IgG. Primary antibodies and the correspondent secondary antibodies are represented in Table 
II. 
After secondary antibody hybridization, membranes were washed two times with 
TBS-T for 5min each and 15min with TBS and scanned in the Odyssey Infrared Imaging 
System (LI-COR, Biosciences Inc.). Data was obtained with the software Odyssey v3.0.16 
(LI-COR, Biosciences Inc.). 
 
TABELA II. Primary antibodies and respective secondary antibodies 
Primary antibody Secondary antibody 
Anti-Hsp27 
Goat anti-mouse IgG 
Anti-Hsp70 
Anti-Hsp90α 
Anti-ubiquitin 
Anti-β tubulin 
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Anti-BiP Goat anti-rabbit IgG 
 
For multiple probing, membranes were incubated with stripping solution (Appendix) 
at RT, long enough to dissociate the antibodies from the membrane. 
 
2.18. Proteasome activity assay 
Proteasome activity can be determined by measuring the intensity of fluorescence 
derived from the cleavage of a labeled peptide (Suc-LLVY-AMC), a substrate for enzymes 
with chemotrypsin-like activity.101  
The three different cell lines were seeded in 60mm dishes and maintained in culture until 
90% of confluence was reached. At this point, culture medium was removed and cells were 
washed with PBS. Then, proteasome lysis assay buffer (Appendix) was added to the culture 
plates placed on ice and, after an incubation of 5min at RT, cells were scrapped and collected 
to 2ml microcentifuge tubes. Total protein extraction was performed as described in 2.16. 
Protein quantification was obtained through the Bradford method, Bradford reagent was 
obtained from Bio-Rad and absorbance was read in the absorbance microplate reader 
(iMark™ Microplate Reader, Bio-Rad). 
To assess proteasome activity, 20µg of protein were incubated with proteasome activity 
buffer (Appendix) in a black 96 multiwell plate (Costar™) to avoid light interferences, platting 
6 wells for each sample. To eliminate unspecific proteasome activity, the proteasome 
inhibitor MG132 (Sigma) was added to 3 wells per sample. The fluorescence emitted from 
the cleavage of Suc-LLVY-AMC (Sigma) was accessed in the fluorometer system of 
Synergy 2 (BioTek®), for one hour with reads every 5min, using 360nm wavelength for 
excitation and 460nm for emission. Results were analyzed in the Gen5™ v.1.11.5 software 
(BioTek). Each experiment was performed with triplicates and repeated seven times. 
 
2.19. SUnSET Method 
As a strategy to obtain a similar number of cells to perform the assay, 5.0 x 105 cells of 
BEAS-2B Mock cells and BEAS-2B tRNASer cells and 1.0 x 105 cells of NCI-H460 Mock 
cells were seeded in 100mm dishes and maintained in culture for three days. 10µg/ml 
puromycin in 1X PBS was added to the culture medium of each culture dish, in a volume 
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corresponding to 10% of culture medium. After 10 min incubation at 37ºC with 5% CO2, the 
culture medium was removed and replaced by fresh culture medium. Cells were once again 
placed in the incubator for 50 min, after which the culture medium was removed and 1X 
PBS was added to wash the culture plate. Cells were detached and pelleted as described in 
2.8.  
Total protein extraction was performed using proteasome lysis assay buffer and as 
described in 2.16 and protein quantification was achieved by the Bradford method, described 
in 2.18. 
Incorporation of puromycin was detected by immunoblotting, so samples were prepared 
to SDS-PAGE. 100µg of total protein was loaded into 10% polyacrylamide gels, separated 
and transferred to nitrocellulose membranes. For the detection of puromycin, membranes 
incubated with anti-puromycin clone 12D10 primary antibody (1:5000 in blocking solution) 
overnight at 4ºC and with goat anti-mouse IgG secondary antibody by 2h at RT, protected 
from the light. Anti-β tubulin was used as internal control and secondary antibody 
fluorescence detection occurred as described in 2.17. 
 
2.20. Insoluble Protein Fraction 
BEAS-2B Mock cells, BEAS-2B tRNASer cells and NCI-H460 Mock cells were seeded 
on 60mm dishes and maintained on culture until about 90% confluence was reached. Cells 
were detached and pelleted, as described before, and suspensions with 5.0 x 106 cells were 
aliquoted after total cell counting in a Neubauer chamber.  
To perform protein extraction, cellular pellets were resuspended in lysis buffer and 
maintained on ice for 30min. Meanwhile, samples were sonicated in a Branson Sonifier S-
250A (Fisher Scientific). Then, samples were centrifuged for 15min at 2300g and at 4ºC in 
a Centrifuge 5415R (Eppendorf®). Supernatants were collected and 5µl was kept apart to 
quantify total protein with the BCA method. The supernatant was centrifuged for 20min at 
16000g, 4ºC. At this point, the supernatant (the soluble protein fraction) was separated from 
the pellet (the insoluble fraction). The pellet was ressuspended in protein lysis buffer and 
10% Triton X-100. Another centrifugation was performed for 20min at 16000g and at 4ºC. 
To finish, the supernatant was discarded and the pellet was resuspended in 50 µl of lysis 
buffer. 
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Relative expression of insoluble protein fraction was obtained though SDS-PAGE, as 
described in 4.6. Samples were solubilized with 2% urea SDS loading buffer (Appendix), 
denatured at 95ºC in the Thermomixer Comfort (Eppendorf®) and loaded into 10% 
polyacrylamide gels. Then, gels were stained with Coomassie Brilliant Blue (Appendix) 
during 2h and the excess was removed with distaining solution (Appendix). Gels were scanned 
in the Odyssey Infrared Imaging System (LI-COR, Biosciences Inc.) and data was obtained 
with the software Odyssey v3.0.16 (LI-COR, Biosciences Inc.). This assay was performed 
with triplicates and repeated three times. 
 
2.21. Statistical analysis 
Statistical analysis was performed in the GraphPad Prim® v6.01 software, applying the 
one-way ANOVA test with Tukey post-test for all the experiments except for proliferation 
assay, which was analyzed with two-way ANOVA test with Tukey post-test.  
 
 
 
 
 
 

  
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
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IX. Results 
3.1.Stable cell lines construction 
To obtain the three stable cell lines two different approaches were applied. BEAS-2B 
Mock cell line and BEAS-2B tRNASer cell line were obtained through electroporation while 
NCI-H460 Mock stable cell line was obtained by lipotransfection. 
The pIRES-DsRED plasmid contains the coding sequence for the DsRed Express2 
fluorescent protein, therefore 48h after transfection it was possible to detect the integration 
of plasmid in cells through fluorescent microscopy and images of transfected BEAS-2B are 
shown in Figure 8 as well images of transfected NCI-H460 cells are shown in Figure 9. 
 
               
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 8. A. BEAS-2B non-transfected and stained with Hoechst dye (20x). B. BEAS-2B transfected with 
1µg of plasmid pIRES-DsRED and stained with Hoechst dye (20x). 
Figure 9. A. NCI-H460 non-transfected and stained with Hoechst dye (20x). B. NCI-H460 transfected with 
the empty pIRES-DsRED plasmid and stained with Hoechst dye (20x). 
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 To ensure that stable cell lines retained the plasmid in their genomes it was performed 
a PCR and the PCR product was sequenced to check if no mutations occurred. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Results from PCR (Figure 10) confirm the genome’s integration of pIRES-DsRED plasmid 
containing the tRNASer in BEAS-2B tRNASer cell line and the empty pIRES-DsRED plasmid 
in BEAS-2B Mock cell line and NCI-H460 Mock cell line. Also, the results from sequencing 
(Figure 11) ensure the absence of mutations. Therefore, the cell line models were validated 
and the study proceeded.  
 
 
 
 
Figure 10. Results from pIRES-DsREd plasmid PCR amplification of BEAS-2B Mock, BEAS-tRNASer 
and NCI-H460 Mock cells. 
Figure 11. Sequencing results from BEAS-2B tRNASer cells PCR products. In the highlighted zone 
is the tRNASer anticodon. 
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3.2. Phenotypic Profilling 
a. Cellular Viability 
Cellular viability was assessed by determining the number of viable cells applying the 
Trypan Blue dye exclusion test. This test is based on the assumption that live cells have 
intact membranes that exclude particular dyes, such as trypan blue. So, nonviable cells 
present blue stained cytoplasm while viable cells have no staining.102 The percentage (%) of 
viability resulted from the ratio between the number of live cells and the total number of 
cells and it is represented in Figure 12.  
Cellular viability assay excluded the possibility of plasmid toxicity in the three cell lines 
since no differences were visible in their cellular viability.  
 
 
 
 
 
 
 
 
 
 
b. Cellular Proliferation 
Cellular proliferation was accessed to verify if deregulation of tRNA pool promotes 
alterations in the proliferative capacity of BEAS-2B tRNASer cells. To do so, cells from the 
three cell lines were counted in a Neubauer chamber excluding nonviable cells, according to 
the trypan blue exclusion principle. The first counting was done before their doubling, at 0h, 
and over the next three days: after 24h, 48h and 72h. Results are represented in Figure 13. 
Figure 12. Effect of pIRES2-DsRED plasmid on cell viability. No differences are observed. Graphic represents 
mean ± SD of three independent experiments. Statistical analysis was performed using the One-Way ANOVA 
with Tukey’s post-test (p > 0.05). 
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In normal cells the production and release of growth-promoting signals is tightly 
controlled so cells can enter and progress through the cell cycle in conditions that favor 
homeostasis. However, deregulation of growth and proliferation promoting signals is 
obvious in cancer cells, which leads to unregulated cell cycle divisions and aberrant cell 
proliferation.66 In this context, results obtained through the proliferation assay show 
differences in NCI-H460 proliferative capacity when compared with BEAS-2B derived cell 
lines, as early as 24h. Proliferation promoting signals are related with other biological 
properties such as cell growth, firmly expressed by the bigger cell size, and the energy 
metabolism, which is typically altered.66 
When comparing BEAS-2B tRNASer cells to the control no differences are observed in 
their proliferative capacity. However, Pavon-Eternod et al. verified that induced 
overexpression of tRNAi
Met  in normal breast cells was enough to prompt increase in 
proliferation capacity but overexpression of other tRNAs failed to do so.86 Withal, the same 
research group verified that the different range of doubling times between normal and cancer 
breast cells has no correlation with mitochondrial and nuclear global tRNA content.85 
 
 
 
 
 
Figure 13. Proliferation capacity of the three cell lines. NCI-H460 Mock cell line has higher proliferation 
capacity than BEAS-2B tRNASer cell line and the control. No differences are observed between BEAS-2B Mock 
and BEAS-2B tRNASer cell lines. Graphic represents mean ± SEM of three independent experiments. Statistical 
analysis was performed using the Two-Way ANOVA with Tukey’s post-test (***p < 0.001). 
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3.3.Tranformation Ability 
The anchorage-dependent colony formation assay was done to access the transformation 
ability of each cell line through their capacity to form colonies consisting in 50 cells, at 
least103 (Figure 14). 
 
This assay was performed to characterize the unlimited reproductive capacity of 
BEAS-2B tRNASer cells and compare it to cancer cells colony formation capacity. Results 
are shown in Figure 15. A significant increase of transformation ability in vitro was visible in 
BEAS-2B tRNASer cells with no statistical differences comparing with NCI-H460 Mock 
cells. This suggests that overexpressing tRNASer is enough to prompt the acquisition of 
transformation ability in vitro in a level comparable with cancer cells. This represents further 
evidence for the hypothesis that deregulation of translational machinery can be a driving 
force for cellular transformation.104 
Similarly, De Marco et al. observed that BEAS-2B cells carrying a mutation on AKT1 
does not show alterations in proliferation capacity in complete medium but increased 
tumorigenic capacity demonstrated by higher transformation ability in vitro and induction 
of tumor formation in vivo.105 
 
 
 
 
Figure 14. Anchorage-dependent colony formation assay. Cells were seeded at low density to assure their 
individualization and were maintained in culture for two weeks. Then colonies were fixed, stained and 
counted. A. BEAS-2B Mock cells; B. BEAS-2B tRNASer cells; C. NCI-H460 Mock cells. Image represents 
results from one independent experiment. 
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 The assay was carried out in vitro conditions that do not mimic in situ 
microenvironment, like cell-to-cell interactions, oxygen and nutrient availability and pH 
levels. Thus, it is not possible to ensure the in vivo behavior of these cells and so in vivo 
assays should be performed to evaluate the influence of tRNA pool deregulation to the 
acquisition of tumorigenic capacity. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Evaluation of transformation ability in vitro, based on the number of colonies. Both BEAS-2B 
tRNASer and NCI-H460 Mock cells showed higher tumorigenic capacity when compared with the control. No 
statistical significant differences were observed between BEAS-2B tRNASer cell line and NCI-H460 Mock 
cell line. Graphic represents mean ± SEM of four independent experiments. Statistical analysis was performed 
using the One-Way ANOVA with Tukey’s post-test (*p < 0.05; ***p < 0.001). 
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3.4.Study of Proteotoxic Stress Induction and Activation of Protein Quality Control 
Pathways 
Despite the protein quality control systems, errors still occur during protein synthesis, 
which can prompt proteotoxic stress resulting from the toxic character of aberrant proteins 
that became nonfunctional and aggregate.49 Proteotoxic stress and quality control pathways 
activation were evaluated in this study by assessing chaperones availability, protein 
synthesis, activation of UPS system and insoluble protein fraction evaluation. These 
mechanisms were chosen based on previously results by co-workers indicating their 
alteration when facing proteotoxic stress conditions. 
 
a. Expression of chaperones 
The Western Blot assay was performed to assess the expression of Hsp90, Hsp70 and 
the small Hsp27 (Figure 16).  
 
 
 
 
 
 
 
  
 
 
 
Surprisingly, the results of HSPs expression obtained from western blot analysis (Figure 
17) do not agree with the “addiction to chaperones” hypothesis, which dictates that high 
levels of chaperones are required to stabilize the increased protein load containing aberrant 
Figure 16. Expression of Hsp90, Hsp70 and Hsp27. β-tubulin represents the internal control. Total protein 
was extracted from BEAS-2B Mock cells (lanes 1, 2 and 3), BEAS-2B tRNASer (lanes 4, 5 and 6) and NCI-
H460 Mock cells (lanes 7, 8 and 9). 10% polyacrylamide gels were loaded with 50µg of total protein. Image 
represents results from one independent experiment. 
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proteins, characteristic of cancer cells.53 In our study, a downregulation of Hsp90α is clear 
in NCI-H460 Mock cells and a tendency is observed in BEAS-2B tRNASer cells. 
 
 
 
 
 
 
 
 
 
 
 
Recently, Gallegos Ruiz et al. performed an integrated genome wide screening to 
analyze resected tumor samples from NSCLC patients and they described a deletion on 
chromosome 14. This deletion was presented in 44% of samples and correlated with overall 
survival, comparing with NSCLC patients with  normal gene dosage at the same locus.90 The 
study revealed that this deletion only affects the expression of HSPAA1 and the consequent 
lower levels of Hsp90α seems to have a crucial role to promote sensitivity to therapeutics, 
probably derived from the more unstable status of oncoproteins when Hsp90α is expressed 
at lower levels.90 
 
 
 
Figure 17. Relative expression of Hsp90α. β-tubulin was used as internal control and data was normalized 
to the control. Statistical analysis indicates decreased expression of Hsp90α in NCI-H460 Mock cells 
comparing with BEAS-2B Mock cells and with BEAS-2B tRNASer cells. No differences in the expression of 
Hsp90α are observed between control and BEAS-2B tRNASer. Graphic represents mean ± SEM of eight 
independent experiments. Statistical analysis was performed using the One-Way ANOVA with Tukey’s post-
test (*p < 0.05; ***p < 0.001). 
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Results of Hsp70 expression also did not match the ‘addiction to chaperones’ hypothesis 
since it is observed a decreased relative expression of Hsp70 in NCI-H460 Mock cells in 
relation with control and BEAS-2B tRNASer cells (Figure 18). 
Despite the contribution of Hsp70 to achieve the malignant phenotype, a protective role 
in lung cancer development is also supported by high levels of this chaperone. 
Overexpression of Hsp70/Hsc70 can sequester mutant p53 and reduce the inhibition of wild-
type p53 due to association with mutant p53. In this way, p53 is free to perform its 
antiproliferative activity, suggesting that high levels of Hsp70 can be detrimental to 
maintenance of tumorigenesis and they can be related with survival advantage.106,107 Note 
that mutations in TP53 are present in 50% of NSCLC cancers.108 
  
The results of Hsp27 relative expression are represented in Figure 19, demonstrating a 
clear decrease in the expression of this chaperone in NCI-H460 Mock cells.  
Despite being normally overexpressed amongst different tumors89, Huang Qi et al. did 
not observe differences in Hsp27 expression in tissue samples from patients with NSCLC, 
suggesting that the high levels of Hsp27 detected in other tumors are related with the 
different functions of Hsp27 in different cell types.109 Alain Michils et al. did not observed 
differences in Hsp27 expression NSCLC samples as well, instead, they detected low levels 
Figure 18. Relative expression of Hsp70. β-tubulin was used as internal control and data was normalized to 
the control. Statistical analysis indicates decreased expression of Hsp70 in NCI-H460 Mock cells comparing 
with control and BEAS-2B tRNASer cells. No differences are observed between control and BEAS-2B 
tRNASer. Graphic represents mean ± SEM of three independent experiments. Statistical analysis was 
performed using the One-Way ANOVA with Tukey’s post-test (*p < 0.05). 
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of Hsp27 in a small set of samples.89 In another study, it was concluded that Hsp27 
overexpression is correlated with a longer survival rate in tissues from NSCLC.107  
 
 
 
  
 
 
 
 
 
 
 
However, even in cells from normal lung different HSP expression patterns are 
detected.107 In a study performed by Marcel Bonay et al. it was observed that only a set of 
normal human lung cells were positive for Hsp90 and Hsp70, meaning that only a subset of 
cells in lung expresses high levels of HSPs. Also, they suggest that high levels of inducible 
Hsp70 and Hsp90 reflect the differentiated states of bronchial epithelial cells, since they are 
required to specific functions accordingly with the physiological state.110  
Considering the dynamic expression of HSPs in the different types of normal and cancer 
cells and even in different physiological and differentiation states, other cell lines from 
normal lung and cancer lung tissues should be tested to better understand the behavior of 
HSPs in normal and lung cancer cells and in the presence of an inducible tRNA 
overexpression.  
Regarding the cells in study, NCI-H460 cell line was obtained from pleural effusions of 
patients with large cell carcinoma, which is commonly located in the periphery of lung in 
the line of airways, while BEAS-2B cell line has its origin in bronchus. The different origins 
Figure 19. Relative expression of Hsp27. β-tubulin was used as internal control and data was normalized to 
the control. Statistical analysis indicates decreased expression of Hsp27 in NCI-H460 Mock cells comparing 
with control and BEAS-2B tRNASer. No differences are observed between control and BEAS-2B tRNASer. 
Graphic represents mean ± SEM of four independent experiments. Statistical analysis was performed using 
the One-Way ANOVA with Tukey’s post-test (***p < 0.001). 
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of cells can also have influence in the unexpected results and derail the normalization with 
the control. 
Still, it should be noted that in this study the total protein was obtained from cell cultures 
in vitro. The model in vitro abolishes the great influence of microenvironment of cancer 
cells, particularly the hypoxia, the low pH and nutrient availability, which are important 
sources of proteotoxic stress.57 
 
b. Protein Synthesis Rate 
Almost all types of stress prompt reduced translation at global levels as a strategy to 
decrease energy costs and production of proteins that could be prejudicial in the demand 
against the cellular stress. At the same time, synthesis of proteins that support cell survival 
under stress is favored.23  
The Surface Sensing of Translation (SUnSET) method represents a strategy to evaluate 
the protein synthesis rate. It is based on the incorporation of puromycin, an analog of 
aminoacyl tRNAs, into nascent polypeptide chains, inhibiting its elongation. Thus, 
puromycin incorporation directly infers about in vitro translation rate.111 Detection of 
puromycin was done by western blot and results are represented in Figure 20. 
Results show that deregulation of tRNA pool does not promote alterations in the protein 
synthesis rate in vitro, but there is a clear increase in protein synthesis rate in NCI-H460 
Mock cells. 
The protein synthesis rate is closely related with the protein content, the DNA content 
and the cell size.112 The tumorigenic process is accompanied by increased protein load 
related with overexpression of oncogenes and polyploidy.53 Particularly, higher levels of 
anti-apoptotic and pro-mitotic proteins are common in cancer cells that are accompanied by 
overexpression of eIF2α.113 Increased levels of this factor allows the cell to maintain the 
increased metabolism and to progress in the cell cycle. At the same time, higher rates of 
protein synthesis allows to outdo metabolic consequences of stress conditions intrinsic to 
cancer cells, as they are the environment stressors and free radicals production.113 Thus, it 
should be interesting to quantify the eIF2α expression and its phosphorylation status to 
explore the mechanisms underlying the protein synthesis deregulation in NCI-H460 Mock 
cells.  
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c. Unfolded Protein Response Activation 
The stress sensor BiP is the main player of the UPR since it recognizes and bind unfolded 
proteins during ER stress, aiming to restore its conformational structure. This leads to BiP 
dissociation from IRE1α, PERK and ATF6 which become activated and up-regulate genes 
that encode proteins involved in protein folding, insurance of its quality and ERAD 
activation.57  
To assess the relative expression of BiP in the three cell lines it was performed a western 
blot assay (Figure 21). 
 
 
 
 
Figure 20. A. Relative rate of protein synthesis. β-tubulin was used as internal control and data was 
normalized to the control. Statistical analysis indicates increased relative rate of protein synthesis in NCI-H460 
Mock cells compared with BEAS-2B Mock cells and BEAS-2B tRNASer. No differences are observed between 
control and BEAS-tRNASer cells. Graphic represents mean ± SEM of four independent experiments. Statistical 
analysis was performed using the One-Way ANOVA with Tukey’s post-test (***p < 0.001). B. Expression of 
puromycin. β-tubulin represents the internal control. Total protein was extracted from BEAS-2B Mock cells 
(lane 1), BEAS-2B tRNASer (lane 2) and NCI-H460 Mock cells (lane 3).  10% polyacrylamide gels were loaded 
with 100µg of total protein. Image represents results from one independent experiment. 
Figure 21. Expression of BiP. β-tubulin represents the internal control. Total protein was extracted from 
BEAS-2B Mock cells (lanes 1, 2 and 3), BEAS-2B tRNASer (lanes 4, 5 and 6) and NCI-H460 Mock cells (lanes 
7, 8 and 9).  8% polyacrylamide gels were loaded with 60µg of total protein. Image represents results from one 
independent experiment. 
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Results show (Figure 22) that the induced overexpression of tRNASer prompt 
overexpression of BiP without differences compared to NCI-H460 Mock cells. 
 
 
 
 
 
 
 
 
 
 
  
Cancer cells are known to be under ER stress triggered by the particular features of the 
microenvironment. So, elevated BiP levels in cancer cells are required to activate pro-
survival and cytoprotective responses to counteract this chronic stress. BiP may interact 
directly with apoptotic pathway intermediates and block caspase activation, leading to 
apoptosis inhibition and cell survival, being overexpressed in malignant forms of cancer 
such as lung cancer.57,114 Likewise, Qi Wang et al. detected an overexpression of BiP in 
cancer lung tissues comparing with normal lung tissues, without differences between types 
of lung cancer despite their intrinsic morphological and molecular heterogeneity. Also, it 
was observed an increase in BiP expression correlated with the tumor stage, suggesting that 
elevated expression of BiP can be a feature of lung cancer which is correlated with its origin 
and progression.115  
It seems that tRNA pool deregulation is enough to activate the UPR response. However, 
the activation of the different branches of UPR should be analysed to understand if the 
activation of UPR in BEAS-2B tRNASer occurs similarly to UPR activation and modulation 
in cancer cells. 
Figure 22. Relative expression of BiP. β-tubulin was used as internal control and data was normalized to the 
control. Statistical analysis indicates increased relative expression of BiP in BEAS-2B tRNASer and NCI-H460 
Mock cells compared to the control. No differences are observed between BEAS-tRNASer and NCI-H460 Mock 
cells. Graphic represents mean ± SEM of five independent experiments. Statistical analysis was performed using 
the One-Way ANOVA with Tukey’s post-test (*p < 0.05); ***p < 0.001). 
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d. Ubiquitin-Proteaseome System Activation 
The UPS is an important system to retain the equilibrium between protein synthesis and 
protein destruction, controlling the turning over of proteins and maintaining the 
homeostasis.57 The 26S proteasome is an ATP-dependent proteolytic complex consisting in 
two subunits, the 20S proteolytic core and the 19S ATP-dependent regulatory cap, which 
degrades polyubiquitinated polypeptide chains to ensure the elimination of damaged or no 
longer essential proteins.101  
Ubiquitin is involved in the regulation of proteolysis as well as other biological 
functions, namely DNA repair, autophagy and signal transduction. The polyubiquitination 
of proteins, allows protein unfolding and degradation in the 26S proteasome.116,117 The 
relative protein ubiquitination was assessed by western blot and results are shown in Figure 
23. 
 
Results showed no differences in the levels of polyubiquitinated proteins among the three 
cell lines, but apparently proteins with higher molecular size are more ubiquitinated, as we 
can see in Figure 23 B. 
Alain Michils et al., in a comparative study between cell lysates from lung carcinomas 
and cell lysates from non-cancerous tissues, also verify that no differences exist in the 
Figure 23. A. Relative protein ubiquitination. β-tubulin was used as internal control and data was normalized 
to the control. No differences are observed between control, BEAS-2B tRNASer cells and NCI-H460 Mock cells. 
Graphic represents mean ± SEM of five independent experiments. Statistical analysis was performed using the 
One-Way ANOVA with Tukey’s post-test. B. Expression of ubiquitin. β-tubulin represents the internal control. 
Total protein was extracted from BEAS-2B Mock cells (lanes 1, 2 and 3), BEAS-2B tRNASer (lanes 4, 5 and 6) 
and NCI-H460 Mock cells (lanes 7, 8 and 9). 10% polyacrylamide gels were loaded with 50µg of total protein. 
Image represents results from one independent experiment. 
 59 
 
expression of ubiquitin between the samples.89 Considering its involvement in basic cellular 
processes whose perturbation leads to malignant transformation, these results were not 
expected.89 
 
Proteasome activity was determined by measuring the intensity of fluorescence derived 
from the cleavage of a labeled peptide (Suc-LLVY-AMC), a substrate for enzymes with 
chymotrypsin-like activity101 and results are represented in Figure 24.  
 
  
 
 
 
 
 
 
 
 
 
Results show that deregulation of tRNA pool through the expression of a single 
tRNA boost the activity of proteasome at levels similar to that observed in NCI-H460 Mock 
cells.  
 UPS is the major eukaryotic proteolytic pathway and it is responsible for eliminate 
most of the soluble misfolded proteins.46 Upregulation of UPS system is evident in cancer 
cells as a strategy to reduce the accumulation of proteins and so to evade apoptosis. Also, 
proteasome is responsible for degradation of cell cycle regulatory proteins, allowing the cells 
to bypass cell cycle checkpoints. Inhibition of 26S proteasome activity has been study as a 
therapeutic in lung cancer.118,119 
 
Figure 24. Relative proteasome activity. β-tubulin was used as internal control and data was normalized to 
the control. Statistical analysis indicate increase in the relative proteasome activity in BEAS-2B tRNASer cells 
compared with the control as well as in NCI-H460 Mock cells. No differences are observed between BEAS-
2B tRNASer cells and NCI-H460 Mock cells. Graphic represents mean ± SEM of seven independent 
experiments. Statistical analysis was performed using the One-Way ANOVA with Tukey’s post-test (**p < 
0.01; ***p < 0.001). 
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e. Insoluble protein fraction 
To verify if alterations exist in protein insoluble profiles, we analyzed insoluble protein 
fractions by SDS-PAGE (Figure 25). 
Results show a clear decline of the insoluble protein fraction both in BEAS-2B tRNASer 
cells and NCI-H460 Mock cells, suggesting that induced tRNASer overexpression leads to 
alterations in protein expression profiles. Probably, these alterations are advantageous to the 
acquisition of the malignant phenotype, since it is visible that BEAS-2B tRNASer cells 
adopted an intermediate phenotype.  
Cancer cells have quantitative and qualitative alterations in protein expression, with a 
preferential expression of key proteins in tumor progression and development, such as 
growth factors, cell-cycle promoters and oncoproteins, particularly c-Myc and VEGF, the 
last known to be upregulated in NSCLC tumors.76,104 This alterations in insoluble protein 
expression in BEAS-2B tRNASer and in NCI-H460 Mock cells can be associated with those 
alterations in insoluble protein expression due to deregulation of tRNA pool. 
Figure 25. A. Relative insoluble protein expression. β-tubulin was used as internal control and data was 
normalized to the control. Statistical analysis indicates decrease of relative insoluble protein fraction in BEAS-
2B tRNASer cells and in NCI-H460 Mock cells. Graphic represents mean ± SEM of three independent 
experiments. Statistical analysis was performed using the One-Way ANOVA with Tukey’s post-test (***p < 
0.001). B. Expression of insoluble protein fraction obtained through SDS-PAGE. Insoluble protein fraction 
was extracted from BEAS-2B Mock cells (lanes 1 and 2), BEAS-2B tRNASer cells (lanes 3 and 4) and NCI-
H460 Mock cells (lanes 5 and 6). 10% polyacrylamide gels were loaded with 20µl of insoluble protein fraction. 
Image represents results from one independent experiment. 
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X. Discussion 
 
Differential expression of tRNAs may represent a mechanism of translational control 
through the codon usage of specific genes.85,120 Between human tissues there are differences 
in individual tRNA expression correlated with the codon usage of highly-expressed tissue 
specific genes.85 The deregulation of tRNA pool and mutations in tRNA genes are associated 
with human diseases.121 Also, deregulation of transcriptional machinery is common in cancer 
cells and it has been proposed as a trigger for the acquisition of the malignant phenotype.84 
Elevated levels of tRNAs have already been documented in breast cancer in a specific 
fashion since there is a preferential overexpression of tRNAs accordingly with the chemical 
properties of their cognate amino acids.85  
To date, data about the effects of tRNA overexpression and how cells respond to it are 
very limited. In this work, a model to study the effects of tRNASer overexpression in BEAS-
2B cells was successfully generated, allowing a comparative analysis between effects 
derived from tRNASer overexpression and the acquisition of a malignant phenotype in vitro. 
BEAS-2B cell line and NCI-H460 cell line were already used to infer about the acquisition 
of malignant features by other researchers.122 
However, it should be noted that the profile of tRNA pool in cells with induced tRNA 
overexpression is dependent on different factors, such as tRNA identity, cells’ genetic 
background and the site of integration in the genome.86 Also, it is still unknown the role of 
individual tRNAs in different cell types and their effect in the transcriptome and the cellular 
physiology and how they are affected by these two factors.11 
In general, cells with overexpression of tRNASer seem to acquire an intermediate 
behavior between control and cancer cells. The transformation ability of cells with induced 
tRNA overexpression is equivalent to that observed in NCI-H460 Mock cells which suggests 
the acquisition of tumorigenic features.  
A study performed by Stoletzki and Eyre-Walke, provided evidences that codon usage 
in E. Coli  is adapted to highly expressed genes to reduce the energy costs derived from 
missense errors that can lead to non- or misfunctional proteins production.123 In multicellular 
eukaryotes the quantification of gene expression and tRNA abundance are difficult due to 
their variation between tissues and developmental stages.124 However, it was observed a 
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positive correlation for the adaptation of codon usage to higher expressed genes, supporting 
the hypothesis that the equilibrium between tRNA pool and codon usage may increase 
translation accuracy and efficiency in a demand to reduce mistranslation.124–126 Thus, we 
cannot exclude the possibility of misfolded protein synthesis derived from tRNA pool 
perturbation by overexpression of tRNASer.  
Results from relative expression of BiP and proteasome activity suggest that UPR and 
UPS quality control pathways were activated in response to proteome instability in BEAS-
2B tRNASer. Since no alteration in size, proliferation capacity and in protein synthesis rate 
are observed, contrarily to NCI-H460 Mock cells, it seems that overexpression of tRNASer 
does not trigger increase in protein load, but it rather affects proteins that are being produced 
as well as translation speed and accuracy of those proteins. The increase in proteasome 
activity to similar levels to those observed in NCI-H460 Mock cells, suggest an increasing 
demand to eliminate aberrant proteins. Therefore, we can conclude that tRNA pool 
deregulation prompts activation of UPR and UPS similarly to NCI-H460 Mock cells. In 
cancer cells the activation of these pathways is chronic and cancer cells can adapt to it and 
use to their advantage the cytoprotective benefits of its activation to survive and progress.57 
The analysis of insoluble protein fractions indicates a progressive reduction of insoluble 
proteins from control cells to NCI-H460 Mock cells, with BEAS-2B tRNASer expressing an 
intermediate phenotype. This reduction in the insoluble protein content can be explained by 
alterations in gene expression profiles but also by a reduction in protein aggregates, whose 
toxic character is incompatible to the higher metabolism of cancer cells, which eliminates 
them by upregulating the autophagy.127 
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XI. Conclusion and Future Work Suggestions 
 
Is tRNA pool deregulation a driven force or a by-product of malignant transformation? 
The question remains unanswered. However, we can conclude that tRNA pool deregulation 
by a unique tRNA overexpression is enough to prompt the acquisition of an intermediated 
behavior suggestive of progressive acquisition of the malignant phenotype. The activation 
of protein quality control pathways show that tRNASer overexpression suggests interferences 
in the stability of the proteome but more studies should be performed to confirm and unveil 
its origin, namely through mass spectrometry.  
To better understand the mechanism of UPR activation it should be quantified the 
activation of IRE1α, PERK and ATF6 branches by western blot. Since autophagy is essential 
for cancer cells to eliminate the protein aggregates derived from highly metabolism, this 
could represent another phenotypic trait to evaluate BEAS-2B tRNASer cells in the 
acquisition of malignancy, and it could be assessed by western blotting or flow cytometry 
analysis. 
Considering the evidences that cancer cells express higher levels of tRNAs and that 
induction of an unique tRNA isoacceptor leads to other tRNAs overexpression86, through 
the tRNA microarray technology we could confirm the tRNASer overexpression in BEAS-
2B tRNASer cell line and assess other perturbations in the tRNA pool. Likewise, patters of 
tRNA pool in NCI-H460 Mock cell line would be obtained, allowing to perform a correlation 
with the tRNA patterns in BEAS-2B tRNASer cells. Besides, the application of cDNA 
microarray technology would be useful to confirm alterations in gene expression patterns in 
BEAS-2B tRNASer cells and to establish a correlation with gene expression profiles of NCI-
H460 Mock cells. Thereby, a correlation between tRNA patterns and the codon usage of 
specific genes in BEAS-2B tRNASer would be possible and we could understand if tRNA 
pool deregulation is a trigger to preferential expression of cancer-related genes. 
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